(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:29.12.1999 Bulletin 1999/52

(21) Application number: 99303985.8

(22) Date of filing: 21.05.1999

(51) Int CI.6: **C12N 15/55**, C12N 9/16, G01N 33/68, C12Q 1/44, C07K 16/40, C12N 15/11, A61K 38/46, A61K 35/00, A61K 48/00

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 28.05.1998 GB 9811500

30.10.1998 GB 9823882 04.12.1998 GB 9826777 09.04.1999 GB 9908247 10.05.1999 GB 9910801

(83) Declaration under Rule 28(4) EPC (expert solution)

(71) Applicants:

 Pfizer Limited Sandwich Kent CT13 9NJ (GB) Designated Contracting States: GB

• PFIZER INC.

Groton, CT 06340 (US)

Designated Contracting States:

BE CH DE DK ES FI FR GR IE IT LI LU MC PT SE AT CY (72) Inventors:

 Lanfear, Jeremy, c/o Pfizer Central Research Sandwich, Kent CT13 9NJ (GB)

 Robas, Nicola Melanie, c/o Pfizer Central Research Sandwich, Kent CT13 9NJ (GB)

(74) Representative: Harding, Charles Thomas et al
D. Young & Co.
21 New Fetter Lane
London EC4A 1DA (GB)

Remarks:

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(54) Phosphodiesterases

(57) Amino acid sequences and nucleotide sequences are described. The amino acid sequences comprise the sequence presented as SEQ ID No. 2 or

SEQ ID No. 4 or SEQ ID No. 15 or SEQ ID No. 17 or SEQ ID No. 19 or a variant, homologue, fragment or derivative thereof.

Description

BACKGROUND OF THE PRESENT INVENTION

5 [0001] The present invention relates to an enzyme. The present invention also relates to a nucleotide sequence encoding same.

[0002] In particular, the present invention relates to novel-nucleic acid sequences encoding novel phosphodiesterase enzymes.

[0003] The present invention also relates to the use of the novel nucleic acid and amino acid sequences in the diagnosis and treatment of disease.

[0004] The present invention also relates to the use of the novel nucleic acid and amino acid sequences to evaluate and/or to screen for agents that can modulate phosphodiesterase activity.

[0005] The present invention further relates to genetically engineered host cells that comprise or express the novel nucleic acid and amino acid sequences to evaluate and/or to screen for agents that can modulate phosphodiesterase activity.

BACKGROUND ART

15

20

[0006] Cyclic nucleotide phosphodiesterases (PDEs) are a family of enzymes that catalyse the degradation of cyclic nucleotides. Cyclic nucleotides, particularly cAMP (i.e. cyclic adenosine 3',5'-monophosphate), are important intracellular second messengers. PDEs are one cellular component that regulate the concentration of cyclic nucleotides.

[0007] In recent years, at least seven PDE enzymes (such as PDEI - PDEVII), as well as many subtypes of these enzymes, have been defined based on substrate affinity and cofactor requirements (Beavo JA and Reifsnyder DH, Trends Pharmacol. Sci. 11:150 [1990]; Beavo J, In: Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action., Beavo J and Housley MD (Eds.). Wiley: Chichester, pp. 3-15 [1990]). Examples of PDEs (i.e. cyclic nucleotide phosphodiesterases) include: PDEI which is a Ca²⁺/Calmodulin-dependent PDE; PDEII which is a cGMP stimulated PDE; PDEIII which is a cGMP inhibited PDE; PDEIV which is a high affinity cAMP-specific PDE; and PDEV which is a cGMP specific PDE.

[0008] Each PDE family may contain two or more isoforms (i.e. there may be two or more PDE isoenzymes). By way of example, mammalian PDE IV, the homologue of the *Drosophila* Dunce gene (Chen CN *et al.*, Proc. Nat. Acad. Sci. (USA) 83:9313 [1986]), is known to have four isoforms in the rat (Swinnen JV *et al.*, Proc. Nat. Acad. Sci. (USA) 86: 5325 [1989]). Human PDEs are also known to occur as isoforms and have splice variants. For example, the cloning of one human isoform of PDEIV from monocytes was reported in 1990 (Livi GP *et al.*, Mol. Cell. Bio., 10:2678 [1990]). By way of further example, other workers have independently cloned three splice variants of PDEIV, which are now designated hPDEIV-B1, hPDEIV-B2, and hPDEIV-B3.

[0009] Teachings on a further cyclic nucleotide phosphodiesterase - namely CN PCDE8 - can be found in WO-A-97/35989. According to WO-A-97/35989, CN PCDE8 has two isozymes - which were designated CN PCDE8A and CN PCDE8B. The term "isozyme" is sometimes referred to in the art as "isoform".

[0010] According to WO-A-97/35989, many inhibitors of different PDEs have been identified and some have undertensive agents and as cardiotonic agents useful in the treatment of congestive heart failure. Rolipram, a PDEIII inhibitor, has been used in the treatment of depression and other inhibitors of PDEIII are undergoing evaluation as anti-inflam-shown to enhance HIV-1 replication in vitro. Therefore, rolipram may inhibit HIV-1 replication (Angel et al 1995 AIDS 9:1137-44). Additionally, based on its ability to suppress the production of TNF alpha and beta and interferon gamma, multiple sclerosis (Sommer et al, 1995 Nat Med 1:244-248) and may be effective in the treatment of tardive dyskinesia

[0011] According to WO-A-97/35989, there are also non-specific PDE inhibitors such as theophylline, used in the treatment of bronchial asthma and other respiratory diseases, and pentoxifylline, used in the treatment of intermittent claudication and diabetes-induced peripheral vascular disease. Theophylline is thought to act on airway smooth muscle function as well as in an anti-inflammatory or immunomodulatory capacity in the treatment of respiratory diseases (Banner et al 1995 Respir J 8:996-1000) where it is thought to act by inhibiting both CN PDE cAMP and cGMP hydrolysis (Banner et al 1995 Monaldi Arch Chest Dis 50:286-292). Pentoxifylline, also known to block TNF-alpha production, may inhibit HIV-1 replication (Angel et al supra). A list of CN PDE inhibitors is given in Beavo 1995 supra.

[0012] It has been suggested that selective inhibitors of PDEs, in addition to their isozymes and their subtypes, will lead to more effective therapy with fewer side effects. For example, see the teachings in the reviews of Wieshaar RE et al, (J. Med. Chem., 28:537 [1985]), Giembycz MA (Biochem. Pharm., 43:2041 [1992]) and Lowe JA and Cheng JB

(Drugs of the Future, 9-807 [1992]).

[0013] Thus, for some applications it is desirable to have a selective inhibition of an individual type of PDE. Hence, the cloning and expression of a novel PDE would greatly aid the discovery of selective inhibitors.

5 SUMMARY ASPECTS OF THE PRESENT INVENTION

[0014] Aspects of the present invention are presented in the claims and in the following commentary.[0015] In brief, some aspects of the present invention relate to:

1. Novel amino acids.

10

15

20

25

30

35

40

45

50

55

- 2. Novel nucleotide sequences.
- 3. Assays using said novel sequences.
- 4. Compounds/compositions identified by use of said assays.
- 5. Expression systems comprising or expressing said novel sequences.
- 6. Methods of treatment based on said novel sequences.
- 7. Pharmaceutical compositions based on said novel sequences.

[0016] Other aspects concerning the amino acid sequence of the present invention and/or the nucleotide sequence of the present invention include: a construct comprising or capable of expressing the sequences of the present invention; a vector comprising or capable of expressing the sequences of the present invention; a plasmid comprising or capable of expressing the sequences of the present invention; an organ comprising or capable of expressing the sequences of the present invention; a transformed host comprising or capable of expressing the sequences of the present invention; a transformed organism comprising or capable of expressing the sequences of the present invention; a transformed organism comprising or capable of expressing the sequences of the present invention. The present invention also encompasses methods of expressing the same, such as expression in a micro-organism; including methods for transferring same.

[0017] For ease of reference, aspects of the present invention are now discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section.

[0018] In the following commentary references to "nucleotide sequence of the present invention" and "amino acid sequence of the present invention" refer respectively to any one or more of the nucleotide sequences presented herein and to any one or more of the amino acid sequences present herein. Also, and as used herein, "amino acid sequence" refers to peptide or protein sequences and may refer to portions thereof. In addition, the term "amino acid sequence of the present invention" is synonymous with the phrase "polypeptide sequence of the present invention". Also, the term "nucleotide sequence of the present invention" is synonymous with the phrase "polynucleotide sequence of the present invention".

DETAILED ASPECTS OF THE PRESENT INVENTION

[0019] According to a first aspect of the present invention there is provided an amino acid sequence comprising the sequence presented as Formula I or a variant, homologue, fragment or derivative thereof; wherein the amino acid sequence is capable of displaying PDE activity.

3

Formula I

- An amino acid sequence comprising any one or more of peptide sequences or amino acids Z1 Z28, any of which peptide sequence or amino acid Z1 Z28 may be separated from another of said peptide sequence or amino acid Z1 Z28 by a suitable peptide sequence or amino acid residue;
- wherein Z1 Z28 are:
 - Z1 = LTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRK
 - Z2 = NK
- Z3 = DE
 - Z4 = PKEVSRYQDTNMQGVVYELNSYIEQRLDTGGDN
 - Z5 = LLLYELSSII
 - Z6 = IATKADGFALYFLGECNNSLC
- 20 |Z7 = F|
 - Z8 = PPG
 - Z9 = KEG
 - Z10 = PRLIPAGPITQGTT
- 25 Z11 =
- SAYVAKSRKTLLVEDILGDERFPRGTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHWGK EAFCLSHQEVATANLAWASVAIHQVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEH IMIYAKNLVNADRCALFQVDHKNKELYSDLFDIGEEKEGKP
 - Z12 =
- FKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNREVDLYTGYTTRNILCMPIVSRG
 SVIGVVQMVNKISGSAFSKTDENNFKMFAVFCALALHCANMYHRIRHSECIYRVTMEKLSY
 HSICTSEEWOGLM
 - Z13 = F
- Z14 = LP
 - Z15 = R
 - Z16= C
 - Z17 = IELFHFDIGPFENMWPGIFVYM
- Z18 = HRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNN
 - Z19 = LFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPL
 - Z20 =

ALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRQL EEMYQTGSLNL

- Z21 = NQSHRDRVIGLMMTACDLCSVTK
 - Z22 = WPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDK
 - Z23 = DEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNL
 - Z24 = QWEKVIRGEETA
- Z25 = WIS
 - Z26 = P
 - Z27 = A
 - Z28 = E
- and; wherein the amino acid sequence is made up of more than 159 amino acid residues.

[0020] For convenie

5

10

15

20

25

30

35

40

nvenie. we now

we now present a Table indicating the codes used



AMINO ACID	THREE LETTER ABBREVIATION	ONE LETTER SYMBOL
Alanine	Ala	Α
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Cysteine	Cys	С
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glycine	Gly	G
Histidine	His	Н
Isoleucine	lle	I
Leucine	Leu	L
Lysine	Lys	К
Methionine	Met	М
Phenylalanine	Phe	F
Proline	Pro	Р
Serine	Ser	S
Threonine	Thr	Τ
Tryptophan	Trp	W
Tyrosine	Tyr	Υ
Valine	Val	V
Any residue	Xaa	X

[0021] Preferably, the amino acid sequence of Formula I comprises at least one or more of Z11, Z12, Z18 and Z20, or analogues thereof.

[0022] The term "analogue" as used herein means a sequence having a sequence similar to that of Formula I but wherein non-detrimental (i.e. not detrimental to enzymatic activity) amino acid substitutions or deletions have been made.

[0023] Preferably, the amino acid sequence of Formula I comprises at least each of Z11, Z12. Z18 and Z20, or analogues thereof.

[0024] Preferably, the amino acid sequence of Formula I comprises at least each of Z11, Z12, Z18 and Z20.

[0025] Preferably, the amino acid sequence of Formula I comprises at least one or more of Z1, Z4, Z17, Z19, Z21, Z22 and Z33, or analogues thereof.

[0026] Preferably, the amino acid sequence of Formula I comprises at least each of of Z1, Z4, Z17, Z19, Z21, Z22 and Z33, or analogues thereof.

[0027] Preferably, the amino acid sequence of Formula I comprises at least each of of Z1, Z4, Z17, Z19, Z21, Z22 and Z33.

[0028] A preferred example of an amino acid sequence comprising the sequence presented as Formula I is the amino acid sequence shown as Formula II or a variant, homologue, fragment or derivative thereof.

55

Formula II

5

10

15

20

25

X0-Z1-X1-Z2-X2-X3-Z3-X4-X5-Z4-X6-Z5-X7-Z6-X8-Z7-X9-Z8-X10-Z9-

X11-Z10-X12-Z11-X13-Z12-X14-Z13-X15-Z14-X16-Z15-X17-Z16-X18-

X19-Z17-X20-Z18-X21-X22-Z19-X23-Z20-X24-Z21-X25-Z22-X26-Z23-

X27-Z24-X28-Z25-X29-Z26-X30-X31-Z27-X32-X33-X34-X35-X36-X37-

Z28-X38

wherein

each of Z1 - Z28 is as defined above;

each of X0 - X38 is independently selected from a suitable peptide sequence or amino acid, and

wherein any one or more of: X0, X28, Z25, X29, Z26, X30, X31, Z27, X32, X33, X34, X35, X36, X37, Z28, and X38 is optional.

[0029] A more preferred example of an amino acid sequence comprising the sequence presented as Formula I is the amino acid sequence shown as Formula III or a variant, homologue, fragment or derivative thereof.

30

Formula III

 $\texttt{LTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRKX}_1 \texttt{NKX}_2 \texttt{X}_3 \texttt{DEX}_4 \texttt{X}_5 \texttt{PKEVSRYQDTN}$ 35 ${\tt MQGVVYELNSYIEQRLDTGGDNX_6LLLYELSSIIX_7IATKADGFALYFLGECNNSLCX_8FX_9}$ $\mathtt{PPGX_{10}KEGX_{11}PRLIPAGPITQGTTX_{12}SAYVAKSRKTLLVEDILGDERFPRGTGLESGTRI}$ QSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLAWASVAIHQVQVCRGLAKQ TELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALFQVDHKNKELYSDLFDIG $\verb"EEKEGKPX" {}_{13} \verb"FKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNREVDLYTGYTTRN"$ 40 ILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCALALHCANMYHRIRHSECI $\tt YRVTMEKLSYHSICTSEEWQGLMX_{14}FX_{15}LPX_{16}RX_{17}CX_{18}X_{19}IELFHFDIGPFENMWPGIFART AND STREET AND STRE$ ${\tt VYMX_{20}HRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNX_{21}X_{22}L}$ ${\tt FTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLX_{23}ALYSTSTMEQHHFSQTVSILQLE}$ 45 $\tt GHNIFSTLSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLX_{24}NQSHRDRV$ ${\tt IGLMMTACDLCSVTKX_{25}WPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKX_{26}DEVP}$ ${\tt QGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLX_{27}QWEKVIRGEETA}$

50

wherein

 $X_1 = N \text{ or } T$

 $X_2 = S \text{ or } A$

 $X_3 = E \text{ or } K$ $X_4 = S \text{ or } P$

 $X_5 = A \text{ or } S$

 $X_6 = Q \text{ or } H$

```
X_7 =
           K or R
X_8 =
           I or V
           T or I
           l or M
X_{11} = K \text{ or } Q
           V or I
          V or I
X_{14} = Q \text{ or } R
X_{15} = T \text{ or } N
X_{16} = V \text{ or } A
X_{17} = L \text{ or } I
X<sub>18</sub> =
          K or R
X_{19} = E \text{ or } D
          V or I
X_{20} =
X_{21} =
          H or N
X_{22} =
           T or G
           T or A
           N or H
X<sub>25</sub> =
          P or L
X_{26} = K \text{ or } R
X_{27} = S \text{ or } N
```

[0030] A more preferred example of an amino acid sequence comprising the sequence presented as Formula I is the amino acid sequence shown as Formula IV or a variant, homologue, fragment or derivative thereof.

Formula IV

X₀LTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRKX₁NKX₂X₃DEX₄X₅PKEVSRYQDT 30 $\mathtt{NMQGVVYELNSYIEQRLDTGGDNX_6LLLYELSSIIX_7IATKADGFALYFLGECNNSLCX_8FX}$ $_{9}$ PPGX $_{10}$ KEGX $_{11}$ PRLIPAGPITQGTTX $_{12}$ SAYVAKSRKTLLVEDILGDERFPRGTGLESGTR IQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLAWASVAIHQVQVCRGLAK QTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALFQVDHKNKELYSDLFDI 35 GEEKEGKPX₁₃FKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNREVDLYTGYTTR NILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCALALHCANMYHRIRHSEC IYRVTMEKLSYHSICTSEEWQGLMX₁₄FX₁₅LPX₁₆RX₁₇CX₁₈X₁₉IELFHFDIGPFENMWPGI $FVYMX_{20}HRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNX_{21}X_{22}$ 40 $\verb|LFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLX|_{23} \verb|ALYSTSTMEQHHFSQTVSILQL|$ EGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLX24NQSHRDR VIGLMMTACDLCSVTKX25WPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKX26DEV PQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLX27QWEKVIRGEETA 45

wherein

25

 $X_0 = S \text{ or } G$ $X_1 = N \text{ or } T$ $X_2 = S \text{ or } A$ $X_3 = E \text{ or } K$ $X_4 = S \text{ or } P$ $X_5 = A \text{ or } S$ $X_6 = Q \text{ or } H$ $X_7 = K \text{ or } R$ $X_8 = I \text{ or } V$ $X_9 = T \text{ or } I$

```
X_{10} =
            l or M
 X_{11} =
            K or Q
            V or I
 X_{12} =
X_{13} =
           V or I
X_{14} =
           Q or R
X_{15} =
           T or N
X_{16} =
           V or A
X_{17} =
           L or I
X_{18} =
           K or R
X_{19} =
            E or D
X_{20} = V \text{ or } I
X_{21} = H \text{ or } N
X_{22} = T \text{ or } G
X_{23} = T \text{ or } A
X_{24} = N \text{ or } H
X_{25} = P \text{ or } L
X_{26} = K \text{ or } R
```

25

30

35

40

45

20 [0031] A preferred example of an amino acid sequence comprising the sequence presented as Formula I is the amino acid sequence shown as Formula V or a variant, homologue, fragment or derivative thereof.

Formula V

X₀LTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRKX₁NKX₂X₃DEX₄X₅PKEVSRYQDT
NMQGVVYELNSYIEQRLDTGGDNX₆LLLYELSSIIX₇IATKADGFALYFLGECNNSLCX₈FX
9PGX₁₀KEGX₁₁PRLIPAGPITQGTTX₁₂SAYVAKSRKTLLVEDILGDERFPRGTGLESGTR
IQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLAWASVAIHQVQVCRGLAK
QTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALFQVDHKNKELYSDLFDI
GEEKEGKPX₁₃FKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNREVDLYTGYTTR
NILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCALALHCANMYHRIRHSEC
IYRVTMEKLSYHSICTSEEWQGLMX₁₄FX₁₅LPX₁₆RX₁₇CX₁₈X₁₉IELFHFDIGPFENMWPGI
FVYMX₂₀HRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNX₂₁X₂₂
LFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLX₂₃ALYSTSTMEQHHFSQTVSILQL
EGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLX₂₄NQSHRDR
VIGLMMTACDLCSVTKX₂₅WPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKX₂₆DEV
PQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLX₂₇QWEKVIRGEETAX₂₈WIS

wherein

 $X_0 =$ S or G $X_1 =$ N or T $X_2 =$ S or A $X_3 =$ E or K $X_4 =$ S or P A or S X₆ = Q or H K or R X₈ = I or V T or I $X_{10} = I \text{ or } M$

```
K or Q
         V or I
         V or I
         Q or R
         T or N
X<sub>16</sub> =
         V or A
X_{17} =
         L or I
X_{18} =
         K or R
X_{19} =
         E or D
X_{20} =
         V or I
X_{21} =
         H or N
         T or G
X_{23} =
         T or A
         N or H
         P or L
         K or R
X_{26} =
         S or N
X_{27} =
X_{28} =
         T or M
```

25

30

35

40

45

A preferred example of an amino acid sequence comprising the sequence presented as Formula I is the amino acid sequence shown as Formula VI or a variant, homologue, fragment or derivative thereof.

Formula VI

X₀LTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRKX₁NKX₂X₃DEX₄X₅PKEVSRYQDT
NMQGVVYELNSYIEQRLDTGGDNX₆LLLYELSSIIX₇IATKADGFALYFLGECNNSLCX₈FX
9PGX₁₀KEGX₁₁PRLIPAGPITQGTTX₁₂SAYVAKSRKTLLVEDILGDERFPRGTGLESGTR
IQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLAWASVAIHQVQVCRGLAK
QTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALFQVDHKNKELYSDLFDI
GEEKEGKPX₁₃FKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNREVDLYTGYTTR
NILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCALALHCANMYHRIRHSEC
IYRVTMEKLSYHSICTSEEWQGLMX₁₄FX₁₅LPX₁₆RX₁₇CX₁₈X₁₉IELFHFDIGPFENMWPGI
FVYMX₂₀HRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNX₂₁X₂₂
LFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLX₂₃ALYSTSTMEQHHFSQTVSILQL
EGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLX₂₄NQSHRDR
VIGLMMTACDLCSVTKX₂₅WPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKX₂₆DEV
PQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLX₂₇QWEKVIRGEETAX₂₈WISX₂₉PX
30X₃₁A

wherein

 $X_0 = S \text{ or } G$ $X_1 = N \text{ or } T$ $X_2 = S \text{ or } A$ $X_3 = E \text{ or } K$ $X_4 = S \text{ or } P$ $X_5 = A \text{ or } S$ $X_6 = Q \text{ or } H$ $X_7 = K \text{ or } R$ $X_8 = I \text{ or } V$ $X_9 = T \text{ or } I$ $X_{10} = I \text{ or } M$

```
X_{11} = K \text{ or } Q
  X_{12} =
            V or I
  X_{13} = V \text{ or } I
 X_{14} = Q \text{ or } R
 X_{15} =
            T or N
  X_{16} =
              V or A
  X_{17} = L \text{ or } I
 X<sub>18</sub> = K or R
 X_{19} = E \text{ or } D
 X_{20} = V \text{ or } I
 X_{21} = H \text{ or } N
 X_{22} =
            T or G
 X_{23} = T \text{ or } A
 X_{24} = N \text{ or } H
X_{25} = Por L
 X_{26} = K \text{ or } R
 X_{27} = S \text{ or } N
 X_{28} = T \text{ or } M
 X_{29} = S \text{ or } G
X_{30} = S \text{ or } G
 X_{31} = V \text{ or } P
```

25

[0032] A more preferred example of an amino acid sequence comprising the sequence presented as Formula I is the amino acid sequence shown as Formula VII or a variant, homologue, fragment or derivative thereof.

Formula VII

 $\texttt{X}_0 \texttt{LTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRKX}_1 \texttt{NKX}_2 \texttt{X}_3 \texttt{DEX}_4 \texttt{X}_5 \texttt{PKEVSRYQDT}$ 30 ${\tt NMQGVVYELNSYIEQRLDTGGDNX_6LLLYELSSIIX_7IATKADGFALYFLGECNNSLCX_8FX}$ $_9\mathtt{PPGX_{10}KEGX_{11}PRLIPAGPITQGTTX_{12}SAYVAKSRKTLLVEDILGDERFPRGTGLESGTR}$ IQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLAWASVAIHQVQVCRGLAK QTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALFQVDHKNKELYSDLFDI 35 ${\tt GEEKEGKPX_{13}FKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNREVDLYTGYTTR}$ NILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCALALHCANMYHRIRHSEC ${\tt IYRVTMEKLSYHSICTSEEWQGLMX_{14}FX_{15}LPX_{16}RX_{17}CX_{18}X_{19}IELFHFDIGPFENMWPGI}$ ${\tt FVYMX_{20}HRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNX_{21}X_{22}}$ 40 $\verb| LFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLX|_{23} \verb| ALYSTSTMEQHHFSQTVSILQL|$ ${\tt EGHNIFSTLSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLX_{24}NQSHRDR}$ $\tt VIGLMMTACDLCSVTKX_{25}WPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKX_{26}DEV$ ${\tt PQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLX_{27}QWEKVIRGEETAX_{28}WISX_{29}PX}$ 45 $_{30}X_{31}AX_{32}X_{33}X_{34}X_{35}X_{36}X_{37}EX_{38}$

wherein

 $X_0 = S \text{ or } G$ $X_1 = N \text{ or } T$ $X_2 = S \text{ or } A$ $X_3 = E \text{ or } K$ $X_4 = S \text{ or } P$ $X_5 = A \text{ or } S$ $X_6 = Q \text{ or } H$ $X_7 = K \text{ or } R$ $X_8 = I \text{ or } V$

T or I $X_{10} =$ I or M K or Q $X_{12} =$ V or I $X_{13} =$ V or I $X_{14} =$ Q or R X₁₅ = T or N $X_{16} =$ V or A X₁₇ = Lorl $X_{18} =$ K or R $X_{19} =$ E or D X₂₀ = V or I $X_{21} =$ H or N $X_{22} =$ T or G $X_{23} =$ T or A $X_{24} =$ N or H P or L $X_{25} =$ $X_{26} =$ K or R X₂₇ = S or N 20 $X_{28} =$ T or M $X_{29} =$ S or G S or G $X_{30} =$ $X_{31} =$ V or P $X_{32} = Q \text{ or } P$ $X_{33} = K \text{ or } S$ $X_{34} =$ A or K $X_{35} = A \text{ or } S$ $X_{36} =$ A or T $X_{37} =$ SorP $X_{38} =$ 30 D or K

45

[0033] Preferred examples of an amino acid sequence comprising the sequence presented as Formula I include the amino acids shown as: SEQ ID No. 2 or SEQ ID No. 4 or SEQ ID No. 15, or an amino acid comprising SEQ ID No. 17 and/or SEQ ID No. 19, or a variant, homologue, fragment or derivative thereof

[0034] It is to be noted that references to Formula I and/or to any one or more of Formula II - Formula VII herein also apply equally to any one or more of: SEQ ID No. 2 or SEQ ID No. 4 or SEQ ID No. 15 or an amino acid comprising SEQ ID No. 17 and/or SEQ ID No. 19.

[0035] An example of a variant of any one of Formula II - Formula VII is an amino acid sequence wherein the group $KRKX_1NKX_2X_3$ is substituted with $KRKX_1DKX_2X_3$

[0036] An example of a variant of any one of Formula II - Formula VII is an amino acid sequence wherein the group LLLYELSSIIX₇.... is substituted with LLLYELNSSIIX₇.....

[0037] Preferably references to Formula I and/or to any one or more of Formula II - Formula VII herein mean any one or more of: SEQ ID No. 2 or SEQ ID No. 4 or SEQ ID No. 15 or an amino acid comprising SEQ ID No. 17 and/or SEQ ID No. 19.

[0038] More preferably references to Formula I and/or to any one or more of Formula II - Formula VII herein mean any one or more of: SEQ ID No. 2 or SEQ ID No. 4.

[0039] According to a second aspect of the present invention there is provided an amino acid sequence comprising the sequence presented as Formula I.

[0040] According to a third aspect of the present invention there is provided a nucleotide sequence encoding the amino acid sequence of the present invention.

[0041] According to a fourth aspect of the present invention there is provided a nucleotide sequence comprising the sequence presented as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or a nucleotide sequence comprising SEQ ID No. 16 and/or SEQ ID No. 18, or a variant, homologue, fragment or derivative thereof.

[0042] According to a fifth aspect of the present invention there is provided a nucleotide sequence comprising the sequence presented as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or a nucleotide sequence comprising SEQ ID No. 16 and/or SEQ ID No. 18.

[0043] According to a sixth aspect of the present invention there is provided a nucleotide sequence that is capable of hybridising to the nucleotide sequence according to the present invention.

[0044] According to a severimespect of the present invention there is provided a nucl de sequence that is capable of hybridising to the nucleotide sequence according to sixth aspect of the present invention.

[0045] According to an eighth aspect of the present invention there is provided a vector comprising the nucleotide sequence according to the present invention.

[0046] According to a ninth aspect of the present invention there is provided a host cell into which has been incorporated the nucleotide sequence according to the present invention.

[0047] According to a tenth aspect of the present invention there is provided an assay method for identifying an agent that can affect PDE11 activity or expression, the assay method comprising contacting an agent with an amino acid according to the present invention or a nucleotide sequence according to the present invention; and measuring the activity or expression of PDE11; wherein a difference between a) PDE activity or expression in the absence of the agent and b) PDE activity or expression in the presence of the agent is indicative that the agent can affect PDEII activity or expression. Preferably the assay is to screen for agents useful in the treatment of sexual dysfunction - such as male erectile dysfunction or female sexual dysfunction.

[0048] According to an eleventh aspect of the present invention there is provided a process comprising the steps of: (a) performing the assay according to the present invention; (b) identifying one or more agents that do affect PDE11 activity or expression; and (c) preparing a quantity of those one or more identified agents.

[0049] According to a twelfth aspect of the present invention there is provided a method of affecting in vivo PDE11 activity or expression with an agent; wherein the agent is capable of affecting PDE11 activity or expression in an in vitro assay method; wherein the in vitro assay method is the assay method of the present invention.

[0050] According to a thirteenth aspect of the present invention there is provided the use of an agent in the preparation 20 of a pharmaceutical composition for the treatment of a disease or condition associated with PDE 11, the agent is capable of having an effect on the activity or expression of PDE when assayed in vitro by the assay method of the present

[0051] According to a fourteenth aspect of the present invention there is provided an enzyme capable of having an immunological reaction with an antibody raised against PDE11.

[0052] According to a fifteenth aspect of the present invention there is provided a nucleotide sequence coding for a PDE, wherein the nucleotide sequence is obtainable from NCIMB 40925 or NCIMB 40926 or NCIMB 41007.

[0053] According to a sixteenth aspect of the present invention there is provided a PDE wherein the PDE is expressable from a nucleotide sequence obtainable from NCIMB 40925 or NCIMB 40926 or NCIMB 41007.

[0054] According to a seventeenth aspect of the present invention there is provided the use of an agent which has an effect on the activity of PDE11 or the expression thereof in the preparation of a pharmaceutical composition for the treatment of a disease or condition associated with PDE11.

[0055] According to a further aspect of the present invention there is provided:

[0056] A nucleotide sequence selected from:

35

40

45

50

(a) the nucleotide sequence presented as SEQ ID No. 1, 3, 14, or a nucleotide sequence comprising SEQ ID No. 16 and/or SEQ ID No. 18:

(b) a nucleotide sequence that is a variant, homologue, derivative or fragment of the nucleotide sequence presented as SEQ ID No. 1, 3, 14, or a nucleotide sequence comprising SEQ ID No. 16 and/or SEQ ID No. 18;

(c) a nucleotide sequence that is the complement of the nucleotide sequence set out in SEQ ID No. 1, 3, 14, or a nucleotide sequence comprising SEQ ID No. 16 and/or SEQ ID No. 18;

(d) a nucleotide sequence that is the complement of a variant, homologue, derivative or fragment of the nucleotide sequence presented as SEQ ID No. 1, 3, 14, or a nucleotide sequence comprising SEQ ID No. 16 and/or SEQ ID

(e) a nucleotide sequence that is capable of hybridising to the nucleotide sequence set out in SEQ ID No. 1, 3, 14, or a nucleotide sequence comprising SEQ ID No. 16 and/or SEQ ID No. 18:

(f) a nucleotide sequence that is capable of hybridising to a variant, homologue, derivative or fragment of the nucleotide sequence presented as SEQ ID No. 1, 3, 14, or a nucleotide sequence comprising SEQ ID No. 16 and/ or SEQ ID No. 18;

(g) a nucleotide sequence that is the complement of a nucleotide sequence that is capable of hybridising to the nucleotide sequence set out in SEQ ID No. 1, 3, 14, or a nucleotide sequence comprising SEQ ID No. 16 and/or

(h) a nucleotide sequence that is the complement of a nucleotide sequence that is capable of hybridising to a variant, homologue, derivative or fragment of the nucleotide sequence presented as SEQ ID No. 1, 3, 14, or a nucleotide sequence comprising SEQ ID No. 16 and/or SEQ ID No. 18;

(i) a nucleotide sequence that is capable of hybridising to the complement of the nucleotide sequence set out in SEQ ID No. 1, 3, 14, or a nucleotide sequence comprising SEQ ID No. 16 and/or SEQ ID No. 18;

(j) a nucleotide sequence that is capable of hybridising to the complement of a variant, homologue, derivative or

fragment of the number de sequence presented as SEQ ID No. 1, 3, 14, or sequence comprising SEQ ID No. 16 and/or SEQ ID No. 18;

- (k) a nucleotide sequence which is degenerate as a result of the genetic code to the nucleotides defined in (a), (b), (c), (d), (e), (f), (g), (h), (i), or (j);
- (I) a nucleotide sequence comprising any one of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) and/or (k).

Other aspects of the present invention include:

[0057] An isolated nucleotide sequence or protein sequence according to the present invention.

[0058] An assay method for identifying an agent that can affect the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof,

the assay method comprising

exposing the nucleotide sequence of the present invention or the expression product ("EP") thereof with an agent;

determining whether the agent modulates (such as affects the expression pattern or activity) the nucleotide sequence of the present invention or the expression product thereof.

[0059] An agent identified by the assay method of the present invention.

[0060] An agent identified by the assay method of the present invention, which agent has hitherto been unknown to have a PDE modulation effect in accordance with the present invention.

[0061] A process comprising the steps of:

- (a) performing the assay of the present invention;
- (b) identifying one or more agents that affect the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof;
- (c) preparing a quantity of those one or more identified agents.

30

35

45

5

10

15

20

25

[0062] A process comprising the steps of:

- (a) performing the assay according to the present invention;
- (b) identifying one or more agents that affect the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof;
 - (c) preparing a pharmaceutical composition comprising one or more identified agents.
- 40 [0063] A process comprising the steps of:
 - (a) performing the assay according to the present invention;
 - (b) identifying one or more agents that affect the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof;
 - (c) modifying one or more identified agents to cause a different effect on the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof.
- [0064] Use of an agent identified by an assay according to the present invention in the manufacture of a medicament which affects the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof.
 - [0065] A method of treating a target (which target can be a mammal, preferably a human), which method comprises delivering (such as administering or exposing) to the target an effective amount of an agent capable of modulating the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof.

 [0066] A method of treating a target (which target can be a mammal, preferably a human), which method comprises delivering (such as administering or exposing) to the target an effective amount of an agent identified by an assay according to the present invention.

[0067] A method of inducing an immunological response in a subject, the method of subject the nucleotide sequence of the present invention or the expression product thereof. prising administering to the

PDE11(PDEXI)

5

20

25

30

35

40

[0068] Thus, the present invention relates to a novel PDE enzyme - which we have called PDE11 (which may otherwise be expressed as PDEXI) - and to a nucleotide sequence encoding same. The present invention also relates to the use of the novel nucleic acid and amino acid sequences in the diagnosis and treatment of disease. The present invention also relates to the use of the novel nucleic acid and amino acid sequences to evaluate and/or to screen for agents that can modulate phosphodiesterase activity. The present invention further relates to genetically engineered host cells that comprise or express the novel nucleic acid and amino acid sequences to evaluate and/or to screen for agents that can modulate phosphodiesterase activity.

[0069] As used herein, the term "PDE11" refers to a novel family of PDEs which, up until now, were uncharacterised. By way of example, we have identified two human isoenzymes of PDE11 - which we have called PDE11A1 and PDE11A2 (sometimes referred to as HSPDE11A1 and HSPDE11A2 respectively). We believe that PDE11A2 is a splice variant of PDE11A1. We have also identified a mouse sequence - which we have called PDE11A3 (sometimes referred to as MmPDE11A3). We have also identified a rat sequence - which we have partially sequenced - which we have PDE11A4 (sometimes referred to as RtPDE11A4).

[0070] For convenience, and unless otherwise stated, reference to PDE11 will include reference to PDE11A1 and/ or PDE11A2 and/or PDE11A3 and/or PDE11A4.

[0071] PDE11 - such as the isoenzymes PDE11A1 and/or PDE11A2 - is believed to be present in, and obtainable from, a variety of sources. By way of example, PDE-11 is found in the striatum and in the corpus cavernosum. By way of further example, and in addition to human and mouse, PDE11 is also available from rat. We also believe that PDE11 is also present in a number of other sources - such as for example: bovine, ovine, porcine, and equine. Preferably, the present invention covers mammalian PDE 11 which includes but is not limited to any of the above sources.

[0072] The PDE11 may be the same as the naturally occurring form - for this aspect, preferably the PDE11 is the non-native amino acid sequence (i.e. it is not present in its natural form and in its natural environment) - or is a variant, homologue, fragment or derivative thereof. In addition, or in the alternative, the PDE11 is isolated PDE11 and/or purified PDE11. The PDE11 can be obtainable from or produced by any suitable source, whether natural or not, or it may be

[0073] The PDE11 coding sequence may be the same as the naturally occuring form - for this aspect, preferably the PDE11 coding sequence is the non-native nucleotide sequence (i.e. it is not present in its natural form and in its natural environment) - or is a variant, homologue, fragment or derivative thereof. In addition, or in the alternative, the PDE11 coding sequence is an isolated PDE11 coding sequence and/or a purified PDE11 coding sequence. The PDEII coding sequence can be obtainable from or produced by any suitable source, whether natural or not, or it may be synthetic,

[0074] PDE11 is believed to be able to catalyse the conversion of cGMP to GMP cGMP is the messenger in the male erectile response. Accordingly, inhibiting the activity of PDE11 is likely to increase the concentration of cGMP present and so enhance the male erectile response. Thus, PDE11 and/or its coding sequence and/or a sequence capable of hybridising thereto is/are useful for screening drug candidates for the treatment of male erectile dysfunction. In addition, it is believed that PDE11 and/or its coding sequence and/or a sequence capable of hybridising thereto is/ are useful for screening drug candidates for the treatment of female sexual dysfunction. Also, PDE11 and/or its coding sequence and/or a sequence capable of hybridising thereto is/are useful for testing the selectivity of drug candidates between different PDEs.

[0075] Preferred aspects of the present invention include a recombinant PDE11 enzyme and a recombinant nucle-

[0076] Preferably the recombinant PDE11 enzyme and/or the recombinant nucleotide sequence of the present invention are a recombinant mammalian PDEII enzyme and/or a recombinant mammalian nucleotide sequence.

[0077] In accordance with the present invention, the recombinant PDE11 enzyme has at least the formula presented as Formula I.

[0078] Either or both of the nucleotide sequence coding for PDE11 or the enzyme PDE11 itself may be used to screen for agents that can affect PDE11 activity. In particular, the nucleotide sequence coding for PDE11 or PDE11 itself may be used to screen for agents that can inhibit PDE11 activity. In addition, the nucleotide sequence coding for PDE11 or the enzyme PDE11 itself may be used to screen for agents that selectively affect PDE11 activity, such as selectively inhibit PDE11 activity.

[0079] Furthermore, the nucleotide sequence coding for PDE11 or a sequence that is complementary thereto may also be used in assays to detect the presence of PDE11 coding sequences in human cells. These assays would provide information regarding the tissue distribution of this enzyme and its biological relevance with respect to particular disease

states.

[0080] The present invention also covers antibodies to PDE11 (including a derivative, fragment, homologue or variant thereof). The antibodies for PDE11 may be used in assays to detect the presence of PDE11 in human cells. These assays would provide information regarding the tissue distribution of this enzyme and its biological relevance with respect to particular disease states.

[0081] In particular, any one or more of the PDE11 isozymes (i.e. PDE11A1 and PDE11A2 or PDE11A3 or PDE11A4), the nucleotide sequences coding for same, the nucleotide sequences that are complementary to same, and the antibodies directed to same may be used in assays to screen for agents that selectively affect one of the isozymes. These assays would provide information regarding the tissue distribution of each of the isozymes and to provide information regarding the biological relevance of each of the isozymes with respect to particular disease states. These assays would also allow workers to test for and identify agents that are useful to affect the expression of or activity of PDE11 - such as in a particular tissue or in a particular disease state.

NATURALLY OCCURRING

15

10

[0082] As used herein "naturally occurring" refers to a PDE11 with an amino acid sequence found in nature.

ISOLATED/PURIFIED

[0083] As used herein, the terms "isolated" and "purified" refer to molecules, either nucleic or amino acid sequences, that are removed from their natural environment and isolated or separated from at least one other component with which they are naturally associated.

BIOLOGICALLY ACTIVE

25

30

[0084] As used herein "biologically active" refers to a PDE11 according to the present invention - such as a recombinant PDE11 - having a similar structural function (but not necessarily to the same degree), and/or similar regulatory function (but not necessarily to the same degree), and/or similar biochemical function (but not necessarily to the same degree) and/or immunological activity (but not necessarily to the same degree) of the naturally occurring PDE11. Specifically, a PDE11 of the present invention has the ability to hydrolyze a cyclic nucleotide, which is one of the characteristic activities of the PDE enzyme of the present invention.

IMMUNOLOGICAL ACTIVITY

35 [0085] As used herein, "immunological activity" is defined as the capability of the natural, recombinant or synthetic PDE11 or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

DERIVATIVE

40

[0086] The term "derivative" as used herein in relation to the amino acid sequence includes chemical modification of a PDE11. Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group.

DELETION

45

[0087] As used herein a "deletion" is defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

INSERTION/ADDITION

50

[0088] As used herein an "insertion" or "addition" is a change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring PDE.

55 SUBSTITUTION

[0089] As used herein "substitution" results from the replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively.

VARIANT/HOMOLOGUE


5

20

25

35

40



[0091] In particular, the term "homology" as used herein may be equated with the term "identity". Here, sequence homology with respect to the nucleotide sequence of the present invention and the amino acid sequence of the present invention can be determined by a simple "eyeball" comparison (i.e. a strict comparison) of any one or more of the sequences with another sequence to see if that other sequence has at least 75 % identity to the sequence(s). Relative sequence homology (i.e. sequence identity) can also be determined by commercially available computer programs that can calculate % homology between two or more sequences. A typical example of such a computer program is CLUSTAL.

[0092] Sequence homology (or identity) may even be determined using any suitable homology algorithm, using for example default parameters. Advantageously, the BLAST algorithm is employed, with parameters set to default values. The BLAST algorithm is described in detail at http://www.ncbi.nih.gov/BLAST/blast_help.html, which is incorporated herein by reference. The search parameters are defined as follows, and are advantageously set to the defined default parameters.

[0093] Advantageously, "substantial homology" when assessed by BLAST equates to sequences which match with an EXPECT value of at least about 7, preferably at least about 9 and most preferably 10 or more. The default threshold for EXPECT in BLAST searching is usually 10.

[0094] BLAST (Basic Local Alignment Search Tool) is the heuristic search algorithm employed by the programs blastp, blastn, blastn, the blastn, and the blastn, these programs ascribe significance to their findings using the statistical methods of Karlin and Altschul (see http://www.ncbi.nib.gov/BLAST/blast_help.html) with a few enhancements. The BLAST programs were tailored for sequence similarity searching, for example to identify homologues to a query sequence. The programs are not generally useful for motif-style searching. For a discussion of basic issues in similarity searching of sequence databases, see Altschul et al (1994) Nature Genetics 6:119-129.

[0095] The five BLAST programs available at http://www.ncbi.nlm.nih.gov perform the following tasks:

blastp compares an amino acid query sequence against a protein sequence database;

30 blastn compares a nucleotide query sequence against a nucleotide sequence database;

blastx compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database;

tblastn compares a protein query sequence against a nucleotide sequence database dynamically translated in all six reading frames (both strands).

tblastx compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

[0096] BLAST uses the following search parameters:

[0097] HISTOGRAM Display a histogram of scores for each search; default is yes. (See parameter H in the BLAST Manual).

[0098] DESCRIPTIONS Restricts the number of short descriptions of matching sequences reported to the number specified; default limit is 100 descriptions. (See parameter V in the manual page). See also EXPECT and CUTOFF.

[0099] ALIGNMENTS Restricts database sequences to the number specified for which high-scoring segment pairs

(HSPs) are reported; the default limit is 50. If more database sequences than this happen to satisfy the statistical significance threshold for reporting (see EXPECT and CUTOFF below), only the matches ascribed the greatest statistical significance are reported. (See parameter B in the BLAST Manual).

[0100] EXPECT The statistical significance threshold for reporting matches against database sequences; the default value is 10, such that 10 matches are expected to be found merely by chance, according to the stochastic model of Karlin and Altschul (1990). If the statistical significance ascribed to a match is greater than the EXPECT threshold, the match will not be reported. Lower EXPECT thresholds are more stringent, leading to fewer chance matches being reported. Fractional values are acceptable. (See parameter E in the BLAST Manual).

[0101] CUTOFF Cutoff score for reporting high-scoring segment pairs. The default value is calculated from the EX-PECT value (see above). HSPs are reported for a database sequence only if the statistical significance ascribed to them is at least as high as would be ascribed to a lone HSP having a score equal to the CUTOFF value. Higher CUTOFF values are more stringent, leading to fewer chance matches being reported. (See parameter S in the BLAST Manual).

16

Typically, significance holds can be more intuitively managed using EXP.

[0102] MATRIX Specify an alternate scoring matrix for BLASTP, BLASTX, TBLASTN and TBLASTX. The default matrix is BLOSUM62 (Henikoff & Henikoff, 1992). The valid alternative choices include: PAM40, PAM120, PAM250 and IDENTITY. No alternate scoring matrices are available for BLASTN; specifying the MATRIX directive in BLASTN requests returns an error response.

[0103] STRAND Restrict a TBLASTN search to just the top or bottom strand of the database sequences; or restrict a BLASTN, BLASTX or TBLASTX search to just reading frames on the top or bottom strand of the query sequence. [0104] FILTER Mask off segments of the query sequence that have low compositional complexity, as determined by the SEG program of Wootton & Federhen (1993) Computers and Chemistry 17:149-163, or segments consisting of short-periodicity internal repeats, as determined by the XNU program of Claverie & States (1993) Computers and Chemistry 17:191-201, or, for BLASTN, by the DUST program of Tatusov and Lipman (see http://www.ncbi.nlm.nih.gov). Filtering can eliminate statistically significant but biologically uninteresting reports from the blast output (e.g., hits against common acidic-, basic- or proline-rich regions), leaving the more biologically interesting regions of the query sequence available for specific matching against database sequences.

[0105] Low complexity sequence found by a filter program is substituted using the letter "N" in nucleotide sequence (e.g., "NNNNNNNNNNNNNNN") and the letter "X" in protein sequences (e.g., "XXXXXXXXX").

[0106] Filtering is only applied to the query sequence (or its translation products), not to database sequences. Default filtering is DUST for BLASTN, SEG for other programs.

[0107] It is not unusual for nothing at all to be masked by SEG, XNU, or both, when applied to sequences in SWISS-PROT, so filtering should not be expected to always yield an effect. Furthermore, in some cases, sequences are masked in their entirety, indicating that the statistical significance of any matches reported against the unfiltered query sequence should be suspect.

[0108] NCBI-gi Causes NCBI gi identifiers to be shown in the output, in addition to the accession and/or locus name. [0109] Most preferably, sequence comparisons are conducted using the simple BLAST search algorithm provided at http://www.ncbi.nlm.nih.gov/BLAST.

[0110] Other computer program methods to determine identify and similarity between the two sequences include but are not limited to the GCG program package (Devereux et al 1984 Nucleic Acids Research 12: 387 and FASTA (Atschul et al 1990 J Molec Biol 403-410).

[0111] Should Gap Penalties be used when determining sequence identity, then preferably the following parameters are used:

FOR BLAST	
GAP OPEN	0
GAP EXTENSION	0

FOR CLUSTAL	DNA	PROTEIN	
WORD SIZE	2	1	K triple
GAP PENALTY	10	10	
GAP EXTENSION	0.1	0.1	

45 [0112] As used herein, the terms "variant", "homologue", "fragment" and "derivative" embrace allelic variations of the sequences.

[0113] The term "variant" also encompasses sequences that are complementary to sequences that are capable of hydridising to the nucleotide sequences presented herein.

HYBRIDISATION

30

35

40

[0114] The term "hybridization" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs J (1994) Dictionary of Biotechnology, Stockton Press, New York NY) as well as the process of amplification as carried out in polymerase chain reaction technologies as described in Dieffenbach CW and GS Dveksler (1995, PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview NY).

[0115] Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Aca-

demic Press, San Diego CA), confer a defined "stringency" as explained below.

[0116] Stringency of hybridisation refers to conditions under which polynucleic acids hybrids are stable. Such conditions are evident to those of ordinary skill in the field. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature (Tm) of the hybrid which decreases approximately 1 to 1.5°C with every 1 % decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridisation reaction is performed under conditions of higher stringency, followed by washes of varying stringency.

[0117] As used herein, high stringency refers to conditions that permit hybridisation of only those nucleic acid sequences that form stable hybrids in 1 M Na+ at 65-68 °C

[0118] Maximum stringency typically occurs at about Tm-5°C (5°C below the Tm of the probe).

[0119] High stringency at about 5°C to 10°C below the Tm of the probe. High stringency conditions can be provided, for example, by hybridisation in an aqueous solution containing 6x SSC, 5x Denhardt's, 1 % SDS (sodium dodecyl sulphate), 0.1 Na+ pyrophosphate and 0.1 mg/ml denatured salmon sperm DNA as non specific competitor. Following hybridisation, high stringency washing may be done in several steps, with a final wash (about 30 min) at the hybridisation temperature in 0.2 - 0.1x SSC, 0.1 % SDS.

[0120] Moderate, or intermediate, stringency typically occurs at about 10°C to 20°C below the Tm of the probe.

[0121] Low stringency typically occurs at about 20°C to 25°C below the Tm of the probe.

[0122] As will be understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridization can be used to identify or detect similar or related polynucleotide sequences.

[0123] Moderate stringency refers to conditions equivalent to hybridisation in the above described solution but at about 60-62°C. In that case the final wash is performed at the hybridisation temperature in 1x SSC, 0.1 % SDS.

[0124] Low stringency refers to conditions equivalent to hybridisation in the above described solution at about 50-52°C. In that case, the final wash is performed at the hybridisation temperature in 2x SSC, 0.1 % SDS.

[0125] It is understood that these conditions may be adapted and duplicated using a variety of buffers, e.g. formamide-based buffers, and temperatures. Denhardt's solution and SSC are well known to those of skill in the art as are other suitable hybridisation buffers (see, e.g. Sambrook, et al., eds. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York or Ausubel, et al., eds. (1990) Current Protocols in Molecular Biology, John Wiley & Sons, Inc.). Optimal hybridisation conditions have to be determined empirically, as the length and the GC content of the probe also play a role.

POLYPEPTIDE OF THE PRESENT INVENTION

30

[0126] Polypeptides of the present invention may be in a substantially isolated form. It will be understood that the polypeptide may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated. A polypeptide of the present invention may also be in a substantially purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the polypeptide in the preparation is a polypeptide of the present invention. Polypeptides of the present invention may be modified for example by the addition of histidine residues to assist their purification or by the addition of a signal sequence to promote their secretion from a cell as discussed below.

[0127] Polypeptides of the present invention may be produced by synthetic means (e.g. as described by Geysen *et al.*, 1996) or recombinantly, as described below.

[0128] In a preferred embodiment, the amino acid sequence *per se* the present invention does not cover the native PDE11 according to the present invention when it is in its natural environment and when it has been expressed by its native nucleotide coding sequence which is also in its natural environment and when that nucleotide sequence is under the control of its native promoter which is also in its natural environment. For ease of reference, we shall call this preferred embodiment the "non-native amino acid sequence".

[0129] The terms "variant", "homologue" or "fragment" in relation to the amino acid sequence for the enzyme of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant enzyme has PDE11 activity, preferably being at least as biologically active as the enzyme shown as SEQ ID No. 2. or SEQ ID No. 4 or SEQ ID No. 15. In particular, the term "homologue" covers homology with respect to structure and/or function. With respect to sequence homology, preferably there is at least 75%, more preferably at least 90% homology to the sequence shown as Formula I. More preferably there is at least 95%, more preferably at least 98%, homology to the sequence shown as Formula I. More preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to the sequence shown as SEQ ID No. 2. or SEQ ID No. 4 or SEQ ID No. 15, or an amino acid sequence comprising SEQ ID No. 17 and/or SEQ ID No. 19. More preferably there is at least 95%, more preferably at least 98%, homology to the sequence shown as SEQ ID No. 2. or SEQ ID No. 4 or SEQ ID No. 15.

[0130] Typically, the consist of amino acid substitutions that could be made and maintain the hydrophobicity/hydrophilicity of the amino acid sequence. Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions provided that the modified sequence retains the ability to act as a PDE enzyme in accordance with present invention. Amino acid substitutions may include the use of non-naturally occurring analogues, for example to increase blood plasma half-life.

[0131] The amino acid sequence of the present invention may be produced by expression of a nucleotide sequence coding for same in a suitable expression system.

[0132] In addition, or in the alternative, the protein itself could be produced using chemical methods to synthesize a PDE amino acid sequence, in whole or in part. For example, peptides can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., Creighton (1983) Proteins Structures And Molecular Principles, WH Freeman and Co, New York NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure).

[0133] Direct peptide synthesis can be performed using various solid-phase techniques (Roberge JY *et al* (1995) Science 269: 202-204) and automated synthesis may be achieved, for example, using the ABI 43 1 A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer. Additionally, the amino acid sequence of PDE, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with a sequence from other subunits, or any part thereof, to produce a variant polypeptide.

[0134] In another embodiment of the invention, a PDE natural, modified or recombinant sequence may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for inhibitors of PDE activity, it may be useful to encode a chimeric PDE protein expressing a heterologous epitope that is recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between a PDE sequence and the heterologous protein sequence, so that the PDE may be cleaved and purified away from the heterologous moiety.

[0135] PDE may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals (Porath J (1992) Protein Expr Purif 3 -.26328 1), protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle, WA). The inclusion of a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and PDE is useful to facilitate purification.

[0136] Specific amino acid sequences of PDE11 are shown as SEQ ID No. 2 and SEQ ID No. 4 and SEQ ID No. 15 and SEQ ID No. 17 and SEQ ID No. 19. However, the present invention encompasses amino acid sequences encoding other members from the PDE11 family which would include amino acid sequences having at least 60% identity (more preferably at least 75% identity) to the amino acid sequence of SEQ ID Nos. 2 or 4 or 15 or 17 or 19. As indicated, suitable generic formulae for the PDE11 family in accordance with the present invention are presented as Formula I or any one of Formula II-Formula VII.

[0137] Polypeptides of the present invention also include fragments of the presented amino acid sequence and variants thereof. Suitable fragments will be at least 5, e.g. at least 10, 12, 15 or 20 amino acids in size.

[0138] Polypeptides of the present invention may also be modified to contain one or more (e.g. at least 2, 3, 5, or 10) substitutions, deletions or insertions, including conserved substitutions.

[0139] Conserved substitutions may be made according to the following table which indicates conservative substitutions, where amino acids on the same block in the second column and preferably in the same line in the third column may be substituted for each other:

Ĺ	į	5		
		_		


30

ALIPHATIC	Non-polar	GAP
		ILV
	Polar - uncharged	CSTM
		NQ
/	Polar - charged	DE
		KR
AROMATIC		HFWY
OTHER		NQDE

55

50

NUCLEOTIDE SEQUENCE OF HE PRESENT INVENTION



[0141] Preferably, the term "nucleotide sequence" means DNA.

15

- [0142] More preferably, the term "nucleotide sequence" means DNA prepared by use of recombinant DNA techniques (i.e. recombinant DNA).
- [0143] In a preferred embodiment, the nucleotide sequence per se of the present invention does not cover the native nucleotide coding sequence according to the present invention in its natural environment when it is under the control of its native promoter which is also in its natural environment. For ease of reference, we shall call this preferred embodiment the "non-native nucleotide sequence".
 - [0144] The nucleotide sequences of the present invention may include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothicate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be carried out in to enhance the *in vivo* activity or life span of nucleotide sequences of the present invention.
- 20 [0145] The present invention also encompasses nucleotide sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof. If the sequence is complementary to a fragment thereof then that sequence can be used a probe to identify similar coding sequences in other organisms etc.
 - [0146] The present invention also encompasses nucleotide sequences that are capable of hybridising to the sequences presented herein, or any derivative, fragment or derivative thereof.
- 25 [0147] The present invention also encompasses nucleotide sequences that are capable of hybridising to the sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof. [0148] The term "variant" also encompasses sequences that are complementary to sequences that are capable of hydridising to the nucleotide sequences presented herein.
- [0149] Preferably, the term "variant" encompasses sequences that are complementary to sequences that are capable of hydridising under stringent conditions (e.g. 65°C and 0.1xSSC {1xSSC = 0.15 M NaCl, 0.015 Na₃ citrate pH 7.0}) to the nucleotide sequences presented herein.
 - [0150] The present invention also relates to nucleotide sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein).
- [0151] The present invention also relates to nucleotide sequences that are complementary to sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein).
 - [0152] Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridizing to the nucleotide sequences presented herein under conditions of intermediate to maximal stringency.
- [0153] In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention under stringent conditions (e.g. 65°C and 0.1xSSC).
 - [0154] Exemplary nucleic acids can alternatively be characterised as those nucleotide sequences which encode a PDE 11 protein and hybridise to the DNA sequences set forth as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18, or a selected fragment of said DNA sequence. Preferred are such sequences encoding PDE 11 which hybridise under high-stringency conditions to the sequence of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 16 or SEQ ID No. 18.
- [0155] Advantageously, the invention provides nucleic acid sequences which are capable of hybridising, under stringent conditions, to a fragment of SEQ. ID. No. 1 or to a fragment of SEQ ID No. 3 or to a fragment of SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18. Preferably, the fragment is between 15 and 50 bases in length. Advantageously, it is about 25 bases in length.
- [0156] The terms "variant", "homologue" or "fragment" in relation to the nucleotide sequence coding for the preferred enzyme of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence codes for or is capable of coding for an enzyme having PDE11 activity, preferably being at least as biologically active as the enzyme encoded by the sequences shown as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence codes for or is capable of coding for an enzyme having PDE11 activity. With respect to sequence homology, preferably there is at least 75%, more preferably at least 85 %, more preferably at least 90% homology to a nucleotide sequence coding for the amino acid sequence shown as Formula I. More preferably there is at least 95%, more preferably at

least 98 homology to a sequence coding for the amino acid sequence own as Formula I. Preferably, with respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to the sequence shown as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18. More preferably there is at least 95%, more preferably at least 98%, homology to the sequence shown as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14.

[0157] As indicated, the present invention relates to a DNA sequence (preferably a cDNA sequence) encoding PDE11. In particular, the present invention relates to cDNA sequences encoding PDE11A1 or PDE11A2 or PDE11A3 or PDE11A4.

[0158] The present invention also relates to DNA segments comprising the DNA sequence of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or allelic variations of such sequences.

[0159] The present invention also relates to polypeptides produced by expression in a host cell into which has been incorporated the foregoing DNA sequences or allelic variations thereof.

[0160] A highly preferred aspect of the present invention relates to a polypeptide comprising the amino acid sequence of Formula I (such as SEQ ID No. 2 or SEQ ID No. 4 or SEQ ID No. 15 or SEQ ID No. 17 or SEQ ID No. 19). For example, the present invention relates to an isolated polypeptide comprising the amino acid sequence of Formula I (such as SEQ ID No. 2 or SEQ ID No. 4 or SEQ ID No. 15 or SEQ ID No. 17 or SEQ ID No. 19).

[0161] The present invention also relates to DNA comprising the DNA sequence of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or an allelic variation thereof.

[0162] The present invention also relates to non-native DNA comprising the DNA sequence of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or an allelic variation thereof.

[0163] A highly preferred aspect of the present invention relates to recombinant DNA comprising the DNA sequence of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or an allelic variation thereof.

[0164] Polynucleotides of the present invention include nucleotide acid sequences encoding the polypeptides of the present invention. It will appreciated that a range of different polynucleotides encode a given amino acid sequence as a consequence of the degeneracy of the genetic code.

[0165] By knowledge of the amino acid sequences set out herein it is possible to devise partial and full-length nucleic acid sequences such as cDNA and/or genomic clones that encode the polypeptides of the present invention. For example, polynucleotides of the present invention may be obtained using degenerate PCR which will use primers designed to target sequences encoding the amino acid sequences presented herein. The primers will typically contain multiple degenerate positions. However, to minimise degeneracy, sequences will be chosen that encode regions of the amino acid sequences presented herein containing amino acids such as methionine which are coded for by only one triplet. In addition, sequences will be chosen to take into account codon usage in the organism whose nucleic acid is used as the template DNA for the PCR procedure. PCR will be used at stringency conditions lower than those used for cloning sequences with single sequence (non-denegerate) primers against known sequences.

30

[0166] Nucleic acid sequences obtained by PCR that encode polypeptide fragments of the present invention may then be used to obtain larger sequences using hybridization library screening techniques. For example a PCR clone may be labelled with radioactive atoms and used to screen a cDNA or genomic library from other species, preferably other mammalian species. Hybridization conditions will typically be conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C).

[0167] Degenerate nucleic acid probes encoding all or part of the amino acid sequence may also be used to probe cDNA and/or genomic libraries from other species, preferably other mammalian species. However, it is preferred to carry out PCR techniques initially to obtain a single sequence for use in further screening procedures.

[0168] In accordance with the present invention, PDE11 polynucleotide sequences which encode PDE11, fragments of the polypeptide, fusion proteins or functional equivalents thereof, may be used to generate recombinant DNA molecules that direct the expression of PDE11 in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence, may be used to clone and express PDE11. As will be understood by those of skill in the art, it may be advantageous to produce PDE-encoding nucleotide sequences possessing non-naturally occurring codons. Codons preferred by a particular prokaryotic or eukaryotic host (Murray E et al (1989) Nuc Acids Res 17:477-508) can be selected, for example, to increase the rate of PDE11 expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence.

[0169] Polynucleotide sequences of the present invention obtained using the techniques described above may be used to obtain further homologous sequences and variants using the techniques described above. They may also be modified for use in expressing the polypeptides of the present invention in a variety of host cells systems, for example to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.

[0170] Altered PDE11 polynucleotide sequences which may be used in accordance with the invention include dele-

tions, insertions or substitution and different nucleotide residues resulting in a polynum de that encodes the same or a functionally equivalent PDE. The protein may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent PDE. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of PDE is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

[0171] Included within the scope of the present invention are alleles of PDE. As used herein, an "allele" or "allelic sequence" is an alternative form of PDE. Alleles result from a mutation, i.e., a change in the nucleic acid sequence, and generally produce altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to deletions, additions or substitutions of amino acids. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

10

15

30

40

[0172] The nucleotide sequences of the present invention may be engineered in order to alter a PDE coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the gene product. For example, mutations may be introduced using techniques which are well known in the art, e. g., site-directed mutagenesis to insert new restriction sites, to alter glycosylation patterns or to change codon preference.

20 [0173] Polynucleotides of the present invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the present invention as used herein.

[0174] Polynucleotides or primers of the present invention may carry a revealing label. Suitable labels include radioisotopes such as ³²P or ³⁵S, enzyme labels, or other protein labels such as biotin. Such labels may be added to polynucleotides or primers of the present invention and may be detected using by techniques known *per se.*

[0175] Polynucleotides such as a DNA polynucleotide and primers according to the present invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.

[0176] In general, primers will be produced by synthetic means, involving a step wise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

[0177] Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15-30 nucleotides) to a region of the nucleotide sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from a fungal, plant or prokaryotic cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector.

[0178] DNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences of the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule.

[0179] As mentioned earlier, the present invention also relates to nucleotide sequences that are capable of hybridising to all or part of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or an allelic variation thereof. These nucleotide sequences may be used in anti-sense techniques to modify PDE11 expression. Alternatively, these sequences (or portions thereof) can be used as a probe, or for amplifying all or part of such sequence when used as a polymerase chain reaction primer.

[0180] In addition to the recombinant DNA sequences, genomic sequences are also of utility in the context of drug discovery. It may be valuable to inhibit the mRNA transcription of a particular isoform rather than to inhibit its translated protein. This is particularly true with PDE11, since the different splice variants may be transcribed from different promoters. There is precedent for multiple promoters directing the transcription of a mouse brain 2',3'-cyclic-nucleotide 3' phosphodiesterase (Kurihara T et al., Biochem. Biophys. Res. Comm. 170: 1074 [1990]).

[0181] Another utility of the invention is that the DNA sequences, once known, give the information needed to design assays to specifically detect each isoenzyme or splice variant. Isozyme-specific PCR primer pairs are but one example of an assay that depends completely on the knowledge of the specific DNA sequence of the isozyme or splice variant. Such an assay allows detection of mRNA for the isozyme to access the tissue distribution and biological relevance of each isozyme to a particular disease state. It also allows identification of cell lines that may naturally express only one

isozyme - a discovery might obviate the need to express recombinant seeds. If specific PDE11 isozymes are shown to associated with a particular disease state, the invention would be valuable in the design of diagnostic assays to detect the presence of isozyme mRNA.

[0182] An abnormal level of nucleotide sequences encoding a PDE11 in a biological sample may reflect a chromosomal aberration, such as a nucleic acid deletion or mutation. Accordingly, nucleotide sequences encoding a PDE11 provide the basis for probes which can be used diagnostically to detect chromosomal aberrations such as deletions, mutations or chromosomal translocations in the gene encoding PDE. PDE11 gene expression may be altered in such disease states or there may be a chromosomal aberration present in the region of the gene encoding a PDE11.

[0183] In an alternative embodiment of the invention, the coding sequence of PDE could be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers MH et al (1980) Nuc Acids Res Symp Ser 215-23, Horn T et al (1980) Nuc Acids Res Symp Ser 225-232).

REGULATORY SEQUENCES

20

45

[0184] Preferably, the polynucleotide of the present invention is operably linked to a regulatory sequence which is capable of providing for the expression of the coding sequence, such as by the chosen host cell. By way of example, the present invention covers a vector comprising the polynucleotide of the present invention operably linked to such a regulatory sequence, i.e. the vector is an expression vector.

[0185] The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.

[0186] The term "regulatory sequences" includes promoters and enhancers and other expression regulation signals.

[0187] The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site.

[0188] Enhanced expression of the polynucleotide encoding the polypeptide of the present invention may also be achieved by the selection of heterologous regulatory regions, e.g. promoter, secretion leader and terminator regions, which serve to increase expression and, if desired, secretion levels of the protein of interest from the chosen expression host and/or to provide for the inducible control of the expression of the polypeptide of the present invention

[0189] Preferably, the nucleotide sequence of the present invention may be operably linked to at least a promoter.

[0190] Aside from the promoter native to the gene encoding the polypeptide of the present invention, other promoters may be used to direct expression of the polypeptide of the present invention. The promoter may be selected for its efficiency in directing the expression of the polypeptide of the present invention in the desired expression host.

[0191] In another embodiment, a constitutive promoter may be selected to direct the expression of the desired polypeptide of the present invention. Such an expression construct may provide additional advantages since it circumvents the need to culture the expression hosts on a medium containing an inducing substrate.

[0192] Examples of strong constitutive and/or inducible promoters which are preferred for use in fungal expression hosts are those which are obtainable from the fungal genes for xylanase (xlnA), phytase, ATP-synthetase, subunit 9 (oliC), triose phosphate isomerase (tpi), alcohol dehydrogenase (AdhA), α-amylase (amy), amyloglucosidase (AG-from the glaA gene), acetamidase (amoS) and glyceraldehyde-3-phosphate dehydrogenase (gpd) promoters.

[0193] Examples of strong yeast promoters are those obtainable from the genes for alcohol dehydrogenase, lactase, 3-phosphoglycerate kinase and triosephosphate isomerase.

[0194] Examples of strong bacterial promoters are the α -amylase and SP02 promoters as well as promoters from extracellular protease genes.

[0195] Hybrid promoters may also be used to improve inducible regulation of the expression construct.

[0196] The promoter can additionally include features to ensure or to increase expression in a suitable host. For example, the features can be conserved regions such as a Pribnow Box or a TATA box. The promoter may even contain other sequences to affect (such as to maintain, enhance, decrease) the levels of expression of the nucleotide sequence of the present invention. For example, suitable other sequences include the Sh1-intron or an ADH intron. Other sequences include inducible elements - such as temperature, chemical, light or stress inducible elements. Also, suitable elements to enhance transcription or translation may be present. An example of the latter element is the TMV 5' signal sequence (see Sleat Gene 217 [1987] 217-225; and Dawson Plant Mol. Biol. 23 [1993] 97).

SECRETION

[0197] Often, it is desirable for the polypeptide of the present invention to be secreted from the expression host into the culture medium from where the polypeptide of the present invention may be more easily recovered. According to the present invention, the secretion leader sequence may be selected on the basis of the desired expression host. Hybrid signal sequences may also be used with the context of the present invention.

[0198] Typical examples of N ologous secretion leader sequences are those original cosidase (AG) gene (glaA - both 18 and 24 amino acid versions e.g. from Aspergillus), the α-factor gene (yeasts e.g. Saccharomyces and Kluyveromyces) or the α -amylase gene (Bacillus).

CONSTRUCTS

10

20

25

30

35

40

[0199] The term "construct" - which is synonymous with terms such as "conjugate", "cassette" and "hybrid" - includes the nucleotide sequence according to the present invention directly or indirectly attached to a promoter. An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Shl-intron or the ADH intron, intermediate the promoter and the nucleotide sequence of the present invention. The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. In each case, the terms do not cover the natural combination of the nucleotide sequence coding for the protein ordinarily associated with the wild type gene promoter and when they are both in their natural environment.

[0200] The construct may even contain or express a marker which allows for the selection of the genetic construct in, for example, a bacterium, preferably of the genus Bacillus, such as Bacillus subtilis, or plants, such as potatoes, sugar beet etc., into which it has been transferred. Various markers exist which may be used, such as for example those encoding mannose-6-phosphate isomerase (especially for plants) or those markers that provide for antibiotic resistance - e.g. resistance to G418, hygromycin, bleomycin, kanamycin and gentamycin.

[0201] Preferably the construct of the present invention comprises at least the nucleotide sequence of the present invention operably linked to a promoter.

VECTORS

[0202] The term "vector" includes expression vectors and transformation vectors and shuttle vectors.

[0203] The term "expression vector" means a construct capable of in vivo or in vitro expression.

[0204] The term "transformation vector" means a construct capable of being transferred from one entity to another entity - which may be of the species or may be of a different species. If the construct is capable of being transferred from one species to another - such as from an E.coli plasmid to a bacterium, such as of the genus Bacillus, then the transformation vector is sometimes called a "shuttle vector". It may even be a construct capable of being transferred from an E. coli plasmid to an Agrobacterium to a plant.

[0205] The vectors of the present invention may be transformed into a suitable host cell as described below to provide for expression of a polypeptide of the present invention. Thus, in a further aspect the invention provides a process for preparing polypeptides according to the present invention which comprises cultivating a host cell transformed or transfected with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the polypeptides, and recovering the expressed polypeptides.

[0206] The vectors may be for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter.

[0207] The vectors of the present invention may contain one or more selectable marker genes. The most suitable selection systems for industrial micro-organisms are those formed by the group of selection markers which do not require a mutation in the host organism. Examples of fungal selection markers are the genes for acetamidase (amoS), ATP synthetase, subunit 9 (oliC), orotidine-5'-phosphate-decarboxylase (pvrA), phleomycin and benomyl resistance (benA). Examples of non-fungal selection markers are the bacterial G418 resistance gene (this may also be used in yeast, but not in filamentous fungi), the ampicillin resistance gene (E. coli), the neomycin resistance gene (Bacillus) and the E.coli uidA gene, coding for β-glucuronidase (GUS).

Vectors may be used in vitro, for example for the production of RNA or used to transfect or transform a host cell. [0209] Thus, polynucleotides of the present invention can be incorporated into a recombinant vector (typically a replicable vector), for example a cloning or expression vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making polynucleotides of the present invention by introducing a polynucleotide of the present invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells are described below in connection with expression

[0210] The present invention also relates to the use of genetically engineered host cells expressing a PDE11 or variant, homologue, fragment or derivative thereof in screening methods for the identification of inhibitors and antagonists of the PDE11 that would modulate phosphodiesterase activity thereby modulating cyclic nucleotide levels. Such genetically engineered host cells could be used to screen peptide libraries or organic molecules capable of modulating PDE11 activity. Antagonists and inhibitors of PDE11, such as antibodies, peptides or small organic molecules will provide the basis for pharmaceutical compositions for the treatment of diseases associated with, for example, male

erectile dysfunction. Such hibitors or antagonists can be administered alone combination with other therapeutics for the treatment of such diseases.

[0211] The present invention also relates to expression vectors and host cells comprising polynucleotide sequences encoding PDE11 or variant, homologue, fragment or derivative thereof for the *in vivo* or *in vitro* production of PDE11 protein or to screen for agents that can affect PDE11 expression or activity.

TISSUE

5

10

15

25

[0212] The term "tissue" as used herein includes tissue per se and organ.

HOST CELLS

[0213] The term "host cell" - in relation to the present invention includes any cell that could comprise the nucleotide sequence coding for the recombinant protein according to the present invention and/or products obtained therefrom, wherein a promoter can allow expression of the nucleotide sequence according to the present invention when present in the host cell.

[0214] Thus, a further embodiment of the present invention provides host cells transformed or transfected with a polynucleotide of the present invention. Preferably said polynucleotide is carried in a vector for the replication and expression of said polynucleotides. The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), fungal, yeast or plant cells.

[0215] The gram-negative bacterium *E. coli* is widely used as a host for heterologous gene expression. However, large amounts of heterologous protein tend to accumulate inside the cell. Subsequent purification of the desired protein from the bulk of *E.coli* intracellular proteins can sometimes be difficult.

[0216] In contrast to *E.coli*, bacteria from the genus *Bacillus* are very suitable as heterologous hosts because of their capability to secrete proteins into the culture medium. Other bacteria suitable as hosts are those from the genera *Streptomyces* and *Pseudomonas*.

[0217] Depending on the nature of the polynucleotide encoding the polypeptide of the present invention, and/or the desirability for further processing of the expressed protein, eukaryotic hosts such as yeasts or other fungi may be preferred. In general, yeast cells are preferred over fungal cells because they are easier to manipulate. However, some proteins are either poorly secreted from the yeast cell, or in some cases are not processed properly (e.g. hyperglycosylation in yeast). In these instances, a different fungal host organism should be selected.

[0218] Examples of suitable expression hosts within the scope of the present invention are fungi such as Aspergillus species (such as those described in EP-A-0184438 and EP-A-0284603) and Trichoderma species; bacteria such as Bacillus species (such as those described in EP-A-0134048 and EP-A-0253455), Streptomyces species and Pseudomonas species; and yeasts such as Kluyveromyces species (such as those described in EP-A-0096430 and EP-A-0301670) and Saccharomyces species. By way of example, typical expression hosts may be selected from Aspergillus niger, Aspergillus niger var. tubigenis, Aspergillus niger var. awamori, Aspergillus aculeatis, Aspergillus nidulans, Aspergillus orvzae, Trichoderma reesei, Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Kluyveromyces lactis and Saccharomyces cerevisiae.

[0219] The use of suitable host cells - such as yeast, fungal and plant host cells - may provide for post-translational modifications (e.g. myristoylation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the present invention.

ORGANISM

45

50

[0220] The term "organism" in relation to the present invention includes any organism that could comprise the nucleotide sequence coding for the recombinant protein according to the present invention and/or products obtained therefrom, wherein a promoter can allow expression of the nucleotide sequence according to the present invention when present in the organism. Examples of organisms may include a fungus, yeast or a plant.

[0221] The term "transgenic organism" in relation to the present invention includes any organism that comprises the nucleotide sequence coding for the protein according to the present invention and/or products obtained therefrom, wherein the promoter can allow expression of the nucleotide sequence according to the present invention within the organism. Preferably the nucleotide sequence is incorporated in the genome of the organism.

[0222] The term "transgenic organism" does not cover the native nucleotide coding sequence according to the present invention in its natural environment when it is under the control of its native promoter which is also in its natural environment. In addition, the present invention does not cover the native protein according to the present invention when it is in its natural environment and when it has been expressed by its native nucleotide coding sequence which is also in its natural environment and when that nucleotide sequence is under the control of its native promoter which

is also in its natural environme

10

20

25

30

[0223] Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, the nucleotide sequence coding for the amino acid sequence according to the present invention, constructs according to the present invention (including combinations thereof), vectors according to the present invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention or the products thereof. The transformed cell or organism could prepare acceptable quantities of the desired compound which would be easily retrievable from, the cell or organism.

TRANSFORMATION OF HOST CELLS/HOST ORGANISMS

[0224] As indicated earlier, the host organism can be a prokaryotic or a eukaryotic organism. Examples of suitable prokaryotic hosts include *E. coli* and *Bacillus subtilis*. Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press) and Ausubel *et al.*, Current Protocols in Molecular Biology (1995), John Wiley & Sons, Inc.

[0225] If a prokaryotic host is used then the nucleotide sequence may need to be suitably modified before transformation - such as by removal of introns.

[0226] In another embodiment the transgenic organism can be a yeast. In this regard, yeast have also been widely used as a vehicle for heterologous gene expression. The species Saccharomyces cerevisiae has a long history of industrial use, including its use for heterologous gene expression. Expression of heterologous genes in Saccharomyces cerevisiae has been reviewed by Goodey et al (1987, Yeast Biotechnology, D R Berry et al, eds, pp 401-429, Allen and Unwin, London) and by King et al (1989, Molecular and Cell Biology of Yeasts, E F Walton and G T Yarronton, eds, pp 107-133, Blackie, Glasgow).

[0227] For several reasons Saccharomyces cerevisiae is well suited for heterologous gene expression. First, it is non-pathogenic to humans and it is incapable of producing certain endotoxins. Second, it has a long history of safe use following centuries of commercial exploitation for various purposes. This has led to wide public acceptability. Third, the extensive commercial use and research devoted to the organism has resulted in a wealth of knowledge about the genetics and physiology as well as large-scale fermentation characteristics of Saccharomyces cerevisiae.

[0228] A review of the principles of heterologous gene expression in Saccharomyces cerevisiae and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes", Yeasts, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).

[0229] Several types of yeast vectors are available, including integrative vectors, which require recombination with the host genome for their maintenance, and autonomously replicating plasmid vectors.

[0230] In order to prepare the transgenic Saccharomyces, expression constructs are prepared by inserting the nucleotide sequence of the present invention into a construct designed for expression in yeast. Several types of constructs used for heterologous expression have been developed. The constructs contain a promoter active in yeast fused to the nucleotide sequence of the present invention, usually a promoter of yeast origin, such as the GAL1 promoter, is used. Usually a signal sequence of yeast origin, such as the sequence encoding the SUC2 signal peptide, is used. A terminator active in yeast ends the expression system.

[0231] For the transformation of yeast several transformation protocols have been developed. For example, a transgenic Saccharomyces according to the present invention can be prepared by following the teachings of Hinnen et al (1978, Proceedings of the National Academy of Sciences of the USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H et al (1983, J Bacteriology 153, 163-168).

[0232] The transformed yeast cells are selected using various selective markers. Among the markers used for transformation are a number of auxotrophic markers such as LEU2, HIS4 and TRP1, and dominant antibiotic resistance markers such as aminoglycoside antibiotic markers, eg G418.

[0233] Another host organism is a plant. The basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material.

[0234] Several techniques exist for inserting the genetic information, the two main principles being direct introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27). Further teachings on plant transformation may be found in EP-

[0235] Thus, the present invention also provides a method of transforming a host cell with a nucleotide sequence shown as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or a derivative, homologue, variant or fragment thereof.

[0236] Host cells transformed with a PDE nucleotide coding sequence may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell may

be secreted or may be called intracellularly depending on the sequence at the vector used. As will be understood by those of skill in the art, expression vectors containing PDE coding sequences can be designed with signal sequences which direct secretion of PDE coding sequences through a particular prokaryotic or eukaryotic cell membrane. Other recombinant constructions may join PDE coding sequence to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins (Kroll *DJ et al* (1993) DNA Cell Biol 12:441-53, see also above discussion of vectors containing fusion proteins).

PRODUCTION OF THE POLYPEPTIDE

[0237] According to the present invention, the production of the polypeptide of the present invention can be effected by the culturing of, for example, microbial expression hosts, which have been transformed with one or more polynucleotides of the present invention, in a conventional nutrient fermentation medium. The selection of the appropriate medium may be based on the choice of expression hosts and/or based on the regulatory requirements of the expression construct. Such media are well-known to those skilled in the art. The medium may, if desired, contain additional components favouring the transformed expression hosts over other potentially contaminating microorganisms.

[0238] Thus, the present invention also provides a method for producing a polypeptide having PDE11 activity, the method comprising the steps of a) transforming a host cell with a nucleotide sequence shown as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or a derivative, homologue, variant or fragment thereof; and b) culturing the transformed host cell under conditions suitable for the expression of said polypeptide.

[0239] The present invention also provides a method for producing a polypeptide having PDE11 activity, the method comprising the steps of a) culturing a host cell that has been transformed with a nucleotide sequence shown as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or a derivative, homologue, variant or fragment thereof under conditions suitable for the expression of said polypeptide; and b) recovering said polypeptide from the host cell culture.

[0240] The present invention also provides a method for producing a polypeptide having PDE11 activity, the method comprising the steps of a) transforming a host cell with a nucleotide sequence shown as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or a derivative, homologue, variant or fragment thereof; b) culturing the transformed host cell under conditions suitable for the expression of said polypeptide; and c) recovering said polypeptide from the host cell culture.

RIBOZYMES

20

25

30

50

[0241] Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by a endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of PDE RNA sequences.

[0242] Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide sequence inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

[0243] Both antisense RNA and DNA molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* or *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells or tissues.

DETECTION

[0244] The presence of the PDE polynucleotide coding sequence can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes, portions or fragments of the sequence presented as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the PDE coding sequence to detect transformants containing PDE DNA or RNA. As used herein "oligonucleotides" or "oligomers" may refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about

20-25 nucleotides which can seed as a probe or amplimer. Preferably, oligonucles es are derived from the 3' region of the nucleotide sequence shown as SEQ ID No: 1 or SEQ ID No: 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18.

[0245] A variety of protocols for detecting and measuring the expression of PDE polypeptide, such as by using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on PDE polypeptides is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton R et al (1990, Serological Methods, A Laboratory Manual, APS Press, St Paul MN) and Maddox DE et al (1983, J Exp Med 15 8:121 1).

[0246] A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic and amino acid assays. Means for producing labelled hybridization or PCR probes for detecting PDE polynucleotide sequences include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled nucleotide. Alternatively, the PDE coding sequence, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides. [0247] A number of companies such as Pharmacia Biotech (Piscataway, NJ), Promega (Madison, WI), and US Biochemical Corp (Cleveland, OH) supply commercial kits and protocols for these procedures. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include

US-A-3,817,837; US-A-3,850,752; US-A-3,939,350; US-A-3,996,345; US-A-4,277,437; US-A-4,275,149 and US-A-4,366,241. Also, recombinant immunoglobulins may be produced as shown in US-A-4,816,567.

[0248] Additional methods to quantitate the expression of a particular molecule include radiolabeling (Melby PC et al 1993 J Immunol Methods 159:235-44) or biotinylating (Duplaa C et al 1993 Anal Biochem 229-36) nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated. Quantitation of multiple samples may be speeded up by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or calorimetric response gives rapid quantitation.

[0249] Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression should be confirmed. For example, if the PDE coding sequence is inserted within a marker gene sequence, recombinant cells containing PDE coding regions can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a PDE coding sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of PDE as well.

[0250] Alternatively, host cells which contain the coding sequence for PDE and express PDE coding regions may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane-based, solution-based, or chip-based technologies for the detection and/or quantification of the nucleic acid or protein.

ANTIBODIES

40

10

15

20

[0251] The amino acid sequence of the present invention can also be used to generate antibodies - such as by use of standard techniques - against the amino acid sequence.

[0252] Procedures well known in the art may be used for the production of antibodies to PDE11 polypeptides. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by a Fab expression library. Neutralizing antibodies, i.e., those which inhibit biological activity of PDE polypeptides, are especially preferred for diagnostics and therapeutics.

[0253] For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc. may be immunized by injection with the inhibitor or any portion, variant, homologue, fragment or derivative thereof or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminium hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (Bacilli Calmette-Guerin) and Corynebacterium parvum are potentially useful human adjuvants which may be employed.

[0254] Monoclonal antibodies to the amino acid sequence may be even prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique originally described by Koehler and Milstein (1975 Nature 256:495-497), the human B-cell hybridoma technique (Kosbor et al (1983) Immunol Today 4:72; Cote et al (1983) Proc Natl Acad Sci 80:2026-2030) and the EBV-hybridoma technique (Cole et al (1985) Monoclonal Antibodies and Cancer Therapy, Alan R Liss Inc, pp

77-96). In addition, the sques developed for the production of "chimeric anthouses", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison et al (1984) Proc Natl Acad Sci 81:6851-6855; Neuberger et al (1984) Nature 312:604-608; Takeda et al (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies (USA-4946779) can be adapted to produce inhibitor specific single chain antibodies.

[0255] Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi *et al* (1989, Proc Natl Acad Sci 86: 3833-3837), and Winter G and Milstein C (1991; Nature 349:293-299).

[0256] Antibody fragments which contain specific binding sites for PDE11 may also be generated. For example, such fragments include, but are not limited to, the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse WD *et al* (1989) Science 256:1275-128 1).

[0257] PDE11-specific antibodies are useful for the diagnosis of conditions and diseases associated with expression of PDE11 polypeptide. A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the formation of complexes between PDE11 polypeptides and its specific antibody (or similar PDE11-binding molecule) and the measurement of complex formation. A two-site, monoclonal based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific PDE11 protein is preferred, but a competitive binding assay may also be employed. These assays are described in Maddox DE et al (1983, J Exp Med 158:121 1). [0258] Anti-PDE11 antibodies are useful for the diagnosis of inflammation, conditions associated with proliferation of hematopoietic cells and HIV infection or other disorders or diseases characterized by abnormal expression of a PDE11. Diagnostic assays for a PDE11 include methods utilizing the antibody and a label to detect a PDE11 polypeptide in human body fluids, cells, tissues or sections or extracts of such tissues. The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter molecules are known to those of skill in the art.

ASSAYS/IDENTIFICATION METHODS

20

25

30

[0259] The present invention also relates to an assay method for detecting the presence of PDE11 in cells (such as human cells) comprising: (a) performing a reverse transcriptase-polymerase chain reaction on RNA (such as total RNA) from such cells using a pair of polymerase chain reaction primers that are specific for PDE11, as determined from the DNA sequence of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or an allelic variation thereof; and (b) assaying the appearance of an appropriately sized PCR (polymerase chain reaction) fragment - such as by agarose gel electrophoresis.

[0260] The present invention also relates to a method of identifying agents (such as compounds, other substances or compositions comprising same) that affect (such as inhibit or otherwise modify) the activity of PDE11 and/or the expression thereof, the method comprising contacting PDE11 or the nucleotide sequence coding for same with the agent and then measuring the activity of PDE11 and/or the expression thereof.

[0261] The present invention also relates to a method of identifying agents (such as compounds, other substances or compositions comprising same) that selectively affect (such as inhibit or otherwise modify) the activity of PDE11 and/or the expression thereof, the method comprising contacting PDE11 or the nucleotide sequence coding for same with the agent and then measuring the activity of PDE11 and/or the expression thereof.

[0262] The present invention also relates to a method of identifying agents (such as compounds, other substances or compositions comprising same) that selectively affect (such as inhibit or otherwise modify) the activity of PDE11A1 or PDE11A2 or PDE11A3 or PDE11A4 and/or the expression thereof, the method comprising contacting the relevant PDE11 or the nucleotide sequence coding for same with the agent and then measuring the activity of the relevant PDE11 and/or the expression thereof.

[0263] The present invention also relates to a method of identifying agents (such as compounds, other substances or compositions comprising same) that affect (such as inhibit or otherwise modify) the activity of PDE11 and/or the expression thereof, the method comprising measuring the activity of PDE11 and/or the expression thereof in the presence of the agent or after the addition of the agent in: (a) a cell line into which has been incorporated recombinant DNA comprising the DNA sequence of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or an allelic variation thereof, or (b) a cell population or cell line that naturally selectively expresses PDE11. Preferably, the activity of PDE11 is determined by the assay method described above.

[0264] The present invention also relates to a method of identifying agents (such as compounds, other substances or compositions comprising same) that selectively affect (such as inhibit or otherwise modify) the activity of PDE11

and/or the expression thereof, we method comprising measuring the activity of PDE1 who the expression thereof in the presence of the agent or after the addition of the agent in: (a) a cell line into which has been incorporated recombinant DNA comprising the DNA sequence of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or an allelic variation thereof, or (b) a cell population or cell line that naturally selectively expresses PDE11. Preferably, the activity of PDE11 is determined by the assay method described above.

[0265] The present invention also relates to a method of identifying agents (such as compounds, other substances or compositions comprising same) that selectively affect (such as inhibit or otherwise modify) the activity of PDE11A1 or PDE11A2 or PDE11A3 or PDE11A4 and/or the expression thereof, the method comprising measuring the activity of the respective PDE11 and/or the expression thereof in the presence of the agent or after the addition of the agent in: (a) a cell line into which has been incorporated recombinant DNA comprising the respective DNA sequence of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or an allelic variation thereof, or (b) a cell population or cell line that naturally selectively expresses the respective PDE11. Preferably, the activity of PDE11 is determined by the assay method described above.

[0266] The present invention also provides a method of screening an agent for modulation (preferably for specific modulation) of PDE11 (or a derivative, homologue, variant or fragment thereof) activity or the expression of the nucleotide sequence coding for same (including a derivative, homologue, variant or fragment thereof), the method comprising the steps of: a) providing a candidate agent; b) combining PDE11 (or the derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof) with the candidate agent for a time sufficient to allow modulation under suitable conditions; and c) detecting modulation of the candidate agent to PDE11 (or the derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof) activity or the expression of the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof).

[0267] The present invention also provides a method of screening an agent for specific binding affinity with PDE11 (or a derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (including a derivative, homologue, variant or fragment thereof), the method comprising the steps of: a) providing a candidate agent; b) combining PDE11 (or the derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof) with the candidate agent for a time sufficient to allow binding under suitable conditions; and c) detecting binding of the candidate agent to PDE11 (or the derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof) in order to ascertain if the candidate agent binds to PDE11 (or the derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof).

[0268] The present invention also provides a method of identifying an agent which is capable of modulating PDE11, the method comprising the steps of: a) contacting the agent with PDE11 (or a derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof), b) incubating the mixture of step a) with a cyclic nucleotide under conditions suitable for the hydrolysis of the cyclic nucleotide, c) measuring the amount of cyclic nucleotide hydrolysis, and d) comparing the amount of cyclic nucleotide hydrolysis of step c) with the amount of cyclic nucleotide hydrolysis obtained with PDE11 (or the derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof) incubated without the compound, thereby determining whether the agent affects (such as stimulates or inhibits) cyclic nucleotide hydrolysis.

[0269] Thus, in certain embodiments of the present invention, PDE11 or a variant, homologue, fragment or derivative thereof and/or a cell line that expresses the PDE11 or variant, homologue, fragment or derivative thereof may be used to screen for antibodies, peptides, or other agent, such as organic or inorganic molecules, that act as modulators of phosphodiesterase activity or for the expression thereof, thereby identifying a therapeutic agent capable of modulating cyclic nucleotide levels. For example, anti-PDE11 antibodies capable of neutralizing the activity of PDE11 may be used to inhibit PDE11 hydrolysis of cyclic nucleotides, thereby increasing their levels. Alternatively, screening of peptide libraries or organic libraries made by combinatorial chemistry with recombinantly expressed PDE11 or a variant, homologue, fragment or derivative thereof or cell lines expressing PDE11 or a variant, homologue, fragment or derivative thereof may be useful for identification of therapeutic agents that function by modulating PDE11 hydrolysis of cyclic nucleotides. Synthetic compounds, natural products, and other sources of potentially biologically active materials can be screened in a number of ways deemed to be routine to those of skill in the art. For example, nucleotide sequences encoding the N-terminal region of PDE11 may be expressed in a cell line which can be used for screening of allosteric modulators, either agonists or antagonists, of PDE11 activity. Alternatively, nucleotide sequences encoding the conserved catalytic domain of PDE11 can be expressed in cell lines and used to screen for inhibitors of cyclic nucleotide hydrolysis.

[0270] The ability of a test agent to interfere with PDE11 activity or cyclic nucleotide hydrolysis may be determined

by measuring PDE11 or cyclic nucleotide levels (as disclosed in Smith 1993 Appl. Biochem. Biotechnol. 41:189-218). There are also commercially available immunoassay kits for the measurement of cAMP and cGMP (eg Amersham International, Arlington Heights, IL and DuPont, Boston, MA). The activity of PDE11 may also be monitored by measuring other responses such as phosphorylation or dephosphorylation of other proteins using conventional techniques developed for these purpose.

[0271] Accordingly, the present invention provides a method of identifying a compound which is capable of modulating the cyclic nucleotide phosphodiesterase activity of a PDE11, or a variant, homologue, fragment or derivative thereof, comprising the steps of a) contacting the compound with a PDE11, or a variant, homologue, fragment or derivative thereof; b) incubating the mixture of step a) with a cyclic nucleotide under conditions suitable for the hydrolysis of the cyclic nucleotide; c) measuring the amount of cyclic nucleotide hydrolysis; and d) comparing the amount of cyclic nucleotide hydrolysis obtained with the PDE11, or a variant, homologue, fragment or derivative thereof, incubated without the compound, thereby determining whether the compound stimulates or inhibits cyclic nucleotide hydrolysis. In one embodiment of the method, the fragment may be from the N-terminal region of the PDE11 and provides a method to identify allosteric modulators of the PDE11 and provides a method to identify inhibitors of cyclic nucleotide hydrolysis.

[0272] A PDE11 polypeptide, its immunogenic fragments or oligopeptides thereof can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The polypeptide employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The abolition of activity or the formation of binding complexes between a PDE11 polypeptide and the agent being tested may be measured.

[0273] Accordingly, the present invention provides a method for screening one or a plurality of compounds for modulation (preferably specific modulation, such as specific binding affinity) of PDE11 or the expression thereof, or a portion thereof or variant, homologue, fragment or derivative thereof, comprising providing one or a plurality of compounds; combining a PDE11 or a nucleotide sequence coding for same or a portion thereof or variant, homologue, fragment or derivative thereof with the or each of a plurality of compounds for a time sufficient to allow modulation under suitable conditions; and detecting binding of a PDE11, or portion thereof or variant, homologue, fragment or derivative thereof, to each of the plurality of compounds, thereby identifying the compound or compounds which modulate a PDE11 or a nucleotide sequence coding for same. In such an assay, the plurality of compounds may be produced by combinatorial chemistry techniques known to those of skill in the art.

[0274] Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the PDE11 polypeptides and is based upon the method described in detail in Geysen, European Patent Application 84/03564, published on September 13, 1984. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with PDE11 fragments and washed. A bound PDE11 is then detected - such as by appropriately adapting methods well known in the art. A purified PDE11 can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

[0275] This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding a PDE11 specifically compete with a test compound for binding a PDE11. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with a PDE11.

AGENTS

20

25

40

[0276] The present invention also provides one or more agents indentified by the assays methods and identification methods of the present invention.

[0277] The agent of the present invention can be, for example, an organic compound or an inorganic compound. The agent can be, for example, a nucleotide sequence that is anti-sense to all or part of the sequence shown as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18.

[0278] The invention further provides an agent of the present invention (or even a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof) or a pharmaceutical composition containing any of the foregoing, for use as a medicament.

[0279] The present invention also provides the use of an agent to affect PDE11 activity (such as to inhibit, modulate or agonise) in the stratum of the brain.

DIAGNOSTICS

[0280] The present invention also provides a diagnostic composition for the detection of PDE11 polynucleotide se-

quences. The diagnostic composition may comprise the polynucleotide SEQ ID No. 1 & EQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or a variant, homologue, fragment or derivative thereof, or a sequence capable of hybridising to all or part of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18 or an allelic variation thereof.

[0281] In order to provide a basis for the diagnosis of disease, normal or standard values from a PDE11 polypeptide expression must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with antibody to a PDE11 polypeptide under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by comparing it to a dilution series of positive controls where a known amount of antibody is combined with known concentrations of a purified PDE11 polypeptide. Then, standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by a disorder or disease related to a PDE11 polypeptide expression. Deviation between standard and subject values establishes the presence of the disease state.

[0282] A PDE11 polynucleotide, or any part thereof, may provide the basis for a diagnostic and/or a therapeutic compound. For diagnostic purposes, PDE11 polynucleotide sequences may be used to detect and quantitate gene expression in conditions, disorders or diseases in which PDE11 activity may be implicated, for example, in male erectile dysfunction.

[0283] A PDE11 encoding polynucleotide sequence may be used for the diagnosis of diseases resulting from expression of PDE11. For example, polynucleotide sequences encoding PDE11 may be used in hybridization or PCR assays of tissues from biopsies or autopsies or biological fluids, such as serum, synovial fluid or tumor biopsy, to detect abnormalities in PDE11 expression. The form of such qualitative or quantitative methods may include Southem or northern analysis, dot blot or other membrane-based technologies; PCR technologies; dip stick, pin or chip technologies; and ELISA or other multiple sample formal technologies. All of these techniques are well known in the art and are in fact the basis of many commercially available diagnostic kits.

[0284] Such assays may be tailored to evaluate the efficacy of a particular therapeutic treatment regime and may be used in animal studies, in clinical trials, or in monitoring the treatment of an individual patient. In order to provide a basis for the diagnosis of disease, a normal or standard profile for PDE expression must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with PDE11 or a portion thereof, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained for normal subjects with a dilution series of positive controls run in the same experiment where a known amount of purified PDE11 is used. Standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by a disorder or disease related to expression of the PDE coding sequence. Deviation between standard and subject values establishes the presence of the disease state. If disease is established, an existing therapeutic agent is administered, and treatment profile or values may be generated. Finally, the assay may be repeated on a regular basis to evaluate whether the values progress toward or return to the normal or standard pattern. Successive treatment profiles may be used to show the efficacy of treatment over a period of several days or several months.

[0285] Thus, the present invention relates to the use of a PDE11 polypeptide, or variant, homologue, fragment or derivative thereof, to produce anti-PDE11 antibodies which can, for example, be used diagnostically to detect and quantitate PDE11 levels in disease states.


[0286] The present invention further provides diagnostic assays and kits for the detection of PDE11 in cells and tissues comprising a purified PDE11 which may be used as a positive control, and anti-PDE11 antibodies. Such antibodies may be used in solution-based, membrane-based, or tissue-based technologies to detect any disease state or condition related to the expression of PDE11 protein or expression of deletions or a variant, homologue, fragment or derivative thereof.

PROBES

45

[0287] Another aspect of the subject invention is the provision of nucleic acid hybridization or PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding PDE coding region or closely related molecules, such as alleles. The specificity of the probe, i.e., whether it is derived from a highly conserved, conserved or non-conserved region or domain, and the stringency of the hybridization or amplification (high, intermediate or low) will determine whether the probe identifies only naturally occurring PDE coding sequence, or related sequences. Probes for the detection of related nucleic acid sequences are selected from conserved or highly conserved nucleotide regions of cyclic nucleotide PDE family members, such as the 3' region, and such probes may be used in a pool of degenerate probes. For the detection of identical nucleic acid sequences, or where maximum specificity is desired, nucleic acid probes are selected from the non-conserved nucleotide regions or unique regions of PDE polynucleotides. As used herein, the term "non-conserved nucleotide region" refers to a nucleotide region that is unique to the PDE coding sequence disclosed herein and does not occur in related family members, such as known cyclic

nucleotide PDEs.



[0289] The nucleic acid sequence for PDE11 can also be used to generate hybridization probes as previously described, for mapping the endogenous genomic sequence. The sequence may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include in situ hybridization to chromosomal spreads (Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York City), flow-sorted chromosomal preparations, or artificial chromosome constructions such as YACs, bacterial artificial chromosomes (BACs), bacterial PI constructions or single chromosome cDNA libraries.

[0290] In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers are invaluable in extending genetic maps. Examples of genetic maps can be found in Science (1995; 270:410f and 1994; 265:1981f). Often the placement of a gene on the chromosome of another mammalian species may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome, such as ataxia telangiectasia (AT), has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 1lq22-23 (Gatti et al (1988) Nature 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc between normal, carrier or affected individuals.

PHARMACEUTICALS

20

25

45

[0291] The present invention also provides a pharmaceutical composition for treating an individual in need of same due to PDE11 activity, the composition comprising a therapeutically effective amount of an agent that affects (such as inhibits) said activity and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

[0292] Thus, the present invention also covers pharmaceutical compositions comprising the agents of the present invention (an agent capable of modulating the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof and/or an agent identified by an assay according to the present invention). In this regard, and in particular for human therapy, even though the agents of the present invention can be administered alone, they will generally be administered in admixture with a pharmaceutical carrier, excipient or diluent selected with regard to the intended route of administration and standard pharmaceutical practice.

[0293] By way of example, in the pharmaceutical compositions of the present invention, the agents of the present invention may be admixed with any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), or solubilising agent(s).

[0294] In general, a therapeutically effective daily oral or intravenous dose of the agents of the present invention is likely to range from 0.01 to 50 mg/kg body weight of the subject to be treated, preferably 0.1 to 20 mg/kg. The agents of the present invention may also be administered by intravenous infusion, at a dose which is likely to range from 0.001-10 mg/kg/hr.

[0295] Tablets or capsules of the agents may be administered singly or two or more at a time, as appropriate. It is also possible to administer the agents of the present invention in sustained release formulations.

[0296] Thus, the present invention also provides a method of treating an individual in need of same due to PDE11 activity comprising administering to said individual an effective amount of the pharmaceutical composition of the present invention.

[0297] Typically, the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

[0298] Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously.

For parenteral administration, the compositions may be best used in the form of a sterile queous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

[0299] For some applications, preferably the compositions are administered orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents.

[0300] For parenteral administration, the compositions are best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood.

[0301] For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

[0302] For oral, parenteral, buccal and sublingual administration to subjects (such as patients), the daily dosage level of the agents of the present invention may typically be from 10 to 500 mg (in single or divided doses). Thus, and by way of example, tablets or capsules may contain from 5 to 100 mg of active agent for administration singly, or two or more at a time, as appropriate. As indicated above, the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. It is to be noted that whilst the above-mentioned dosages are exemplary of the average case there can, of course, be individual instances where higher or lower dosage ranges are merited and such dose ranges are within the scope of this invention.

20 [0303] Generally, in humans, oral administration of the agents of the present invention is the preferred route, being the most convenient and, for example in male erectile dysfunction (MED), avoiding the well-known disadvantages associated with intracavernosal (i.c.) administration. A preferred oral dosing regimen in MED for a typical man is from 25 to 100 mg of agent when required. In circumstances where the recipient suffers from a swallowing disorder or from impairment of drug absorption after oral administration, the drug may be administered parenterally, e.g. sublingually or buccally.

[0304] For veterinary use, the agent of the present invention is typically administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and route of administration which will be most appropriate for a particular animal. However, as with human treatment, it may be possible to administer the agent alone for veterinary treatments.

[0305] Typically, the pharmaceutical compositions - which may be for human or animal usage - will comprise any one or more of a pharmaceutically acceptable diluent, carrier, excipient or adjuvant. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. As indicated above, the pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).

[0306] In some embodiments of the present invention, the pharmaceutical compositions will comprise one or more of: an agent that has been screened by an assay of the present invention; an agent that is capable of interacting with any one or more of SEQ ID No. 1, SEQ ID No 2, SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 14 or SEQ ID No. 15 or SEQ ID No. 16 or SEQ ID No. 17 or SEQ ID No. 18 or SEQ ID No. 19 including derivatives, fragments, homologues or variants thereof or sequences capable of hybridising to SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14 or SEQ ID No. 16 or SEQ ID No. 18.

[0307] Included in the scope of the invention are oligonucleotide sequences, antisense RNA and DNA molecules and ribozymes, which function to destabilize PDE11 mRNA or inhibit translation of a PDE11. Such nucleotide sequences may be used in conditions where it would be preferable to increase cyclic nucleotide levels, such as in inflammation.

[0308] A PDE11 antisense molecule may provide the basis for treatment of various abnormal conditions related to, for example, increased PDE11 activity - such as male erectile dysfunction.

[0309] A PDE11 nucleic acid antisense molecule may be used to block the activity of the PDE11 in conditions where it would be preferable to elevate cyclic nucleotide levels.

[0310] Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of recombinant PDE11 sense or antisense molecules to the targeted cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors containing PDE11. Alternatively, recombinant PDE11 can be delivered to target cells in liposomes.

[0311] The full length cDNA sequence and/or its regulatory elements enable researchers to use PDE11 as a tool in sense (Youssoufian H and HF Lodish 1993 Mol Cell Biol 13:98-104) or antisense (Eguchi et al (1991) Annu Rev Biochem 60:631-652) investigations of gene function. Oligonucleotides, designed from the cDNA or control sequences obtained from the genomic DNA can be used in vitro or in vivo to inhibit expression. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions. Appropriate oligonucleotides, which can be 20 nucleotides in length, may be used to isolate PDE 11 sequences or closely related molecules from human libraries.

[0312] Additionally, 1 expression can be modulated by transfecting 2 or tissue with expression vectors which express high levels of a PDE11 fragment in conditions where it would be preferable to block phosphodiesterase activity thereby increasing cyclic nucleotide levels. Such constructs can flood cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies of the vector are disabled by endogenous nucleases. Such transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

[0313] Modifications of gene expression can be obtained by designing antisense sequences to the control regions of the PDE gene, such as the promoters, enhancers, and introns.

[0314] Oligonucleotides derived from the transcription initiation site, e.g., between -10 and +10 regions of the leader sequence, are preferred. Antisense RNA and DNA molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Similarly, inhibition can be achieved using Hogeboom base-pairing methodology, also known as "triple helix" base pairing. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules.

[0315] Thus the invention provides a pharmaceutical composition comprising an agent of the present invention (or even a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof) together with a pharmaceutically acceptable diluent, excipient or carrier.

[0316] The pharmaceutical composition could be for veterinary (i.e. animal) usuage or for human usuage.

[0317] Thus, the present invention therefore also relates to pharmaceutical compositions comprising effective amounts of inhibitors or antagonists of PDE11 protein (including anti-sense nucleic acid sequences) in admixture with a pharmaceutically acceptable diluent, carrier, excipient or adjuvant (including combinations thereof).

[0318] The present invention relates to pharmaceutical compositions which may comprise all or portions of PDE11 polynucleotide sequences, PDE11 antisense molecules, PDE11 polypeptides, protein, peptide or organic modulators of PDE11 bioactivity, such as inhibitors, antagonists (including antibodies) or agonists, alone or in combination with at least one other agent, such as stabilizing compound, and may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.

SUMMARY

20

. 25

35

45

50

55

- 30 [0319] In summary the present invention provides inter alia:
 - 1. Novel amino acids.
 - 2. Novel nucleotide sequences.
 - 3. Assays using said novel sequences.
 - Compounds/compositions identified by use of said assays.
 - 5. Expression systems comprising or expressing said novel sequences.
 - Methods of treatment based on said novel sequences.
 - 7. Pharmaceutical compositions based on said novel sequences.

40 DEPOSITS

[0320] The following samples were deposited in accordance with the Budapest Treaty at the recognised depositary The National Collections of Industrial and Marine Bacteria Limited (NCIMB) at 23 St. Machar Drive, Aberdeen, Scotland, United Kingdom, AB2 1RY on 6 March 1998:

E. coli pPDE11A1	NCIMB number NCIMB 40925
E. coli pPDE11A2	NCIMB number NCIMB 40926

NCIMB 40925 comprises HSPDE11A1.

NCIMB 40926 comprises HSPDE11A2.

[0321] The following sample was deposited in accordance with the Budapest Treaty at the recognised depositary The National Collections of Industrial and Marine Bacteria Limited (NCIMB) at 23 St. Machar Drive, Aberdeen, Scotland, United Kingdom, AB2 1RY on 9 February 1999:

E. coli pMmPDE11A3 NCIMB number NCIMB 41007

NCIMB 41007 comprises MmPDE11A3.

[0322] The present invention also encompasses sequences derivable and/or expressible from those deposits and embodiments comprising the same. The present invention also encompasses partial sequences derivable and/or expressable from those deposits and embodiments comprising the same, wherein those partial sequences code for active enzymatic sites. The present invention also encompasses proteins comprising sequences derivable and/or expressable from those deposits and embodiments comprising the same. The present invention also encompasses proteins comprising partial sequences derivable and/or expressable from those deposits and embodiments comprising the same, wherein those partial sequences code for active enzymatic sites.

[0323] The present invention also encompasses sequences derivable and/or expressable from those deposits and embodiments comprising the same.

INTRODUCTION TO THE EXAMPLES SECTION AND THE FIGURES

[0324] The present invention will now be described, by way of example only, with reference to the accompanying drawings in which:-

Figure 1 which presents a schematic diagram;

Figure 2 which presents a Northen blot photographic image;

Figure 3 which presents a schematic diagram;

10

15

25

35

Figure 4 which presents a nucleotide sequence and an amino acid sequence;

Figure 5 which presents a nucleotide sequence, an amino acid sequence and an alignment of protein sequences;

Figure 6 which presents a graph;

Figure 7 which presents Hanes Plots;

30 Figure 8 which presents photomicrographs;

Figure 9 which presents a photograph;

Figure 10 which presents a sequence alignment; and

Figure 11 which presents a sequence alignment.

[0325] In slightly more detail, Figure 1 is a schematic alignment of bovine PDE5, IMAGE clone 298975 and PDE11A1 illustrating the various relevant functional domains shared by PDE11A1 with other phosphodiesterases and the region encompassed by the partial PDE11A1 sequence present in the IMAGE clone 298975.

[0326] In slightly more detail, Figure 2 is a Northern blot illustrating the tissue distribution of expression of PDE11A.

[0327] In slightly more detail, Figure 2 is a schematic diagram illustrating the strategy used to clone a full length cDNA for PDE11A1, bars are not to scale, CN refers to caudate nucleus.

[0328] In slightly more detail, Figure 4A is SEQ ID No.1 which is the nucleotide sequence coding for PDE11A1, ATG translation initiation indicated by double underline.

[0329] In slightly more detail, Figure 4B is SEQ ID No.2 which is the protein sequence for PDE11A1.

[0330] In slightly more detail, Figure 5A is SEQ ID No.3 which is the nucleotide sequence coding for PDE11A2, ATG translation initiation codon indicated by double underline.

[0331] In slightly more detail, Figure 5B is SEQ ID No.4 which is the protein sequence for PDE11A2.

[0332] In slightly more detail, Figure 5C is an alignment of the amino termini of PDE11A1 and PDE11A2 illustrating the region of divergence between the 2 splice variants.

[0333] In slightly more detail, Figure 6 is a graph showing relative hydrolytic activity of PDE11 against cAMP or cGMP in either PDE11 infected or mock infected *Sf*9 cells.

[0334] In slightly more detail, Figure 7 presents Hanes Plots used to calculate Km and Vmax values for PDE11A1 against either cAMP or cGMP.

[0335] In slightly more detail, Figure 8 presents in situ analysis of PDE11 expression photomicrographs in situ hybridisation analysis of various tissues showing expression of PDE11. In more detail, Figure 8 is a photomicrograph showing expression of PDE11 in a variety of tissues, on the left are photomicrographs taken under light field and on

taken under dark field to allow detection of the signal grains around sites of expression. Panel A illustrates expression of PDE11 in a subset of epithelial cells within the prostate, area 1 expression of PDE11 in a prostatic duct and area 2 a prostatic duct where expression is absent. Panel B illustrates expression of PDE11 in the striatum region of the human brain. Expression is clearly limited to the neuronal nuclei present in grey matter (area 1) whereas white matter (area2) is devoid of PDE11 expression. Panel C shows expression of PDE11 in ganglia cells of the eosophageal sphincter. Panel D illustrates expression of PDE11 in a subset of endothelial cells within vessels of the corpus cavernosum. Arrowheads serve to illustrate precise areas of expression.

[0336] In slightly more detail, Figure 9 presents a photograph demonstrating that PDE11 antibodies can detect the

PDE11 protein. Crude lysates from insect cells either infected with the PDE11 baculovirus or from uninfected cells were electrophoresed by PAGE. The proteins on the gel were then blotted onto nitro-cellulose membrane. This blot was used to study the relative specificity of the two PDE11 antibodies. Ab-1 was derived from peptide SEQ ID No. 8 and Ab-2 was derived from peptide ID SEQ No. 9.

EXAMPLES

15

EXPERIMENTAL SECTION

Materials and Methods

Northern Hybridisation and Probe preparation

[0337] Northern blots, obtained from Clontech (Clontech Laboratories, 1020 East Meadow Circle, Palo Alto, California, 94303, USA), were prehybridised for 1 hour in Expresshyb hybridisation solution (Clontech - Clontech Laboratories, 1020 East Meadow Circle, Palo Alto, California, 94303, USA) at 55°C before a radiolabelled PDE11A1 fragment (DNA was labelled using the Megaprime random labelling system (Amersham (Amersham place, Little Chalfont, Bucks, HP7 9NA UK)) strictly following the manufacturers instructions with 50µCi of ³²P-dATP) was added to fresh Expresshyb and hybridised to the blot overnight at 55°C, with gentle shaking. Blots were then washed 3X at room temperature for 10 minutes each in 2XSSC (150mM NaCl, 30mM Na.citrate) followed by 2 washes in 0.2XSSC (15mM NaCl, 3mM Nacitrate) at 55°C for 20 minutes each. Blots were then exposed to autoradiographic film.

30

40

Polymerase Chain Reactions (PCR)

[0338] PCRs were performed using standard reagents and conditions. Briefly, all reaction buffers and enzymes were obtained in kit format from either Clontech (Clontech Laboratories, 1020 East Meadow Circle, Palo Alto, California, 94303, USA) (for rapid amplification of cDNA ends (RACE) reactions) or from Life Technologies (3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF UK) for standard PCR. Oligonucleotides were obtained from a commercial supplier (OSWEL DNA services, Lab 5005, Medical And Biological Sciences Building, University of Southampton, Bolderwood, Bassett Crescent East, Southampton, SO16 7PX UK) and used at a concentration of 400nM. Reactions were performed on a MJ Research PTC-200 thermal cycler, using cycling parameters as recommended by the manufacturer of the kit being used.

Cloning of PCR products

[0339] PCR derived DNA fragments were cloned using the TOPO cloning system (Cat No. K3001-0-1) supplied by Invitrogen (De Schelp 12, 9351 NV Leek, The Netherlands), following the methods as outlined in the manufacturers method book and using the reagents as supplied

Phosphodiesterase assays on crude insect cell lysates

[0340] Crude lysates were assayed for phosphodiesterase activity using [3H] -cGMP or [3H] - cAMP (Amersham - Amersham place, Little Chalfont, Bucks, HP7 9NA UK). To 25µl of crude lysate was added 15µl of buffer C (20mM Tris.HCL (pH 7.4), 5mM MgCl₂.6H₂0) and 25 µl of buffer D (Buffer C + BSA @ 2mg/ml). The reaction was then initiated with 50µl of substrate and the tube incubated with shaking at 30°C for 15 minutes. The tubes were then transferred to a boiling water bath for 2 minutes then onto ice for 10 minutes. 25µl of a 1.5mg/ml aqueous solution of snake venom (Ophiophagus hannah, Sigma {Sigma-Aldrich Company Limited, Fancy Road, Poole, Dorset, BH12 4QH UK}, V-0376) was then added mixed and returned to 30°C for a further 10 minutes with shaking. Tubes were then returned to ice for 5 minutes when 500µl of resin slurry was added, thoroughly mixed and allowed to stand on ice for a further 15 minutes. Tubes were then centrifuged for 10 minutes at 2000 rpm after which 150µl of supernatant was removed and added to

2ml of Starscint (Packhard), manual and subjected to liquid scintillation counting.

[0341] Activity of phosphodiesterases present are expressed in pmol/min/ml fraction by means of the following formula:

$$\frac{\text{DPM of sample-DPM of blanks}}{\text{mean DPM of totals-mean DPM of background}} \times \frac{625}{150} \times \frac{50 \text{pmols}}{10 \text{ mins}} \times 100$$

[0342] Active crude lysates were then flash frozen in a dry ice ethanol bath and stored at -80°C.

10 Purification of Protein from crude lysate

[0343] Crude Sf9 lysates containing the expressed protein-FLAG fusion were passed down a FLAG antibody affinity column (Agarose M2 affinity gel beads to which a purified IgG1 monoclonal anti-FLAG antibody had been conjugated by hydrazide linkage) using a Pharmacia FPLC system (LKB.UV-MII) {Pharmacia Biotech, 23 Grosvenor Road, St Albans, Herts, AL1 3AW. UK}. Purified protein was eluted under conditions exactly as specified by the manufacturer of the affinity beads, split into aliquots and stored at -80°C for subsequent analysis.

Phosphodiesterase assays on affinity purified protein

20 [0344] Substrate was prepared by adding 14.7μl [3H]-cGMP (Amersham - Amersham place, Little Chalfont, Bucks, HP7 9NA UK) to 20μl Buffer C (as above). In 96 well format 25μl of Buffer D (see above) was added to all wells. 25μl sample was added to all wells followed by 50μl of substrate to initiate the reaction. Samples were incubated for 30 minutes at 30°C before addition of 50μl SPA beads, these were left for 20 minutes before being read on a scintillation counter.

Western Blotting

5

25

40

[0345] Insect cells were pelleted by centrifugation and resuspended in lysis buffer (50mM Tris.HCL (pH 6.8), 100mM dithiothreitol, 2% SDS, 0.2% bromophenol blue, 20% glycerol), sonicated, placed in a boiling waterbath for 10 minutes and electrophoresed under reducing conditions on SDS PAGE (Novex NuPAGE 4-12% Bis-TRIS reducing gel, Kit NP0000). The proteins were then transferred to a nitro-cellulose membrane using the Novex NuPAGE western transfer system. The western blot was then incubated in PBS/0.1% Tween20/5% dried milk and 4°C overnight. The blot was then incubated for 1 hour in PBS/0.1% Tween20/5% dried milk/1/500 dilution of the primary antibody. Washes were then performed with PBS/Tween20 for 3X 1 minute and 1X 10 minutes prior to a wash in PBS/Tween20/5% dried milk 3X 1 minute and IX 10 minutes. The secondary antibody (Goat anti-rabbit IgG (H+L)- alkaline phosphatase conjugate (Bio-Rad 1706518) was then added to this same solution and incubated for 45 minutes at room temperature with shaking. The blot was then washed 3X 1 minute and 1 X 10 minutes in PBS/Tween20 before detection using 5-bromo-4-chloro-3-indolyl phosphate and Nitro Blue Tetrazolium (BCIP/NBT, Sigma B1911 (Sigma-Aldrich Company Limited, Fancy Road, Poole, Dorset, BH12 4QH UK)).

Example 1

The identification of PDE11A1

[0346] The clone (IMAGE clone id 298975) was obtained from Research Genetics (2130, Memorial Pkwy, SW Hunts-ville, AL 358801, USA) as a stab culture in L-agar. Bacteria from the stab culture were streaked onto a 37mm L-agar plate in the presence of ampicillin at a concentration of 100mg/ml. After overnight growth at 37°C a single clone was picked, using sterile technique, into 5ml of LB-broth containing ampicillin at a concentration of 100mg/ml and grown at 37°C overnight with shaking (220 rpm). Plasmid DNA was isolated from the bacteria using a standard commercially available miniprep kit (Qiagen™) and strictly following the manufacturers instructions. The isolated DNA was then subjected to full length sequencing, using standard kits and reagents and an ABI (PE Applied Biosystems Incorporated) automated sequencer.

[0347] Full length sequencing revealed that IMAGE clone 298975 contains a nucleotide insert of 1779 bp. Database homology searches using the BLAST (Basic Local Alignment Search Tool (Altshul SF (1993) J.Mol. Evol. 36:290-300; Altshul, SF et al (1990) J. Mol. Biol. 215:403-410) were performed and showed that the DNA insert in IMAGE clone 298975 contained the sequence present in the EST (expressed sequence(expressed sequence tag) database, that this sequence was homologous to known PDEs, and that 298975 also contained extensive stretches of additional DNA sequence, 5' to the EST, which are also homologous to known PDEs. Further analysis of this sequence was performed

to determine the preserve of any open reading frames, ATG translation initiation one and TGA, TAA, TAG terminator codons. This revealed that clone 298975 contained a putative ORF (open reading frame) extending from an ATG initiator at base pair position + 13 all the way through to the 3' limit of the sequence. There was no indication of a terminator codon at the 3' end of the clone suggesting the cDNA was not complete at the 3' end.

IMAGE clone 298975 contains a fragment of a potential novel class of PDE

[0348] Detailed bioinformatic analysis comparing the sequence of the insert of 298975 and known PDEs indicate that the sequence of 298975 may encode a fragment of a member of a novel family of PDEs. The reason for this is the relative lack of similarity between 298975 and other PDEs compared to the relative similarity between, for instance, PDE6A and PDE6B. The similarity between 298975 and other PDEs is more comparable to the similarity between, for example PDE5 and PDE6A. This is illustrated in TABLE 1 (shown below) which illustrates the percentage similarity of the peptide sequence between 298975, PDE 6A, PDE6B and PDE5 over the region for which sequence from 298975 was available (see also below).

TABLE 1

	PDE6A	PDE6B	PDE5	PDE11
PDE6A	100	77.7	39.7	34.1
PDE6B		100	41.1	34.1
PDE5			100	35.5
PDE11				100

[0349] Table 1 illustrates the percentage similarity between PDE11 and other PDE gene family members and shows that PDE11 is equally distant to PDE5, PDE6A and PDE6B, in contrast to the PDE6s which have a greater degree of similarity to each other. This suggests that PDE11 constitutes a new PDE gene family rather than be a sub-type of a known family.

[0350] For this reason the partial sequence contained within the IMAGE clone 298975 was putatively named, according to current guidelines on PDE nomenclature (Beavo et al. Molecular Pharmacology, 46:399-405), as PDE11A1. [0351] An alignment using the Clustal program (Thompson *et al.* (1994). Nucleic Acids Research, 22:4673-4680.) between the PDE11A1 sequence fragment and bovine PDE5 (PDE5 was selected since functionally this is one of the most well characterised known PDEs) was performed to determine the presence, if any, of the functional domains observed in other PDEs. This is illustrated in FIGURE 1 (panel B), in schematic form, and shows that the sequence fragment of PDE11A1, contained in 298975, overlaps substantially with PDE5 but that it terminates at residue 669 in the PDE5 sequence. This would indicate that substantial 3' sequence for PDE11A1 may be present in addition to that contained within 298975. The presence in PDE11A1 of 2 putative zinc-binding motifs (HXXXHX₈₋₂₀D) supports the hypothesis that PDE11A1 encodes a functional phosphodiesterase enzyme.

40 Example 2

55

5

10

15

20

25

Isolation of a putative full length cDNA clone for PDE11A1

[0352] To facilitate the isolation of a full length cDNA for PDE11A1 containing the 3' end of the coding region and a terminator codon, the expression of PDE11A1 was determined in a range of tissues using Northern hybridisation. This data (illustrated in FIGURE 2) shows that while the messenger RNA (length 9.5kb), which hybridises to PDE11A1, is present in several tissues, it is particularly highly expressed in the caudate nucleus and putamen regions of the brain. Therefore, caudate nucleus cDNA (Clontech - Clontech Laboratories, 1020 East Meadow Circle, Palo Alto, California, 94303, USA) was used as a template for a PCR based approach (see methods) to generate extra 3' sequence. Initial attempts at 3' RACE were unsuccessful so an alternative strategy was devised to generate further 3' sequence. This was achieved by using an oligonucleotide:

RP1:

5'-TC NCC YTG RTC RTA RAA YTC- 3', SEO ID No. 5

[0353] This was based upon senserved sequences observed in alignments of PDEs and 6 and was used as the 3' primer.

[0354] A second oligonucleotide, the 5' primer was also used:

GSP1:

5' -TAC TTC AGA ACA ATC ACA CG- 3', SEQ ID No. 6

[0355] This was based upon known PDE11A1 sequence. A PCR carried out using these primers (the PCR was set up using reagents obtained from a PCR Reagent System kit (Life Technologies - 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF UK) and following the manufacturers instructions, with standard cycling parameters) resulted in the generation of a fragment, which upon cloning into the TOPO vector and full length sequencing proved to overlap with the PDE11A1 sequence derived from IMAGE clone 298975 at it's 5' end and to extend the 3' sequence a further 400bp towards the 3' end of PDE11A1. However, this fragment did not contain a terminator codon indicating that further PDE11A1 at the 3' end remained to be isolated.

[0356] To test this hypothesis 3' RACE was carried out on caudate nucleus Marathon Ready™ cDNA (Clontech Clontech Laboratories, 1020 East Meadow Circle, Palo Alto, California, 94303, USA) with SEQ ID No. 6 (see above) and the 3' primer supplied with the 3'RACE kit (Clontech Clontech Laboratories, 1020 East Meadow Circle, Palo Alto, California, 94303, USA), using reagents and methodologies recommended by the manufacturer). These RACE products were used to generate a mini-library of 2000 clones in the TOPO vector (Invitrogen - De Schelp 12, 9351 NV Leek, The Netherlands). This mini-library was screened by hybridisation with a probe derived from the 3' end of the extended fragment derived above. 5 clones were identified which upon sequencing proved to contain further 3' PDE related sequences. These clones also contained an in frame terminator codon, indicating the 3' limit of the putative coding sequence within this cDNA. The procedure used to isolate a full length PDE11A1 cDNA is summarised schematically in FIGURE 3. Analysis of all 3 fragments allowed the assembly of a contiguous sequence of 2557 bp which contains an ORF of 789 residues. The full length cDNA sequence for PDE11A1 is given in FIGURE 4A (SEQ ID No. 1) with the translation of the largest open reading frame within this cDNA given in FIGURE 4B (SEQ ID No. 2).

[0357] Like all mammalian phosphodiesterases sequenced to date PDE11A1 contains a conserved catalytic domain sequence of approximately 250 amino acids in the carboxyl-terminal half of the protein that is thought to be essential for catalytic activity. This segment comprises amino acids 499 to 731 in SEQ ID 4 and is also indicated schematically in FIGURE 1 (panel C) and exhibits sequence conservation with the corresponding region of other PDEs.

Example 3

5

10

15

25

30

35

45

Isolation of a 5' splice variant of PDE11A1

[0358] In order to guard against the possibility that the ATG, translation initiation codon indicated in FIGURE 4A, is not the most 5' ATG in PDE11A1, 5'RACE was performed on caudate nucleus MarathonReady™ cDNA (Clontech - Clontech Laboratories, 1020 East Meadow Circle, Palo Alto, California, 94303, USA) to isolate further upstream sequence. The 5' primer used was the adapter primer supplied in the 5' RACE kit (Clontech - Clontech Laboratories, 1020 East Meadow Circle, Palo Alto, California, 94303, USA) the 3' primer used was the oligonucleotide:

GSP3:

5'- TCT CCA AGG AAA TAC AGT GC- 3' SEQ ID No. 7

[0359] The reaction conditions were as specified by the manufacturers instructions. The resulting 5' RACE products were cloned into the TOPO vector (Invitrogen - De Schelp 12, 9351 NV Leek, The Netherlands) and analysed for the presence of PDE11A1 related sequences by hybridisation screening with a probe derived from the 5' end of PDE11A1. This analysis revealed the presence of an upstream 190 bp coding sequence. It is concluded that the ATG indicated in FIGURE 4A may represent the genuine translation initiation codon for PDE11A1. Sequence analysis of several of the 5'RACE clones revealed the presence of a splice variant of PDE11A1, named PDE11A2 which differs in the coding region whereby the terminal 23 codons are replaced, in PDE11A2, by an alternative 25 codons. FIGURE 5C illustrates an alignment of the amino termini of PDE11A1 and A2 for comparison. The full cDNA sequence and translation are given in FIGURES 5A and 5B. PDE11A1 and PDE11A2 also differ in the sequences 5' to the known ATG initiation

codons. One interesting eservation is that PDE11A2 may not possess the properties of kinase A potential phosphorylation site when detected using the prosite program (Bairoch et al., The PROSITE database, its status in 1997. Nucleic Acids Res. 25:217-221(1997)).

5 Example 4

10

20

30

45

50

PDE11A1 shows cyclic nucleotide hydrolytic activity when expressed in the baculovirus system

[0360] PDE11A1 protein was generated using the baculovirus expression system based on *Autographa californica* nuclear polyhedrosis virus (AcNPV) infection of *Spodoptera frugiperda* insect cells (*St*9 cells). Briefly, PDE11 was cloned into the donor plasmid pFASTBAC-FLAG which contains a mini-Tn7 transposition element. The recombinant plasmid was transformed into DH10BAC competent cells which contain the parent bacmid bMON14272 (AcNPV infectious DNA) and a helper plasmid. The mini-Tn7 element on the pFASTBAC donor can transpose to the attTn7 attachment site on the bacmid thus introducing PDE11 into the viral genome. Colonies containing recombinant bacmids are identified by disruption of the *lacZ* gene. The PDE11/bacmid construct can then be isolated and infected into insect cells (*St*9 cells) resulting in the production of infectious recombinant baculovirus particles and expression of recombinant PDE11A1-FLAG fusion protein.

[0361] The phosphodiesterase activity of the crude cell extracts was measured using a modification of the assay procedure described for the cGs-PDE in Martins et al.. J.Biol.Chem., 257:1973-1979 (See also materials and methods). Cells were harvested and extracts prepared 24, 48 and 72 hours after transfection. The results of the assays are presented in FIGURE 6 where the results shown are averages of 3 separate infections. Infection of the insect S/9 cells resulted in the expression of approximately 10-15 fold higher levels of both cAMP and cGMP phosphodiesterase activity than in mock infected cells. These results confirm that PDE11A1 cDNA encodes a phosphodiesterase which is able to hydrolyse both cAMP and cGMP.

[0362] The crude lysate material was purified by FPLC using a column containing agarose beads (M2 affinity gel) to which a purified IgG₁ monoclonal anti-FLAG antibody had been conjugated by hydrazide linkage (Eastman Kodak). This allows the specific retention on the column of the recombinant material (since this is fused to the FLAG epitope) whilst the endogenous insect proteins are washed off in the eluate. The recombinant material is then washed off under conditions of low pH. This purified material was more suitable for detailed enzymatic and inhibitor studies. The purity of the material is assessed by coomassie staining after sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) or through western blotting onto a nitro-cellulose membrane of an unstained SDS-PAGE (containing recombinant PDE11A1) and analysis with the IgG1 monoclonal anti-FLAG epitope antibody. The PDE11A1-FLAG fusion protein is detected due to the interaction between the anti-FLAG antibody and the FLAG epitope which is fused to the PDE11A1 protein.

[0363] The phosphodiesterase activity of the purified PDE11A1-FLAG fusion protein was assayed using a commercially available SPA (scintillation proximity assay) kit (Amersham - Amersham place, Little Chalfont, Bucks, HP7 9NA UK) for either cAMP or cGMP. This was used to permit the determination of the Km value for PDE11A1 against cAMP and cGMP by determining the enzyme activity at a range of substrate concentrations allowing the calculation of an approximate Vmax value for the enzyme. The results of these experiments are given in FIGURE 7 and show that the Km for PDE11A1 against cAMP is 400nM and about 4mM against cGMP, indicating that the enzyme has a higher affinity for cAMP over cGMP. Thus, the PDE11 enzyme of the present invention has an affinity for cAMP and cGMP, but wherein it has a higher affinity for cAMP than cGMP. Preferably, the enzyme has an affinity of an order of at least about 5 for cAMP than cGMP, more preferably an affinity of an order of at least about 6 for cAMP than cGMP, more preferably an affinity of an order of at least about 8 for cAMP than cGMP, more preferably an affinity of an order of about 10 (or more) for cAMP than cGMP.

Example 5

In situ hybridisation studies with PDE11A1

[0364] This analysis was carried to investigate the potential function of PDE11A1 and as to what therapeutic opportunities may be exploited by inhibiting this enzyme. Accordingly a PDE11A1 riboprobe (see methods) was generated and radiolabelled with 35S. Examples of this sort of analysis are illustrated in FIGURE 8, illustrating expression in endothelial cells of the corpus cavernosum, ganglia in the gut, epithelial cells of the prostate and neuronal nuclei of the striatal region of the brain. These data may serve to illustrate the multitude of opportunities which inhibition of PDE11 activity may represent.

Example 6

10

15

20

25

35

40

Generation of PDE11 antibodies

5 [0365] Two anti-peptide PDE11 anti-bodies have been generated by a commercial supplier of these reagents (Zeneca CRB - Cambridge Research Biochemicals, Gadbrook Park, Northwich, Cheshire, CW9 7RA. UK).
[0366] The first peptide sequence was:

MEDGPSNNASC (SEQ ID No. 8)

and corresponded to residues 01 to 12 of PDE11A1.

[0367] The second peptide sequence was:

EDESAPKEVSRYC (SEQ ID No.9)

and corresponded to residues 64-77 of PDE11A1.

[0368] These sequences were generated using standard procedures by Zeneca CRB (Cambridge Research Biochemicals, Gadbrook Park, Northwich, Cheshire, CW9 7RA. UK) and injected into rabbits using a standard antigen injection regimen. Anti-bodies were supplied as serum and were characterised by Western blot against recombinantly produced PDE11A1 protein. The data from this experiment is given in FIGURE 9 and shows that both antibodies (Ab1 and Ab-2) are capable of detecting the recombinant PDE11 protein when present in a background of insect protein present in the crude lysate.

Example 7

[0369] A cDNA containing the full coding sequence of PDE11A1 is obtained from human caudate nucleus cDNA (Clontech catalogue # 7191-1 {Clontech Laboratories, 1020 East Meadow Circle, Palo Alto, California, 94303, USA}) using the polymerase chain reaction (PCR) and the following oligonucleotides:

5' primer:

TTC GGA TCC GAC ATG GAA GAT GGA CC (SEQ ID No. 10)

and the 3' primer:

GGT GAC TAG TGC TCA ATC TTC AGA TGC (SEQ ID No. 11)

with the PCR reagent system (Life Technologies, Catalogue # 10198-018 (3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF UK)) in a reaction volume of 100 μ l or by using conventional hybridisation screening.

[0370] The full sequence for PDE11A1 is provided herein. We have also isolated a splice variant of PDE11A1, namely PDE11A2 which differs at the amino terminus as indicated herein. The remainder of the sequence of PDE11A2 is identical to PDE11A1. PDE11A2 can also be obtained from caudate nucleus cDNA using the appropriate primers and a PCR protocol or by hybridisation screening.

[0371] The coding sequence of the PDE11A1 cDNA encodes a protein of 789 amino acid residues. The coding sequence of the PDE11A2 cDNA encodes a protein of 791 amino acid residues.

[0372] Sequence ID No. 1 is the full sequence for the PDE11A1 cDNA. Sequence ID No. 2 is the translated protein sequence for PDE11A1. Sequence ID No. 3 is the full sequence for the PDE11A2 cDNA. Sequence ID No. 4 is the translated protein sequence for PDE11A2.

Example 8



The Mouse Sequence

5 [0373] A mouse homologue for PDE11 was found in a clone (IMAGE clone 760844). This homologue was anlaysed according to the protocols layed out above for human PDE11A1. Full length sequecing of the insert within this clone revealed that it contained an insert of 1068 bp of which an internal 900bp corresponded very closely to human PDE11. [0374] The following is a partial nucletide sequence derived from Image clone 760844. The sequence in bold indicates the region of the insert of this clone that has high homology to human PDE11.

SEQ ID No. 12

- 15 CCAACCCCGGCTCATCCCTGCGGGGCCCATCACCCAGGGTACCACCATCTCTGCCTACGTGGCCAAGTCTAGG AAGACGTTGTTGGTAGAGGATATCCTTGGGGATGAGCGATTTCCTCGAGGTACTGGCCTGGAATCAGGAACCC GCATCCAGTCTGTTCTTTGCTTGCCCATTGTCACTGCCATTGGAGACTTGATTGGCATCCTTGAACTGTACAG 20 GCAATACACCAGGTGCAGGTGTGTAGAGGTCTCGCCAAACAGACCGAACTGAATGACTTCCTACTCGACGTAT CAAAGACATACTTTGATAACATAGTTGCCATAGACTCTCTACTTGAACACATCATAATATATGCAAAAAATCT AGTGAACGCCGACCGCTGCGCGCTCTTCCAGGTGGACCACAAGAACAAGAGCTGTACTCGGACCTGTTTGAC 25 ATTGGGGAGAGAAGGAGGAGACCCATCTTCAAGAAGACCAAGGAGATCAGATTTTCCATTGAGAAAGGGA TTGCTGGTCAAGTGGCAAGAACAGGCGAAGTCTTGAACATTCCCGATGCCTACGCGGACCCTCGCTTTAACAG GGAGGTGGACCTGTACACAGGCTACACCACGAGGAACATTCTGTGTATGCCCATAGTGAGCCGAGGCAGCGTG 30 TGTTTGCTGTCTTCTGCGCACTGGCCTTGCACTGTGCTAACGCCAGATGGAAAAGCCTAGCTTCTCTCCCCTG GGTCAGCTGGGAAGGTTTGCTAGCTTGCCTGCACTGTGGCAAAGACCTGAGGACCTGGAATGGTGACCACTGT CTGACGTGCACAGTCTTTCCTGCCTCTGTGACACCCGCTTGGGATA
- 35 [0375] The following is the protein translation of the sequence indicated in bold above, it is 300 residues long and does not contain either an ATG translation initiator codon or a TGA,TAA or TAG terminator codon. We therefore believed that it represented a fragment of the mouse PDE11 cDNA.

40 SEQ ID No. 13

45

50

FLGECNNSLCVFIPPGMKEGQPRLIPAGPITQGTTISAYVAKSRKTLLVEDILGDERFPRGTGLESGTRIQSV LCLPIVTAIGDLIGILELYRHWDKEAFCLSHQEVATANLAWASVAIHQVQVCRGLAKQTELNDFLLDVSKTYF DNIVAIDSLLEHIIIYAKNLVNADRCALFQVDHKNKELYSDLFDIGEEKEGKPIFKKTKEIRFSIEKGIAGQV ARTGEVLNIPDAYADPRFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVF CALALHCA

[0376] Figure 10 shows the sequence alignment to Human PDE11A1 between residues 126 and 425. This is alignment was generated using the BLAST algorithm of human PDE11A1 protein sequence and mouse PDE11 protein sequence.

[0377] Thus, we believed that IMAGE clone 760844 contained a DNA sequence the majority of which is very closely related to human PDE11 and would therefore represent a mouse homologue of the human PDE11 gene. Whilst this cDNA may only contain a fragment of the mouse gene it does represent a variant of the human PDE11 cDNA sequence.

[0378] Based on this belief, we then fully sequenced the mouse PDE11 and its coding sequence.

[0379] In this respect, the full cDNA sequence of cloned mouse PDE 11 is provided herein as SEQ ID No. 14. The

mouse PDE 11 sequence itselve presented as SEQ ID No. 15. The mouse sequence MMPDE11A3. sometimes referred to as:

[0380] Figure 11 shows a sequence comparison between the human PDE11 sequences (HSPDE11A1, HSPDE11A2) and the mouse PDE11 sequence (MPDE11A3). As can be seen, there is a close match between the sequences.

[0381] In situ hybridisation studies showed that MMPDE11A3 coding sequences are localised in high levels in the

Example 9

10 The Rat Sequence

[0382] A rat homologue for PDE11 was found, which we have called PDE11A4. We have been able to sequence parts of this homolgue. In this respect, two nucleotide sequences are presented as SEQ ID No. 16 and SEQ ID No. 18. The two respective amino acid sequences are SEQ ID No. 17 and SEQ ID No. 19. Data analysis reveals a very high homology with the human and rat sequences presented herein.

SUMMARY

15

20

25

40

45

50

55

[0383] In summary the present invention provides and the Examples show inter alia:

- 1. Novel amino acids.
- Novel nucleotide sequences.
- Assays using said novel sequences.
- 4. Compounds/compositions identified by use of said assays.
- 5. Expression systems comprising or expressing said novel sequences.
- 6. Methods of treatment based on said novel sequences.
- 7. Pharmaceutical compositions based on said novel sequences.

[0384] All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in 30 the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims. 35



[0385]


5

10

SEQUENCE LISTINGS

SEQ ID NO. 1 (Nucleotide sequence coding for PDE11A1)

	TTCGGCTCCGACATGGAAG <u>ATG</u> GACCTTCTAATAATGCGAGCTGCTTCCGAAGGCTGACC	60
15	GAGTGCTTCCTGAGCCCCAGTTTGACAGATGAAAAAGTGAAGGCATATCTTTCTCTTCAC	120
13	$\tt CCCCAGGTATTAGATGAATTTGTATCTGAAAGTGTTAGTGCAGAGACAGTAGAGAAATGG$	180
	CTGAAGAGGAAGAACAACAAATCAGAAGATGAATCAGCTCCTAAGGAAGTCAGCAGGTAC	240
	CAAGATACGAATATGCAGGGAGTTGTATATGAACTAAACAGCTATATAGAACAACGGTTG	300
	GACACAGGAGGAGACAACCAGCTACTCCTCTATGAACTGAGCAGCATCATTAAAATAGCC	360
20	${\tt ACAAAAGCCGATGGATTTGCACTGTATTTCCTTGGAGAGTGCAATAATAGCCTGTGTATA}$	420
20	TTCACGCCACCTGGGATAAAGGAAGGAAAACCCCGCCTCATCCCTGCTGGGCCCATCACT	480
	${\tt CAGGGCACCACCGTCTCTGCTTATGTGGCCAAGTCCAGGAAAACACTGCTAGTAGAAGAC}$	540
	ATCCTTGGAGATGAACGATTTCCAAGAGGTACTGGACTGGAATCAGGGACTCGTATCCAG	600
	${\tt TCTGTTCTTTGCTTACCAATTGTCACTGCAATTGGTGACTTGATTGGTATTCTCGAGCTG}$	660
25	${\tt TATCGGCACTGGGGCAAAGAAGCCTTCTGTCTTAGTCACCAGGAGGTTGCAACAGCAAAT}$	720
	$\tt CTTGCCTGGGCTTCAGTAGCAATACATCAGGTGCAGGTATGCAGAGGCCTTGCCAAACAG$	780
	ACAGAATTGAATGACTTCCTACTCGACGTATCAAAAACATATTTTGATAACATAGTTGCA	840
	${\tt ATAGATTCTCTACTTGAACACATAATGATATTGCAAAAAACCTGGTGAATGCCGATCGT}$	900
	$\tt TGTGCACTTTTCCAGGTGGACCATAAGAACAAGGAGTTATATTCAGACCTTTTTGATATT$	960
30	$\tt GGAGAGGAAAAGGAAAACCTGTCTTCAAGAAGACCAAAGAGATAAGATTTTCAATT$	1020
	${\tt GAGAAAGGAATTGCTGGCCAAGTAGCAAGAACAGGGGAAGTCCTGAACATTCCAGATGCC}$	
	${\tt TATGCAGACCCACGCTTTAACAGAGAAGTAGACTTGTACACAGGCTACACCACGCGGAAC}$	1140
	$\tt ATCCTGTGCATGCCCATCGTCAGCCGAGGCAGCGTGATAGGTGTGCAGATGGTCAAC$	1200
	${\tt AAAATCAGTGGCAGTGCCTTCTCTAAAACAGATGAAAACAACTTCAAAATGTTTGCCGTC}$	1260
<i>35</i>	TTTTGTGCTTTAGCCTTACACTGTGCTAATATGTATCATAGAATTCGCCACTCAGAGTGC	1320
	$\tt ATTTACCGGGTAACGATGGAAAAGCTGTCCTACCATAGCATTTGTACTTCAGAAGAGTGG$	1380
	${\tt CAAGGTCTCATGCAATTCACCCTTCCCGTGCGTCTCTGCAAAGAAATTGAATTATTCCAC}$	1440
	$\cdot \texttt{TTTGACATTGGTCCTTTTGAAAACATGTGGCCTGGAATTTTTGTCTACATGGTTCATCGG}$	1500
	${\tt TCCTGTGGGACATCCTGCTTTGAGCTTGAAAAGTTGTGTCGTTTTATTATGTCTGTGAAG}$	
40	${\tt AAGAACTATCGGCGGGTTCCTTATCACAACTGGAAGCATGCGGTCACTGTAGCACACTGC}$	1620
	${\tt ATGTATGCCATACTTCAGAACAATCACACGCTTTTCACAGACCTTGAGCGCAAAGGACTG}$	1680
	$\tt CTGATTGCGTGTCTGTGTCATGACCTGGACCACAGGGGCTTCAGTAACAGCTACCTGCAG$	1740
	AAGTTCGACCACCCTCTGACCGCTCTCTACTCCACCTTCCACCATGGAGCAGCACCACTTC	1800
	${\tt TCCCAGACTGTGCCATCCTTCAGTTGGAAGGGCACAATATCTTCTCCACTCTGAGCTCC}$	1860
45	${\tt AGTGAATATGAGCAGGTGCTTGAGATCATCCGCAAAGCCATCATTGCCACAGACCTTGCT}$	1920
	${\tt TTATACTTTGGAAACAGGAAGCAGTTGGAAGAGATGTACCAGACCGGATCACTAAACCTT}$	1980
	${\tt AATAATCAATCACATAGAGACCGTGTAATTGGTTTGATGATGACTGCCTGTGACCTTTGT}$	2040
	TCTGTGACAAAACCGTGGCCCGTTACAAAATTGACGGCAAATGATATATAT	2100
	TGGGCTGAGGGTGATGAAATGAAGAAATTGGGAATACAGCCTATTCCTATGATGGACAGA	2160
50	GACAAGAAGGATGAAGTCCCCCAAGGCCAGCTTGGGTTCTACAATGCCGTGGCCATTCCC	2220
	TGCTATACAACCCTTACCCAGATCCTCCCTCCCACGGAGCCTCTTCTGAAAGCATGCAGG	2280
	GATAATCTCAGTCAGTGGGAGAAGGTGATTCGAGGGGAGGAGACTGCAACCTGGATTTCA	2340
	TCCCCATCCGTGGCTCAGAAGGCAGCTGCATCTGAAGATTGAGCACTGGTCACCCTGACA	2400
	CGCTGTCCCACCTACAGATCCTCATCTTGCTTCTTTGACATTCTTTTCCTTTTTTGGGGG	2460
55	GGGTGGGGGGAACCTGCACCTGGTAACTGGGGTGCAAACCTCTTCAAGAAGGTAACATCA	2520
	AATAAATAAGTCAAGCAGAAAAAAAAAAAAAAA	255



5



MEDGPSNNASCFRRLTECFI.SPSI.TDEVIKAVI OF UPON THE	
MEDGPSNNASCFRRLTECFLSPSLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRK NNKSEDESAPKEVSRYODTNMOGNAVELNGVLTSON	60
NNKSEDESAPKEVSRYQDTMMQGVVYELNSYIEQRLDTGGDNQLLLYELSSIIKIATKAD GFALYFLGECNNSLCIFTPPGIKEGKPRLIPAGPITQGTTVSAYVAKSRKTLLVEDILGD ERFPRGTGLESGTRIOSVICI BIJTALGDI	120
ERFPRGTGLESGTRIOSVICIPIUTA ICENTICALISTICALI	186
ERFPRGTGLESGTRIQSVLCLPIVTAIGDLIGITELYRHWGKEAFCLSHQEVATANLAWA SVAIHQVQVCRGLAKOTFINDFILDVSVZYZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ	240
SVAIHQVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALF QVDHKNKELYSDLFDIGFEKEGKRUFFKERV	300
QVDHKNKELYSDLFDIGEEKEGKPVFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADP RFNREVDLYTGYTTRNILCMPIVEDCEVLGIRONDERFORMER	360
RFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCAL ALHCANMYHRIRHSECIYRVTMEYISYNGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	420
ALHCANMYHRIRHSECIYRVTMEKLSYHSICTSEEWQGLMQFTLPVRLCKEIELFHFDIG PFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAI LQNNHTLFTDLERKGLLIACICUN DIRGONANIA	480
LQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLTALYSTSTMEQHHFSQTV SILQLEGHNIFSTLSSSEYFOWEITHWAY	540
EVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSV AQKAAASED 789	720
AQKAAASED 789	780

SEQ ID NO. 3 (Nucleotide sequence coding for PDE11A2)

ACATAGCTGGGTGCAATGTAAGTGCCTGGGTGAAGT
ACATAGCTGGGTGCAATGTAAGTGCCTGGCTGAAGTTTGACACGCGAACGGACGG
AGTCGTTGAAGCCACAGTCGTGAATGGAGACCAGGAGTTGGACTCTGCAACACCAAGGT 120 TCGGAGGATAGGACAGAAGAAGACCAGGAGCCATGGAGTGAATAGTGGGAGTGAGCAGAAG 180 AAGATCCTGAGATGGAAGCCATGGAGCCCTGGAGAGGTGTGACCCGGC 240
AAGATCCTGAGATGGAAGGTAGCACGCCGTGGAGAGCCCTGGAGAGGTGTGACCCGGC 240
AAGATCCTGAGATGGAAGGTAGCACGGCTTGGAGAGCCCCTGGAGAGGGTGTGACCCGGC 240 GAAGCCAGATGCTCCAGAGAGCAGCAGCTTCAAGAGCGGAGCCTCAAGAGGGAA 300
GAAGCCAGATGCTCCAGAGAGCAGGTTTGACAGTTCAGAAGCGGAGCCTCAAGAGGGAA 300 TTCACCCCCAGGTATTAGATGAATTTGTATCTGAAAGTGTAAGAGCATATCTTTCTC 360 AATGGCTGAAGAGAAGAACAACAAACTGAAAGTGTTAGTGCAGAGACAGTAGAGA 420
ATCGTTGTGCACTTTTCCAGGTGGACCATAAGAACAGGAGTTATATTCAGACCTTTTTG 1200
ATATTGGAGAGGAAAGGAAAACCTGTCTTCAAGAAGACCAAAGACTTATTTTTTTT
CAATTGAGAAAGGAATTGCTGGCCAAGTAGCAGACAGAGACAAAGAGATTAT 1260 ATGCCTATGCAGACCCACGCTTTAAAGAACAGAGAACAGGGGAAGTCCTGAACATTCCAG 1320
TTGCTTTATACTTTGGAAACAGGAAGCAGTTGGAAGAGCATCACTAA 2220
2220

	ACCTTAATAATCAATCACATAGAGACCGTGTAATTGGTTTGATGATGACTGCCTGTGACC TTTGTTCTGTGACAAAACCGTGGCCCGTTACAAAATTGACGGCAAATGATATATAT	
	AATTCTGGGCTGAGGGTGATGAAATGAAGAAATTGGGAATACAGCCTATTCCTATGATGG	
5	ACAGAGACAAGAAGGATGAAGTCCCCCAAGGCCAGCTTGGGTTCTACAATGCCGTGGCCA	
	TTCCCTGCTATACAACCCTTACCCAGATCCTCCCTCCCACGGAGCCTCTTCTGAAAGCAT	
	GCAGGGATAATCTCAGTCAGTGGGAGAAGGTGATTCGAGGGGAGAGACTGCAACCTGGA	
	TTTCATCCCCATCCGTGGCTCAGAAGGCAGCTGCATCTGAAGATTGAGCACTGGTCACCC	
	TGACACGCTGTCCCACCTACAGATCCTCATCTTGCTTCTTTGACATTCTTTTTCCTTTTTTT	
10	GGGGGGGTGGGGGAACCTGCACCTGGTAACTGGGGTGCAAACCTCTTCAAGAAGGTAA CATCAAATAAATAAGTCAAGCAGAAAAAAAAAA	2760
	SEQ ID NO. 4 (Amino acid sequence of PDE11A2)	
15	one in the sequence of 1 Desires)	
10	MEGSTAWSSEAEPQEGRSQMLQRAGLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLK	60
	RKNNKSEDESAPKEVSRYQDTNMQGVVYELNSYIEQRLDTGGDNQLLLYELSSIIKIATK	120
	ADGFALYFLGECNNSLCIFTPPGIKEGKPRLIPAGPITQGTTVSAYVAKSRKTLLVEDIL	
20	GDERFPRGTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLA	240
	WASVAIHQVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCA	300
	LFQVDHKNKELYSDLFDIGEEKEGKPVFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYA	
25 `	DPRFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFC	
	ALALHCANMYHRIRHSECIYRVTMEKLSYHSICTSEEWQGLMQFTLPVRLCKEIELFHFD	
	IGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMY	
30	AILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLTALYSTSTMEQHHFSQ	
	TVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNN	
	QSHRDRVIGLMMTACDLCSVTKPWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDK	
35	KDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSP	780
	SVAQKAAASED 791	
	SEQ ID No. 5	
40		
	TCNCCYTGRTCRTARAAYTC	
	•	
45	SEQ ID No. 6	
	TACTTCAGAACAATCACACG	
50	INCITCAGAACAATCACACG	

SEQ ID No. 7

5	TCTCCAAGGAAATACAGT	GC
---	--------------------	----

SEQ ID No. 8

10

20

25

35

MEDGPSNNASC

SEQ ID No. 9

EDESAPKEVSRYC

SEQ ID No. 10


TTCGGATCCGACATGGAAGATGGACC

30 SEQ ID No. 11

GGTGACTAGTGCTCAATCTTCAGATGC

SEQ ID No. 12

40 ${\tt CCAACCCCGGCTCATCCCTGCGGGGCCCATCACCCAGGGTACCACCATCTCTGCCTACGTGGCCAAGTCTAGG}$ AAGACGTTGTTGGTAGAGGATATCCTTGGGGATGAGCGATTTCCTCGAGGTACTGGCCTGGAATCAGGAACCCGCATCCAGTCTGTTCTTTGCCTTGCCCATTGTCACTGCCATTGGAGACTTGATTGGCATCCTTGAACTGTACAG 45 GCAATACACCAGGTGCAGGTGTAGAGGTCTCGCCAAACAGACCGAACTGAATGACTTCCTACTCGACGTAT CAAAGACATACTTTGATAACATAGTTGCCATAGACTCTCTACTTGAACACATCATAATATATGCAAAAAATCT AGTGAACGCCGACCGCTGCGCGCTCTTCCAGGTGGACCACAAGAACAAGGAGCTGTACTCGGACCTGTTTGACATTGGGGAGGAGGAGGGGGAAGCCCATCTTCAAGAAGACCAAGGAGATCAGATTTTCCATTGAGAAAGGGA TTGCTGGTCAAGTGGCAAGAACAGGCGAAGTCTTGAACATTCCCGATGCCTACGCGGACCCTCGCTTTAACAG 50 ${\tt GGAGGTGGACCTGTACACGAGGCTACACCACGAGGAACATTCTGTGTATGCCCATAGTGAGCCGAGGCAGCGTG}$ TGTTTGCTGTCTTCTGCGCACTGGCCTTGCACTGTGCTAACGCCAGATGGAAAAGCCTAGCTTCTCCCCCTG GGTCAGCTGGGAAGGTTTGCTAGCTTGCCTGCACTGTGGCAAAGACCTGAGGACCTGGAATGGTGACCACTGT 55 CTGACGTGCACAGTCTTTCCTGCCTCTGTGACACCCGCTTGGGATA



15

20

25

30

35

40

45

50

55

FLGECNNSLCVFIPPGMKEGQPRLIPAGPITQGTTISAYVAKSRKTLLVEDILGDERFPRGTGLESGTRIQSV LCLPIVTAIGDLIGILELYRHWDKEAFCLSHQEVATANLAWASVAIHQVQVCRGLAKQTELNDFLLDVSKTYF DNIVAIDSLLEHIIIYAKNLVNADRCALFQVDHKNKELYSDLFDIGEEKEGKPIFKKTKEIRFSIEKGIAGQV ARTGEVLNIPDAYADPRFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVF CALALHCA

SEQ ID No. 14 (Nucleotide sequence of PDE11A3)

GGAGGAGGAGGCGCCGCCGATGCTGGCGCGCGGCGGAGGAGGACAAGAGGCAGCTCCCTTGAGCG TCCCCCAGGCAGTAGTCACCGCAGCAGCGGTGGCAGCAGCGGTGGCAGCGGCGGCGGCGGCGGCGGCTCTTCCT CCGGCTCTGCCGCTGGCCGAACTCTTTGGCGGCCCCGAGGCGCCCTTCCCCCTTGCCACCGTTTGGCC GCTGCCCTTCGGCTCCGACATGGAAGATGGACCCTCTAACAATGCGAGTTGCTTCCGAAGGCTGACCGAGTGT TTCCTCAGCCCCAGTTTGACGGATGAAAAGGTGAAGGCCTATCTTTCTCTCCATCCCAGGTATTAGATGAAT TTGTTTCTGAAAGTGTTAGTGCAGAGACTGTGGAAAAGTGGCTGAAGAGGAAAACCAACAAAGCAAAAGATGA ACCATCTCCCAAGGAAGTCAGCAGGTACCAGGATACGAATATGCAGGGAGTCGTGTACGAGCTGAACAGCTAC ATAGAGCAGCGCCTGGACACGGGGGGGGACAACCACCTGCTCCTCTATGAGCTCAGCAGCATCATCAGGATAG CGGGATGAAGGAAGGCCAACCCCGGCTCATCCCTGCAGGGCCCATCACCCAGGGTACCACCATCTCTGCCTAC GTGGCCAAGTCTAGGAAGACGTTGTTGGTAGAGGATATCCTTGGGGATGAGCGATTTCCTCGAGGTACTGGCC TGGAATCAGGAACCCGCATCCAGTCTGTTCTTTGCTTGCCCATTGTCACTGCCATTGGAGACTTGATTGGCAT CCTTGAACTGTACAGGCACTGGGGCAAAGAGGCCTTCTGCCTCAGCCATCAGGAGGTTGCAACAGCCAATCTT GCTTGGGCTTCCGTAGCAATACACCAGGTGCAGGTGTGTAGAGGTCTCGCCAAACAGACCGAACTGAATGACT TCCTACTCGACGTATCAAAGACATACTTTGATAACATAGTTGCCATAGACTCTCTACTTGAACACATCATGAT ATATGCAAAAAATCTAGTGAACGCCGACCGCTGCGCGCTCTTCCAGGTGGACCACAAGAACAAGGAGCTGTAC TCGGACCTGTTTGACATTGGGGAGGAGGAGGGGGAAGCCCATCTTCAAGAAGACCAAGGAGATCAGATTTT CCATTGAGAAAGGGATTGCTGGTCAAGTGGCAAGAACAGGCGAAGTCTTGAACATTCCCGATGCCTACGCGGA CCCTCGCTTTAACAGGGAGGTGGACCTGTACACAGGCTACACCACGAGGAACATTCTGTGTATGCCCATAGTG AGAACAACTTCAAGATGTTTGCTGTCTTCTGCGCACTGGCCTTGCACTGTGCTAACATGTACCACAGGATCCG CCACTCAGAATGCATCTACAGGGTTACCATGGAGAAGCTTTCCTACCACAGCATCTGCACCTCCGAGGAGTGG CAAGGCCTCATGCGCTTCAACCTACCAGCACGCATCTGCCGGGACATCGAGCTATTCCACTTTGACATTGGTC CTTTCGAGAACATGTGGCCTGGGATCTTTGTCTACATGATCCATCGGTCTTGTGGGACATCCTGTTTTGAACT TGAAAAATTGTGCCGTTTTATCATGTCTGTGAAGAAGAACTATCGGCGGGTTCCTTACCACAACTGGAAGCAT

GCAGTCACGGTGGCACACTGCATGTATGCCATACTTCAAAACAACAATGGCCTCTTCA AGACCTCGAGCGCA AAGGCCTGCTAATTGCGTGTCTGTGCCATGACCTGGACCACAGGGGCTTCAGTAACAGCTACCTGCAGAAGTT $\tt CGACCACCCCTGGCGGCGCTGTACTCCACCTCCACCATGGAGCAACACCACTTCTCCCAGACGGTGTCCATC$ $\tt CTTCAGCTGGAAGGGCACAATATCTTCTCCACCCTGAGCTCCAGCGAGTACGAGCAGGTGCTGGAGATCATCC$ ${\tt AGGGTCGCTGAACCTCCACAACCAGTCCCATCGAGACCGTGTCATCGGCTTGATGATGACTGCCTGTGATCTT}$ $\tt GTGATGAGATGAAGATGGGCCATACAGCCCATTCCTATGATGGACAGAGACAAGCGAGATGAAGTCCCTCA$ GAGCCTCTGCTGAAGGCCTGCAGGGATAACCTCAATCAGTGGGAGAAGGTAATTCGCGGGGAAGAGACAGCAA TGTGGATTTCAGGCCCAGGCCCGGCGCCTAGCAAGAGCACACCTGAGAAGCTGAACGTGAAGGTTGAAGACTG ${\tt TCAAGGGGTGAAAACCCCCTGTCAGAAGGTACCGTCGCATATCCATGTGAAGCAGACGACTCCCTGCTTGCCG}$ CCTGCATCCTCCCATGAGGGTGTGGCCAGTTCCCTGGTTCTGTGCCATGCTGCTTGGTGGCATTGGTTAG ${\tt GAATGGGACACGCCCCTTGTTGTGAAGTTTACATGTGACCTTCTTATAGGTTAACTGAGTTTGTGGCCTGG}$ ATCCAGGGGACACAGGGTACATCCCAGGCATCGGGGAACTGAAGCTCTCACTTCAAACCATGTCAAAGAATTA AAACACCTCCCCTCCCCTCACTGTAGCCTTCGGCAACTGCGCCAATCCCTTTATACAAAGAAAATAAAAGTA AGGCATATAAATTTAAAAAAAAAAAAAAA

SEQ ID No. 15 (Amino acid sequence of PDE11A3)

MEDGPSNNASCFRRLTECFLSPSLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRKTNKAKDEPSPKEVSRYQDTN
MQGVVYELNSYIEQRLDTGGDNHLLLYELSSIIRIATKADGFALYFLGECNNSLCVFIPPGMKEGQPRLIPAGPITGGTT
ISAVVAKSRKTLLVEDILGDERFPRGTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLAWA
SVAIHQVQVCRGLAKQTELNDFILDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALFQVUHKNKELYSDLFDIGEEK
EGKPIFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVMKISG
SAFSKTDENNFKMFAVPCALALHCAMMYHRIRHSECIYRVTMEKLSYHSICTSEWGGLMRFRLPARICRDIELFHFDIG
PFENMWPGIFVYMIHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVEHCMYAILQNNNGLFTDLERKGLLIAC
LCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLECHNIFSTLSSSEVEQVLEIIRKAIIATDLALYFG
NRKQLEEMYQTGSLNLHNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKRD
EVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLNQWEKVIRGEETAMMISGPGPAPSKSTPEKLNVKVED

SEQ ID No. 16

5

10

15

20

25

30

35

40

45

Partial sequence obtained from a rat clone representing the first 1250 bp of rat PDE11.

SEQ ID No. 17

10

5

MEDGPSNNASCFRRLTECFLSPSLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRKN DKAEDEPSPKEVSRYQDTNMQGVVYELNSYIEQRLDTGGDNHLLLYELNSIIRIATKADGF ALYFLGECNNSLCVFTPPGMKEGOPRLIPAGPITQGTT

15

SEQ ID No. 18

Partial sequence obtained from a rat clone containing rat PDE11.

AATCTCGCTTGGGCTTCCGTAGCAATACACCAGGTGCAGGTGCAGAGGTCTCGCCAAGC
AGACCGAACTGAATGACTTCCTGCTCGATGTATCAAAGACATACTTTGATAACATAGTCGC
CATAGACTCTCTACTTGAACACATCATGATATATGCAAAAAATCTAGTGAACGCCGACCGC
TGCGCGCTCTTCCAGGTGGACCACAAGAACAAGGAGCTGTACTCGGACCTGTTTGACATTG
GGGAGGAGAAGGAGGGGAAGCCCGTCTTCAAGAAGACCAAGGAGATCAGATTTTCCATTGA
GAAAGGGATTGCTGGTCAAGTGGCAAGAACGGGAGAGTCCTGAACATTCCTGATGCCTAC
GCAGACCCGCGCTTTAACAGGGAGGTGGACCTGTACACAGGCTATACCACGCGGAACATTC
TGTGTATGCCCATAGTGAGCCGCGGCAGCGTGATCGGTGGTGCAAATGGTTAACAAGAT
CAGCGGCAGCGCCTTCTCCAAGACGGATGAGAACAACTTCAAGATGAAGGGC

35

SEQ ID No. 19

40 C

NLAWASVAIHQVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADR CALFQVDHKNKELYSDLFDIGEEKEGKPVFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAY ADPRFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKM

45

50



SEQUENCE LISTING

	024,
5	
	<110> Pfizer Limited
	Pfizer Incorporated
10	<120> Phosphodiesterase Enzymes
	<130> P004205EP CTH
15	<140> EP 99303985.8
	<141> 1999-05-21
20	<150> GB 9811500.9
20	<151> 1998-05-28
	<150> GB 9823882.7
25	<151> 1998-10-30
	<150> GB 9826777.6
	<151> 1998-12-04
30	<150> GB 9908247.1
	<151> 1999-04-09
35	<150> GB 9910801.1
	<151> 1999-05-10
	<160> 47
40	<170> PatentIn Ver. 2.1
	<210> 1
45	<211> 2554
	<212> DNA

<213> Homo sapiens

50

<400> 1


	ttcggctccg	acatggaaga	tggaccttct	aataatgcga	gctgcttccg	aaggctgacc	60
5	gagtgcttcc	tgagccccag	tttgacagat	gaaaaagtga	aggcatatct	ttctcttcac	120
J	ccccaggtat	tagatgaatt	tgtatctgaa	agtgttagtg	cagagacagt	agagaaatgg	180
	ctgaagagga	agaacaacaa	atcagaagat	gaatcagctc	ctaaggaagt	cagcaggtac	240
	caagatacga	atatgcaggg	agttgtatat	gaactaaaca	gctatataga	acaacggttg	300
10	gacacaggag	gagacaacca	gctactcctc	tatgaactga	gcagcatcat	taaaatagcc	360
	acaaaagccg	atggatttgc	actytatttc	cttggagagt	gcaataatag	cctgtgtata	420
	ttcacgccac	ctgggataaa	ggaaggaaaa	cccgcctca	tccctgctgg	gcccatcact	480
	cagggcacca	ccgtctctgc	ttatgtggcc	aagtccagga	aaacactgct	agtagaagac	540
15	atccttggag	atgaacgatt	tccaagaggt	actggactgg	aatcagggac	tcgtatccag	600
	tctgttcttt	gcttaccaat	tgtcactgca	attggtgact	tgattggtat	tctcgagctg	660
	tatcggcact	ggggcaaaga	agccttctgt	cttagtcacc	aggaggttgc	aacagcaaat	720
	cttgcctggg	cttcagtagc	aatacatcag	gtgcaggtat	gcagaggcct	tgccaaacag	780
20	acagaattga	atgacttcct	actcgacgta	tcaaaaacat	attttgataa	catagttgca	840
	atagattctc	tacttgaaca	cataatgata	tatgcaaaaa	acctggtgaa	tgccgatcgt	900
	tgtgcacttt	tccaggtgga	ccataagaac	aaggagttat	attcagacct	ttttgatatt	960
	ggagaggaaa	aggaaggaaa	acctgtcttc	aagaagacca	aagagataag	attttcaatt	1020
25	gagaaaggaa	ttgctggcca	agtagcaaga	acaggggaag	tcctgaacat	tccagatgcc	1080
	tatgcagacc	cacgctttaa	cagagaagta	gacttgtaca	caggctacac	cacgcggaac	1140
	atcctgtgca	tgcccatcgt	cagccgaggc	agcgtgatag	gtgtggtgca	gatggtcaac	1200
	aaaatcagtg	gcagtgcctt	ctctaaaaca	gatgaaaaca	acttcaaaat	gtttgccgtc	1260
30	ttttgtgctt	tagccttaca	ctgtgctaat	atgtatcata	gaattcgcca	ctcagagtgc	1320
	atttaccggg	taacgatgga	aaagctgtcc	taccatagca	tttgtacttc	agaagagtgg	1380
	caaggtctca	tgcaattcac	ccttcccgtg	cgtctctgca	aagaaattga	attattccac	1440
	tttgacattg	gtccttttga	aaacatgtgg	cctggaattt	ttgtctacat	ggttcatcgg	1500
35	tcctgtggga	catcctgctt	tgagcttgaa	aagttgtgtc	gttttattat	gtctgtgaag	1560
	aagaactatc	ggcgggttcc	ttatcacaac	tggaagcatg	cggtcactgt	agcacactgc	1620
		tacttcagaa	_				
40		gtctgtgtca					
40		accetetgae					
		tgtccatcct					
	agtgaatatg	agcaggtgct	tgagatcatc	cgcaaagcca	tcattgccac	agaccttgct	1920
45		gaaacaggaa					
		cacatagaga					
		aaccgtggcc					
		gtgatgaaat					
	gacaagaagg	atgaagtccc	ccaaggccag	cttgggttct	acaatgccgt	ggccattccc	2220

	tgo	ctat	acaa	ccc	ttaco	ca q	gatc	ctcc	ct c	ccac	ggag	c ct	cttc	tgaa	agc	atgcagg	2280
	gat	aat	ctca	gtca	agtg	ga g	gaag	gtga	tt c	gagg	ggag	g ag	actg	caac	ctg	gatttca	2340
5	tcc	cca	tccg	tgg	ctcaç	gaa g	gca	gctgo	ca to	ctgaa	agat	t ga	gcac	tggt	cac	- cctgaca	2400
	cgc	tgt	ccca	ccta	acaga	atc c	ctcat	tcttq	gc ti	ctt	tgac	a tt	cttt	tcct	ttt	ttggggg	2460
	ggg	tgg	gggg	aaco	etgea	icc t	ggta	aacto	gg gg	gtgca	aac	c tc	ttcaa	agaa	ggta	acatca	2520
	aat	aaat	taag	tcaa	agcaç	jaa a	aaaa	aaaa	aa aa	aaa							2554
10																	
		.0> 2	-													•	
		1> 7															
15		2> I															
	<21	3> F	omo	sapi	ens												
20		0> 2															
20			ı Asp	Gly			Asn	Asn	Ala	Ser	Cys	Phe	Arg	Arg	Leu	Thr	
	1				5					10					15		
	61			_													
25	GIU	Cys	Phe			Pro	Ser	Leu	Thr	Asp	Glu	Lys	Val	Lys	Ala	Tyr	
				20					25					30			
	Lou	50*		***	D	~ 1	•	_									
	Leu	ser	ьец 35	His	Pro	Gin	Val		Asp	Glu	Phe	Val			Ser	Val	
30			33					40					45				
	Ser	Ala	Glu	Thr	₩.	GI.	T 150	//\	T	T	•	•	_	_			
		50		Thr	Val	Giu	55 55	пр	reu	гÀа	Arg		Asn	Asn	Lys	Ser	
							33					60					
35	Glu	Asp	Glu	Ser	Ala	Pro	Lvs	Glin	Va 1	Sor	A *~~	Mar-	C1 =	3 am	m>	•	
	65	_				70	-,-	014	٧۵١	261	75	TYL	GIII	ASD	Thr	Asn 80	
											,,					80	
40	Met	Gln	Gly	Val	Val	Tyr	Glu	Leu	Asn	Ser	Tvr	Ile	Glu	Gl n	Ara	Leu	
40					85	_				90	-2-		010	0	95	Dea	
															,,		
	Asp	Thr	Gly	Gly	Asp	Asn	Gln	Leu	Leu	Leu	Tyr	Glu	Leu	Ser	Ser	Ile	
45				100					105		_			110			
	Ile	Lys	Ile	Ala	Thr	Lys	Ala	Asp	Gly	Phe	Ala	Leu	Tyr	Phe	Leu	Gly	
			115					120					125			_	
50																	

													,			
	Glu	Cys	Asn	Asn	Ser	Leu	Cys 135	Ile	Phe	Thr	Pro	Pro	Gly	Ile	Lys	Glu
5																
	Gly 145	Lys	Pro	Arg	Leu	Ile 150	Pro	Ala	Gly	Pro	Ile 155	Thr	Gln	Gly	Thr	Thr 160
			_													
10	Val	Ser	Ala	Tyr	Val 165	Ala	Lys	Ser	Arg	Lys 170	Thr	Leu	Leu	Val	Glu 175	Asp
	~ 1 _	•	G1			_	_,	_								
15	11e	Leu	GIĀ	Asp 180	GIU	Arg	Phe	Pro	Arg 185	Gly	Thr	Gly	Leu	Glu 190	Ser	Gly
	Thr	Ara	Tle	Gln	Ser	v=1	Leu	Cvc	Lou	B∽o	T10	Wa 1		21-	Tlo	C1
			195	5111	JCI	V	Deu	200	Deu	FIO	116	val	205	AIG	TIE	GIY
20	Asp	Leu	Ile	Gly	Ile	Leu	Glu	Leu	Tvr	Ara	His	Tro	Glv	Lvs	Glu	Ala
	_	210	•	_			215			3		220		-3-		
25	Phe	Cys	Leu	Ser	His	Gln	Glu	Val	Ala	Thr	Ala	Asn	Leu	Ala	Trp	Ala
	225					230					235					240
	Ser	Val	Ala	Ile	His	Gln	Val	Gln	Val	Cys	Arg	Gly	Leu	Ala	Lys	Gln
30					245					250					255	
	Thr	Glu	Leu	Asn	Asp	Phe	Leu	Leu		Val	Ser	Lys	Thr		Phe	Asp
35				260					265					270		
	Asn	Ile	Val 275	Ala	Ile	Asp	Ser	Leu 280	Leu	Glu	His	Ile	Met 285	Ile	Tyr	Ala
40																
40	Lys	Asn 290	Leu	Val	Asn	Ala	Asp 295	Arg	Cys	Ala	Leu	Phe 300	Gln	Val	Asp	His
	.	>	•	01		_	_		_		_					
45	305	ASN	rys	Glu		1yr 310	Ser	Asp	Leu	Phe	Asp 315	Ile	GIY	Glu	Glu	Lys 320
	Glu	Glv	Lvs	Pro	Va1	Pho	Ive	T.ve	ሞኮ∽	Ive	Gl»	T1_	Δra	Pho	Sor	Tla
50		~-1	- , 0		325		⊷y 3	n X s	1111	330	JIU	-1-C	.rry	-116	335	**6

	Glu	ı Lys	Gly	Ile 340		G13	/ Gln	Va]	Ala 345		Thr	Gly	Glu	Va]		ı Asn
5	Ile	Pro	Asp	Ala	Tyr	Ala	Asp	Pro			. Asn	Arg	Glu			Leu
			355					360					365			
10	Туг	370		Tyr	Thr	Thr	375	Asn	Ile	Leu	Суз	Met 380		Ile	val	Ser
15	Arg 385	Gly	Ser	Val	Ile	Gly 390		Val	Gln	Met	Val 395	Asn	Lys	Ile	Ser	Gly 400
20	Ser	Ala	Phe	Ser	Lys 405	Thr	Asp	Glu	Asn	Asn 410	Phe	Lys	Met	Phe	Ala 415	
	Phe	Суз	Ala	Leu 420	Ala	Leu	His	Cys	Ala 425	Asn	Met	Tyr	His	Arg 430		Arg
25	His	Ser	Glu 435	Cys	Ile	Tyr	Arg	Val 440	Thr	Met	Glu	Lys	Leu 445	Ser	Tyr	His
30	Ser	Ile 450	Суз	Thr	Ser	Glu	Glu 455	Trp	Gln	Gly	Leu	Met 460	Gln	Phe	Thr	Leu
35	Pro 465	Val	Arg	Leu	Cys	Lys 470	Glu	Ile	Glu	Leu	Phe 475	His	Phe	Asp	Ile	Gly 480
	Pro	Phe	Glu	Asn	Met 485	Trp	Pro	Gly	Ile	Phe 490	Val	Tyr	Met	Val	His 495	Arg
40	Ser	Cys	Gly	Thr 500	Ser	Cys	Phe	Glu	Leu 505	Glu	Lys	Leu	Суѕ	Arg 510	Phe	Ile
45	Met	Ser	Val 515	Lys	Lys	Asn		Arg 520	Arg	Val	Pro	Tyr	His 525	Asn	Trp	Lys
50	His	Ala 530	Val	Thr	Val :	Ala	His 535	Cys	Met	Tyr		Ile 540	Leu	Gln	Asn	Asn

			1											,			
		His 545	Thr	Leu	Phe	Thr	Asp 550	Leu	Glu	Arg	Lys	Gly 555	Leu	Leu	Ile	Ala	Cys 560
	I	Leu	Cys	His	Asp	Leu 565	Asp	His	Arg	Gly	Phe 570	Ser	Asn	Ser	Tyr	Leu 575	Gln
10	I	Ċys	Phe	Asp	His 580	Pro	Leu	Thr	Ala	Leu 585	Tyr	Ser	Thr	Ser	Thr 590	Met	Glu
15	Ó	Sln	His	His 595	Phe	Ser	Gln	Thr	Val 600	Ser	Ile	Leu	Gln	Leu 605	Glu	Gly	His
20	,	Asn	Ile 610	Phe	Ser	Thr	Leu	Ser 615	Ser	Ser	Glu	Tyr	Glu 620	Gln	Val	Leu	Glu
		11e 525	Ile	Arg	Lys	Ala	Ile 630	Ile	Ala	Thr	Asp	Leu 635	Ala	Leu	Tyr	Phe	Gly 640
25	2	Asn	Arg	Lys	Gln	Leu 645	Glu	Glu	Met	туг	Gln 650	Thr	Gly	Ser	Leu	Asn 655	Leu
30	2	sn	Asn	Gln	Ser 660	His	Arg	Asp	Arg	Val 665	Ile	Gly	Leu	Met	Met 670	Thr	Ala
35	c	`ys	Asp	Leu 675	Суз	Ser	Val	Thr	Lys 680	Pro	Trp	Pro	Val	Thr 685	Lys	Leu	Thr
	A		Asn 690	Asp	Ile	Tyr	Ala	Glu 695	Phe	Trp	Ala	Glu	Gly 700	Asp	Glu	Met	Lys
40		ys 05	Leu	Gly	Ile	Gln	Pro 710	Ile	Pro	Met	Met	Asp 715	Arg	Asp	Lys	Lys	Asp 720
45	G	lu	Val	Pro		Gly 725	Gln	Leu	Gly	Phe	Tyr 730	Asn	Ala	Val	Ala	Ile 735	Pro
50	C	ys	туг		Thr 740	Leu	Thr	Gln	Ile	Leu 745	Pro	Pro	Thr	Glu	Pro 750	Leu	Leu



gaagccagat gctccagaga gcaggtttga cagatgaaaa agtgaaggca tatctttctc 360 ttcaccccca ggtattagat gaatttgtat ctgaaagtgt tagtgcagag acagtagaga 420 aatggctgaa gaggaagaac aacaaatcag aagatgaatc agctcctaag gaagtcagca 480 ggtaccaaga tacgaatatg cagggagttg tatatgaact aaacagctat atagaacaac 540 35 ggttggacac aggaggagac aaccagctac tcctctatga actgagcagc atcattaaaa 600 tagccacaaa agccgatgga tttgcactgt atttccttgg agagtgcaat aatagcctgt 660 gtatattcac gccacctggg ataaaggaag gaaaaccccg cctcatccct gctgggccca 720 tcactcaggg caccaccgtc tctgcttatg tggccaagtc caggaaaaca ctgctagtag 780 40 aagacateet tggagatgaa egattteeaa gaggtaetgg aetggaatea gggaetegta 840 tecagtetgt tetttgetta ecaattgtea etgeaattgg tgaettgatt ggtatteteg 900 agetgtateg geactgggge aaagaageet tetgtettag teaccaggag gttgcaacag 960 caaatettge etgggettea gtagcaatae ateaggtgea ggtatgeaga ggeettgeea 1020 45 aacagacaga attgaatgac ttcctactcg acgtatcaaa aacatatttt gataacatag 1080

50

55

ttgcaataga ttctctactt gaacacataa tgatatatgc aaaaaacctg gtgaatgccg 1140 atcgttgtgc acttttccag gtggaccata agaacaagga gttatattca gacctttttg 1200 atattggaga ggaaaaggaa ggaaaacctg tcttcaagaa gaccaaagag ataagatttt 1260

```
caattgagaa aggaattgct ggccaagtag caagaacagg ggaagtcctg aacattccag 1320
        atgcctatgc agacccacgc tttaacagag aagtagactt gtacacaggc tacaccacgc 1380
        ggaacateet gtgcatgeec ategteagee gaggeagegt gataggtgtg gtgcagatgg 1440
5
        tcaacaaaat cagtggcagt gccttctcta aaacagatga aaacaacttc aaaatgtttg 1500
        ccgtcttttg tgctttagcc ttacactgtg ctaatatgta tcatagaatt cgccactcag 1560
        agtgcattta ccgggtaacg atggaaaagc tgtcctacca tagcatttgt acttcagaag 1620
        agtggcaagg tctcatgcaa ttcacccttc ccgtgcgtct ctgcaaagaa attgaattat 1680
10
        tccactttga cattggtcct tttgaaaaca tgtggcctgg aatttttgtc tacatggttc 1740
        ateggteetg tgggacatee tgetttgage ttgaaaagtt gtgtegtttt attatgtetg 1800
        tgaagaagaa Ctatcggcgg gttccttatc acaactggaa gcatgcggtc actgtagcac 1860
        actgcatgta tgccatactt cagaacaatc acacgctttt cacagacctt gagcgcaaag 1920
15
        gactgctgat tgcgtgtctg tgtcatgacc tggaccacag gggcttcagt aacagctacc 1980
        tgcagaagtt cgaccacct ctgaccgctc tctactccac ttccaccatg gagcagcacc 2040
        acttctccca gactgtgtcc atccttcagt tggaagggca caatatcttc tccactctga 2100
20
        gctccagtga atatgagcag gtgcttgaga tcatccgcaa agccatcatt gccacagacc 2160
        ttgctttata ctttggaaac aggaagcagt tggaagagat gtaccagacc ggatcactaa 2220
        accttaataa tcaatcacat agagaccgtg taattggttt gatgatgact gcctgtgacc 2280
        tttgttctgt gacaaaaccg tggcccgtta caaaattgac ggcaaatgat atatatgcag 2340
25
        aattctgggc tgagggtgat gaaatgaaga aattgggaat acagcctatt cctatgatgg 2400
        acagagacaa gaaggatgaa gtcccccaag gccagcttgg gttctacaat gccgtggcca 2460
        ttccctgcta tacaaccctt acccagatcc tccctcccac ggagcctctt ctgaaagcat 2520
        gcagggataa tctcagtcag tgggagaagg tgattcgagg ggaggagact gcaacctgga 2580
30
        tttcatcccc atccgtggct cagaaggcag ctgcatctga agattgagca ctggtcaccc 2640
        tgacacgctg tcccacctac agatcctcat cttgcttctt tgacattctt ttccttttt 2700
        gggggggtg gggggaacct gcacctggta actggggtgc aaacctcttc aagaaggtaa 2760
       catcaaataa ataagtcaag cagaaaaaaa aaaaaaaa
                                                                          2798
35
       <210> 4
        <211> 791
        <212> PRT
40
       <213> Homo sapiens
       <400> 4
       Met Glu Gly Ser Thr Ala Trp Ser Ser Glu Ala Glu Pro Gln Glu Gly
45
       Arg Ser Gln Met Leu Gln Arg Ala Gly Leu Thr Asp Glu Lys Val Lys
                     20
                                         25
                                                             30
```

59

50

5	Ala Tyr Leu Ser Leu His Pro Gln Val Leu Asp Glu Phe Val Ser Glu 35 40 45
	Ser Val Ser Ala Glu Thr Val Glu Lys Trp Leu Lys Arg Lys Asn Asn 50 55 60
10	Lys Ser Glu Asp Glu Ser Ala Pro Lys Glu Val Ser Arg Tyr Gln Asp 65 70 75 80
15	Thr Asn Met Gln Gly Val Val Tyr Glu Leu Asn Ser Tyr Ile Glu Gln 85 90 95
20	Arg Leu Asp Thr Gly Gly Asp Asn Gln Leu Leu Leu Tyr Glu Leu Ser 100 105 110
	Ser Ile Ile Lys Ile Ala Thr Lys Ala Asp Gly Phe Ala Leu Tyr Phe 115 120 125
25	Leu Gly Glu Cys Asn Asn Ser Leu Cys Ile Phe Thr Pro Pro Gly Ile 130 135 140
30	Lys Glu Gly Lys Pro Arg Leu Ile Pro Ala Gly Pro Ile Thr Gln Gly 145 150 155 160
35	Thr Thr Val Ser Ala Tyr Val Ala Lys Ser Arg Lys Thr Leu Leu Val 165 170 175
40	Glu Asp Ile Leu Gly Asp Glu Arg Phe Pro Arg Gly Thr Gly Leu Glu 180 185 190
40	Ser Gly Thr Arg Ile Gln Ser Val Leu Cys Leu Pro Ile Val Thr Ala 195 200 205
<i>45</i>	Ile Gly Asp Leu Ile Gly Ile Leu Glu Leu Tyr Arg His Trp Gly Lys 210 215 220
50	Glu Ala Phe Cys Leu Ser His Gln Glu Val Ala Thr Ala Asn Leu Ala 225 230 235 240

											•					
	Trp	Ala	Ser	Val	Ala 245	Ile	His	Gln	Val	Gln 250	Val	Cys	Arg	Gly	Leu 255	Ala
5	Lys	Gln	Thr	Glu 260	Leu	Asn	Asp	Phe	Leu 265	Leu	Asp	Val	Ser	Lys 270	Thr	Tyr
10	Phe	Asp	Asn 275	Ile	Val	Ala	Ile	Asp 280	Ser	Leu	Leu	Glu	His 285	Ile	Met	Ile
15	Tyr	Ala 290	Lys	Asn	Leu	Val	Asn 295	Ala	Asp	Arg	Cys	Ala 300	Leu	Phe	Gln	Val
20	Asp 305	His	Lys	Asn	Lys	Glu 310	Leu	Tyr	Ser	Asp	Leu 315	Phe	Asp	Ile	Gly	Glu 320
	Glu	Lys	Glu	Gly	Lys 325	Pro	Val	Phe	Lys	Lys 330	Thr	Lys	Glu	Ile	Arg 335	Phe
25	Ser	Ile	Glu	Lys 340	Gly	Ile	Ala	Gly	Gln 345	Val	Ala	Arg	Thr	Gly 350	Glu	Val
30	Leu	Asn	Ile 355	Pro	Asp	Ala	Tyr	Ala 360	Asp	Pro	Arg	Phe	Asn 365	Arg	Glu	Val
35	Asp	Leu 370	Tyr	Thr	Gly	Tyr	Thr 375	Thr	Arg	Asn	Ile	Leu 380	Сув	Met	Pro	Ile
	Val 385	Ser	Arg	Gly	Ser	Val 390	Ile	Gly	Val	Val	Gln 395	Met	Val	Asn	Lys	Ile 400
40	Ser	Gly	Ser	Ala	Phe 405	Ser	Lys	Thr	Asp	Glu 410	Asn	Asn	Phe	Lys	Met 415	Phe
45	Ala	Val	Phe	Cys 420	Ala	Leu	Ala	Leu	His 425	Cys	Ala	Asn	Met	Tyr 430	His	Arg
50	Ile	Arg	His 435	Ser	Glu	Cys		Tyr 440	Arg	Val	Thr	Met	Glu 445	Lys	Leu	Ser

	Tyr His Ser Ile Cys Thr Ser Glu Glu Trp Gln Gly Leu Met Gln Phe 450 455 460
5	Thr Leu Pro Val Arg Leu Cys Lys Glu Ile Glu Leu Phe His Phe Asp 465 470 475 480
10	Ile Gly Pro Phe Glu Asn Met Trp Pro Gly Ile Phe Val Tyr Met Val 485 490 495
15	His Arg Ser Cys Gly Thr Ser Cys Phe Glu Leu Glu Lys Leu Cys Arg 500 505 510
20	Phe Ile Met Ser Val Lys Lys Asn Tyr Arg Arg Val Pro Tyr His Asn 515 520 525
	Trp Lys His Ala Val Thr Val Ala His Cys Met Tyr Ala Ile Leu Gln 530 535 540
25	Asn Asn His Thr Leu Phe Thr Asp Leu Glu Arg Lys Gly Leu Leu Ile 545 550 555 560
30	Ala Cys Leu Cys His Asp Leu Asp His Arg Gly Phe Ser Asn Ser Tyr 565 570 575
<i>35</i>	Leu Gln Lys Phe Asp His Pro Leu Thr Ala Leu Tyr Ser Thr Ser Thr 580 585 590
	Met Glu Gln His His Phe Ser Gln Thr Val Ser Ile Leu Gln Leu Glu 595 600 605
40	Gly His Asn Ile Phe Ser Thr Leu Ser Ser Glu Tyr Glu Gln Val 610 615 620
45	Leu Glu Ile Ile Arg Lys Ala Ile Ile Ala Thr Asp Leu Ala Leu Tyr 625 630 635 640
50	Phe Gly Asn Arg Lys Gln Leu Glu Glu Met Tyr Gln Thr Gly Ser Leu 645 650 655

	Asn	Leu	Asn	Asn 660	Gln	Ser	His	Arg	Asp 665	Arg	Val	Ile	Gly	Leu 670	Met	Met
5	Thr	Ala	Cys 675	Asp	Leu	Cys	Ser	Val 680	Thr	Lys	Pro	Trp	Pro 685	Val	Thr	Lys
10	Leu	Thr 690	Ala	Asn	Asp	Ile	Tyr 695	Ala	Glu	Phe	Trp	Ala 700	Glu	Gly	Asp	Glu
15	Met 705	Lys	Lys	Leu	Gly	Ile 710	Gln	Pro	Ile	Pro	меt 715	Met	Asp	Arg	Asp	Lys 720
20	Lys	Asp	Glu	Val	Pro 725	Gln	Gly	Gln	Leu	Gly 730	Phe	Tyr	Asn	Ala	Val 735	Ala
•	Ile	Pro	Суз	Tyr 740	Thr	Thr	Leu	Thr	Gln 7 4 5	Ile	Leu	Pro	Pro	Thr 750	Glu	Pro
25	Leu	Leu	Lys 755	Ala	Суз	Arg	Asp	Asn 760	Leu	Ser	Gln	Trp	Glu 765	Lys	Val	Ile
30	Arg	Gly 770	Glu	Glu	Thr	Ala	Thr 775	Trp	Ile	Ser	Ser	Pro 780	Ser	Val	Ala	Gln
35	Lys 785	Ala	Ala	Ala	Ser	Glu 790	Asp									
40	<21 <21	0> 5 1> 20 2> DI 3> A:		icia:) Sec	men	•									
45	<22 <22 <22	0> 1> m: 2> (:	isc_:	featı	ıre											

	<220>	
	<223> Description of Artificial Sequence: Primer	
5	Actificial Sequence: Primer	
	<400> 5	
	tenceytgrt crtaraayte	
		20
10		
	<210> 6	
	<211> 20	
15	<212> DNA	
	<213> Artificial Sequence	
	<220>	
20	<223> Description of Artificial Sequence: Primer	
	<400> 6	
	tacttcagaa caatcacacg	
25		20
23		
	<210> 7	
	<211> 20	
30	<212> DNA	
	<213> Artificial Sequence	
	<220>	
35	<223> Description of Artificial Sequence: Primer	
	<400> 7	
	tctccaagga aatacagtgc	
40		20
	<210> 8	
	<211> 11	
	<212> PRT	
45	<213> Artificial Sequence	
	<220>	
50	<223> Description of Artificial Sequence: Synthetic sequence	
J.		

	<400> 8
	Met Glu Asp Gly Pro Ser Asn Asn Ala Ser Cys
5	1 5 10
10	<210> 9
	<211> 13
	<212> PRT
	<213> Artificial Sequence
15	
	<220>
	<223> Description of Artificial Sequence: Synthetic
	sequence
20	
	<400> 9
	Glu Asp Glu Ser Ala Pro Lys Glu Val Ser Arg Tyr Cys
25	1 5 10
20	
	·
30	<210> 10
	<211> 26
	<212> DNA
	<213> Artificial Sequence
35	
	<220>
	<223> Description of Artificial Sequence: Primer
	<400> 10
40	
	ttcggatccg acatggaaga tggacc 26
45	<210> 11
40	<211> 27
	<212> DNA

55

50

<213> Artificial Sequence

```
<220>
          <223> Description of Artificial Sequence: Primer
  5
          <400> 11
          ggtgactagt gctcaatctt cagatgc
                                                                             27
 10
          <210> 12
          <211> 1068
          <212> DNA
          <213> Mus sp.
 15
         <400> 12
         atttgcactg tactttcctt ggagagtgca ataatagcct gtgtgtgttc ataccacccg 60
         ggatgaagga aggccaaccc cggctcatcc ctgcggggcc catcacccag ggtaccacca 120
 20
         tetetgeeta egtggeeaag tetaggaaga egttgttggt agaggatate ettggggatg 180
         agegatttcc tegaggtact ggeetggaat caggaaceeg catecagtet gttetttget 240
         tgcccattgt cactgccatt ggagacttga ttggcatcct tgaactgtac aggcactggg 300
         acaaagaggc cttctgcctc agccatcagg aggttgcaac agccaatctt gcttgggctt 360
25
         ccgtagcaat acaccaggtg caggtgtgta gaggtctcgc caaacagacc gaactgaatg 420
         acttectact egacgtatea aagacatact ttgataacat agttgeeata gactetetae 480
         ttgaacacat cataatatat gcaaaaaatc tagtgaacgc cgaccgctgc gcgctcttcc 540
30
         aggtggacca caagaacaag gagctgtact cggacctgtt tgacattggg gaggagaagg 600
         aggggaagcc catcttcaag aagaccaagg agatcagatt ttccattgag aaagggattg 660
        ctggtcaagt ggcaagaaca ggcgaagtet tgaacattee egatgeetae geggaecete 720
        gctttaacag ggaggtggac ctgtacacag gctacaccac gaggaacatt ctgtgtatgc 780
35
        ccatagtgag ccgaggcagc gtgattggcg tggtgcagat ggtgaacaag atcagcggta 840
        gcgccttctc caagacagac gagaacaact tcaagatgtt tgctgtcttc tgcgcactgg 900
        ccttgcactg tgctaacgcc agatggaaaa gcctagcttc tctcccctgg gtcagctggg 960
        aaggtttgct agcttgcctg cactgtggca aagacctgag gacctggaat ggtgaccact 1020
40
        gtctgacgtg cacagtettt cctgcctctg tgacacccgc ttgggata
                                                                           1068
        <210> 13
        <211> 300
        <212> PRT
       <213> Mus sp.
```

66

50

	<40	0> 1	3													
5	Phe 1	Leu	Gly	Glu	Cys 5	Asn	Asn	Ser	Leu	Cys 10	Val	Phe	Ile	Pro	Pro 15	Gly
	Met	Lys	Glu	Gly 20	Gln	Pro	Arg	Leu	Ile 25	Pro	Ala	Gly	Pro	Ile 30	Thr	Glr
10	Gly	Thr	Thr 35	Ile	Ser	Ala	Tyr	Val 40	Ala	Lys	Ser	Arg	Lys 45	Thr	Leu	Leu
15	Val	Glu 50	Asp	Ile	Leu	Gly	Asp 55	Glu	Arg	Phe	Pro	Arg 60	Gly	Thr	Gly	Leu
20	Glu 65	Ser	Gly	Thr	Arg	Ile 70	Gln	Ser	Val	Leu	Cys 75	Leu	Pro	Ile	Val	Thr 80
25	Ala	Ile	Gly	Asp	Leu 85	Ile	Gly	Ile	Leu	Glu 90	Leu	Tyr	Arg	His	Trp 95	Asp
	Lys	Glu	Ala	Phe 100	Cys	Leu	Ser	His	Gln 105	Glu	Val	Ala	Thr	Ala 110	Asn	Leu
30	Ala	Trp	Ala 115	Ser	Val	Ala	Ile	His 120	Gln	Val	Gln	Val	Cys 125	Arg	Gly	Leu
35	Ala	Lys 130	Gln	Thr	Glu	Leu	Asn 135	Asp	Phe	Leu	Leu	Asp 140	Val	Ser	Lys	Thr
40	Tyr 145	Phe	Asp	Asn	Ile	Val 150	Ala	Ile	Asp	Ser	Leu 155	Leu	Glu	His	Ile	Ile 160
	Ile	Tyr	Ala	Lys	Asn 165	Leu	Val	Asn	Ala	Asp 170	Arg	Cys	Ala	Leu	Phe 175	Gln
45	Val	Asp	His	Lys 180	Asn	Lys	Glu	Leu	Tyr 185	Ser	Asp	Leu		Asp 190	Ile	Gly
50																

	Glu Glu Lys Glu Gly Lys Pro Ile Phe Lys Lys Thr Lys Glu Ile Arg 195 200 205	
5	Phe Ser Ile Glu Lys Gly Ile Ala Gly Gln Val Ala Arg Thr Gly Glu	
10	Val Leu Asn Ile Pro Asp Ala Tyr Ala Asp Pro Arg Phe Asn Arg Glu	
	230 235 240	
15	Val Asp Leu Tyr Thr Gly Tyr Thr Thr Arg Asn Ile Leu Cys Met Pro 245 250 255	
20	Ile Val Ser Arg Gly Ser Val Ile Gly Val Val Gln Met Val Asn Lys 260 265 270	
	Ile Ser Gly Ser Ala Phe Ser Lys Thr Asp Glu Asn Asn Phe Lys Met 275 280 285	
25	Phe Ala Val Phe Cys Ala Leu Ala Leu His Cys Ala 290 295 300	
30		
35	<210> 14 <211> 3606 <212> DNA <213> Mus sp.	
	<400> 14	
40	acgcgtccgc tcctcatctg ccttccacct ccccgcgcgt ctcccgagaa gggagggcgc 60)
	agcggcggct ggaggaggag gaggcggcgg cggcgatgct ggcggcggcg gcggaggagg 12 aggacaagag gcagctccct tgagcgtccc cccaggcagt agtcaccgca gcagcggtgg 18	0
	dageageggt ggeageggeg getetteete tegeetgega tteaaggett 24	^
45	additional decoded decoded attaced codedatte certages 30	^
	aggreeacyc cycycygact cotoggattt toogggogoo ggogggggt gcootagoot 36	Λ
	- day to	^
50	cottgecace gtttggccgc tgcccttcgg ctccgacatg gaagatggac cctctaacaa 480 tgcgagttgc ttccgaaggc tgaccgagtg tttcctcagc cccagtttga cggatgasac 544	0

	ggtgaaggcc	tatctttctc	tccatcccca	ggtattagat	gaatttgttt	ctgaaagtgt	600
	tagtgcagag	actgtggaaa	agtggctgaa	gaggaaaacc	aacaaagcaa	aagatgaacc	660
5	atctcccaag	gaagtcagca	ggtaccagga	tacgaatatg	cagggagtcg	tgtacgagct	720
v	gaacagctac	atagagcagc	gcctggacac	gggcggggac	aaccacctgc	tcctctatga	780
	gctcagcagc	atcatcagga	tagccacaaa	agccgacgga	tttgcactgt	acttccttgg	840
	agagtgcaat	aatagcctgt	gtgtgttcat	accacccggg	atgaaggaag	gccaaccccg	900
10	gctcatccct	gcagggccca	tcacccaggg	taccaccatc	tctgcctacg	tggccaagtc	960
	taggaagacg	ttgttggtag	aggatatcct	tggggatgag	cgatttcctc	gaggtactgg	1020
	cctggaatca	ggaacccgca	tccagtctgt	tctttgcttg	cccattgtca	ctgccattgg	1080
	agacttgatt	ggcatccttg	aactgtacag	gcactggggc	aaagaggcct	tctgcctcag	1140
15	ccatcaggag	gttgcaacag	ccaatcttgc	ttgggcttcc	gtagcaatac	accaggtgca	1200
	ggtgtgtaga	ggtctcgcca	aacagaccga	actgaatgac	ttcctactcg	acgtatcaaa	1260
	gacatacttt	gataacatag	ttgccataga	ctctctactt	gaacacatca	tgatatatgc	1320
	aaaaaatcta	gtgaacgccg	accgctgcgc	gctcttccag	gtggaccaca	agaacaagga	1380
20	gctgtactcg	gacctgtttg	acattgggga	ggagaaggag	gggaagccca	tcttcaagaa	1440
	gaccaaggag	atcagatttt	ccattgagaa	agggattgct	ggtcaagtgg	caagaacagg	1500
	cgaagtcttg	aacattcccg	atgcctacgc	ggaccctcgc	tttaacaggg	aggtggacct	1560
	gtacacaggc	tacaccacga	ggaacattct	gtgtatgccc	atagtgagcc	gaggcagcgt	1620
25		gtgcagatgg					
		aagatgtttg					
		cgccactcag					
		acctccgagg					
30		atcgagctat					
		tacatgatcc					
		atcatgtctg					
		acggtggcac					
35		gagcgcaaag					
		aacagctacc					
		gagcaacacc					
40		tccaccctga					
40		gccaccgacc					
		gggtcgctga					
		gcctgtgatc					
45		atatatgcag					
		cctatgatgg					
		gctgtggcca ctgaaggcct					
		gcaatgtgga					
50	JJJ~5~~U	= -uuugugga	aggeet	waacccaaca	cccagcaaya	gcacacccya	2020

	gaagetgaac gtgaaggttg aagactgate etgaagtgac gteetgatgt etgeecagea 2880
	accgactcaa cctgcttctg tgacttcgtt ctttttgttt tcaaggggtg aaaaccccct 2940
5	gtcagaaggt accgtcgcat atccatgtga agcagacgac tccctgcttg ccgcacacac 3000 ctcggacagt gagcaaccca ggctctgcg tgttgagag
	ctcggacagt gagcaaccca ggctctgccg tgttcagacg tcggctactc cgtggctcca 3060
	cctgacctcc gaatgctatt tgctcccagg ccagcactgc actgtctgga gggggcagag 3120
	accacaggag aggttcttgc ctgcatcctc coatgaggag agggggagag 3120
10	accacaggag aggttettge etgeatecte ceatgagggt gtggecagtt ecetggttet 3180 gtteatgt gecettett aggattggt aggattgga cacacgecee ttgttgtaa 3240
	gtttacatgt gaccttctta taggttaact gagtttgtgg cctgggacac atgtaatgaa 3240 ggtcacagtc cacaggtgac agagaatcc assettet
	ggtcacagtc cacaggtgac agagaatcc 22225555
15	tgctctttca gtctatctgg gggcacatag gtgagtctgc tccactcaga aggaagcata 3420
	acttcaaacc atgtcaaaga attaaaacac gtgagttege tccactcaga aggaagcata 3420
	acttcaaacc atgtcaaaga attaaaacac etcecetece eetcactgta geetteggea 3540
	actgcgccaa tccctttata caaagaaaat aaaagtaagg catataaatt taaaaaaaaa 3600
20	3606
	<210> 15
	<211> 796
	<212> PRT
25	<213> Mus sp.
	-
	<400> 15
	Met Glu Asp Gly Pro Som Assa
30	Met Glu Asp Gly Pro Ser Asn Asn Ala Ser Cys Phe Arg Arg Leu Thr
	10 15
	Glu Cys Phe Leu Ser Pro Ser Inc. 71
	Glu Cys Phe Leu Ser Pro Ser Leu Thr Asp Glu Lys Val Lys Ala Tyr
35	25 30
	Leu Ser Leu His Pro Cla Vol T
	Leu Ser Leu His Pro Gln Val Leu Asp Glu Phe Val Ser Glu Ser Val
	40 45
40	Ser Ala Glu Thr Val Glu Luc T
	Ser Ala Glu Thr Val Glu Lys Trp Leu Lys Arg Lys Thr Asn Lys Ala
	55 60
	Lys Asp Glu Pro Ser Pro I
45	Lys Asp Glu Pro Ser Pro Lys Glu Val Ser Arg Tyr Gln Asp Thr Asn
	70 75 80
	Met Gln Gly Val Val Tyr Glu Leu Asn Ser Tyr Ile Glu Gln Arg Leu
50	90 95

	Asp	Thr	Gly	Gly 100	Asp	Asn	His	Leu	Leu 105	Leu	Tyr	Glu	Leu	Ser 110	Ser	Ile
5	Ile	Arg	Ile 115	Ala	Thr	Lys	Ala	Asp 120	Gly	Phe	Ala	Leu	Tyr 125	Phe	Leu	Gly
10	Glu	Cys 130	Asn	Asn	Ser	Leu	Cys 135	Val	Phe	Ile	Pro	Pro 140	Gly	Met	Lys	Glu
15	Gly 145	Gln	Pro	Arg	Leu	Ile 150	Pro	Ala	Gly	Pro	Ile 155	Thr	Gln	Gly	Thr	Thr 160
20	Ile	Ser	Ala	Tyr	Val 165	Ala	Lys	Ser	Arg	Lys 170	Thr	Leu	Leu	Val	Glu 175	Asp
	Ile	Leu	Gly	Asp 180	Glu	Arg	Phe	Pro	Arg 185	Gly	Thr	Gly	Leu	Glu 190	Ser	Gly
25	Thr	Arg	Ile 195	Gln	Ser	Val	Leu	Суs 200	Leu	Pro	Ile	Val	Thr 205	Ala	Ile	Gly
30	Asp	Leu 210	Ile	Gly	Ile	Leu	Glu 215	Leu	Tyr	Arg	His	Trp 220	Gly	Lys	Glu	Ala
35	Phe 225	Cys	Leu	Ser	His	Gln 230	Glu	Val	Ala	Thr	Ala 235	Asn	Leu	Ala	Trp	Ala 240
	Ser	Val	Ala	Ile	His 245	Gln	Val	Gln	Val	Cys 250	Arg	Gly	Leu	Ala	Lys 255	Gln
40	Thr	Glu	Leu	Asn 260	Asp	Phe	Leu	Leu	Asp 265	Val	Ser	Lys	Thr	Tyr 270	Phe	Asp
45	Asn	Ile	Val 275	Ala	Ile	Asp	Ser	Leu 280	Leu	Glu	His	Ile	Met 285	Ile	Tyr	Ala
50	Lys	Asn 290	Leu	Val	Asn	Ala	Asp 295	Arg	Cys	Ala	Leu	Phe 300	Gln	Val	Asp	His

5	Lys Asn Lys Glu Leu Tyr Ser Asp Leu Phe Asp Ile Gly Glu Glu Lys 305 310 315 320
	Glu Gly Lys Pro Ile Phe Lys Lys Thr Lys Glu Ile Arg Phe Ser Ile 325 330 335
10	Glu Lys Gly Ile Ala Gly Gln Val Ala Arg Thr Gly Glu Val Leu Asn 340 · 345 350
15	Ile Pro Asp Ala Tyr Ala Asp Pro Arg Phe Asn Arg Glu Val Asp Leu 355 360 365
20	Tyr Thr Gly Tyr Thr Thr Arg Asn Ile Leu Cys Met Pro Ile Val Ser 370 375 380
25	Arg Gly Ser Val Ile Gly Val Val Gln Met Val Asn Lys Ile Ser Gly 385 390 395 400
	Ser Ala Phe Ser Lys Thr Asp Glu Asn Asn Phe Lys Met Phe Ala Val 405 410 415
30	Phe Cys Ala Leu Ala Leu His Cys Ala Asn Met Tyr His Arg Ile Arg 420 425 430
35	His Ser Glu Cys Ile Tyr Arg Val Thr Met Glu Lys Leu Ser Tyr His 435 440 445
40	Ser Ile Cys Thr Ser Glu Glu Trp Gln Gly Leu Met Arg Phe Asn Leu 450 455 460
	Pro Ala Arg Ile Cys Arg Asp Ile Glu Leu Phe His Phe Asp Ile Gly 465 470 475 480
45	Pro Phe Glu Asn Met Trp Pro Gly Ile Phe Val Tyr Met Ile His Arg 485 490 495
50	Ser Cys Gly Thr Ser Cys Phe Glu Leu Glu Lys Leu Cys Arg Phe Ile 500 505 510

		•									,					
5	Met	Ser	Val 515	Lys	Lys	Asn	Tyr	Arg 520	Arg	Val	Pro	Tyr	His 525	Asn	Trp	Lys
·	His	Ala 530	Val	Thr	Val	Ala	His 535	Cys	Met	Tyr	Ala	Ile 540	Leu	Gln	Asn	Asn
10	Asn 545	Gly	Leu	Phe	Thr	Asp 550	Leu	Glu	Arg	Lys	Gly 555	Leu	Leu	Ile	Ala	Cys 560
15	Leu	Cys	His	Asp	Leu 565	Asp	His	Arg	Gly	Phe 570	Ser	Asn	Ser	Tyr	Leu 575	Gln
20	Lys	Phe	Asp	His 580	Pro	Leu	Ala	Ala	Leu 585	Tyr	Ser	Thr	Ser	Thr 590	Met	Glu
	Gln	His	His 595	Phe	Ser	Gln	Thr	Val 600	Ser	Ile	Leu	Gln	Leu 605	Glu	Gly	His
25	Asn	Ile 610	Phe	Ser	Thr	Leu	Ser 615	Ser	Ser	Glu	Tyr	Glu 620	Gln	Val	Leu	Glu
30	Ile 625	Ile	Arg	Lys	Ala	Ile 630	Ile	Ala	Thr	Asp	Leu 635	Ala	Leu	Tyr	Phe	Gly 640
35	Asn	Arg	Lys	Gln	Leu 645	Glu	Glu	Met	Tyr	Gln 650	Thr	Gly	Ser	Leu	Asn 655	Leu
	His	Asn	Gln	Ser 660	His	Arg	Asp	Arg	Val 665	Ile	Gly	Leu	Met	Met 670	Thr	Ala
40	Cys	Asp	Leu 675	Cys	Ser	Val	Thr	Lys 680	Leu	Trp	Pro	Val	Thr 685	Lys	Leu	Thr
45	Ala	Asn 690	Asp	Ile	Tyr	Ala	Glu 695	Phe	Trp	Ala	Glu	Gly 700	Asp	Glu	Met	Lys
50	Lys 705	Leu	Gly	Ile	Gln	Pro 710	Ile	Pro	Met	Met	Asp 715	Arg	Asp	Lys	Arg	Asp 720

5	Glu Val Pro Gln Gly Gln Leu Gly Phe Tyr Asn Ala Val Ala Ile Pro 725 730 735
	Cys Tyr Thr Thr Leu Thr Gln Ile Leu Pro Pro Thr Glu Pro Leu Leu 740 745 750
10	Lys Ala Cys Arg Asp Asn Leu Asn Gln Trp Glu Lys Val Ile Arg Gly 755 760 765
15	Glu Glu Thr Ala Met Trp Ile Ser Gly Pro Gly Pro Ala Pro Ser Lys 770 775 780
20	Ser Thr Pro Glu Lys Leu Asn Val Lys Val Glu Asp 785 790 795
25	<210> 16 <211> 487 <212> DNA <213> Rattus sp.
30	<400> 16 CCttatagae gataman
<i>35</i>	ccttatggaa gatggacct ctaacaatgc gagttgcttc cgaaggctga ccgagtgttt 60 cctcagcccc agtttgacgg atgaaaaggt gaaggcctat ctttccctcc atcccaggt 120 gaaaaacgac aaagcagaag atgaaccatc tcctaaggaa gtcagcaggt accaggacac 240 gaacatgcag ggagtcgtgt accaggacac 240
40	gaacatgcag ggagtcgtgt acgagctgaa cagctacata gagcagcgcc tggacaccgg 300 cgacggattt gcactgtact tccttggaga gtgcaataat agtctgtgtg tcttcacacc 420 acccggaatg aaggaaggtc aacccgtct catcccgca gggcccatca cccagggcac 480
<i>15</i>	<210> 17 <211> 160

55

50

<212> PRT

<213> Rattus sp.

	<400	0> 1														
	Met 1	Glu	Asp	Gly	_	Ser	Asn	Asn	Ala		Cys	Phe	Arg	Arg		Thr
5	1				5					10					15	
	Glu	Cys	Phe	Leu	Ser	Pro	Ser	Leu		Asp	Glu	Lys	Val		Ala	Tyr
				20					25					30		
10	Leu	Ser	Leu	His	Pro	Gln	Val	Leu	Asp	Glu	Phe	Val	Ser	Glu	Ser	Val
			35					40					45			
15	Ser	Ala	Glu	Thr	Val	Glu	Lys	Trp	Leu	Lys	Arg	Lys	Asn	Asp	Lys	Ala
		50					55					60				
	Glu	Asp	Glu	Pro	Ser	Pro	Lys	Glu	Val	Ser	Arg	Tyr	Gln	Asp	Thr	Asn
20	65					70					75					80
	Met	Gln	Gly	Val	Val	Tyr	Glu	Leu	Asn	Ser	Tyr	Ile	Glu	Gln	Arg	Leu
					85					90					95	
25	Asp	Thr	Gly	Gly	Asp	Asn	His	Leu	Leu	Leu	Tvr	Glu	Leu	Asn	Ser	Ile
			_	100	-				105		-3-			110		
<i>30</i>	Ile	Ara	Ile	Ala	Thr	Ivs	Ala	Aen	Glv	Dhe	Δla	T. . 211	ጥኒታዮ	Dhe	T.011	Glv
		3	115			_, 5		120	U1,	1	niu	Deu	125	riic	Deu	GIY
	Glu	Cve	Acn	Asn	Ser.	Ten	Cira	17-1	Dho		77-0	Dwa	C1	Vor	T	0 1
35	014	130	nan	ASII	Ser	Dea	135	vai	PIIE	THE	PIO	140	GIY	met	Lys	GIU
	Clv	Cl n	Dwa	2	T	T1 -	D		~ 3.		-1.			~3		_,
	145	GIII	PIO	Arg	Leu	11e	Pro	Ala	GIY	Pro	11e	Thr	GIn	GIY	Thr	Thr 160
40																
	<210)> 18	3													
		.> 54														
45		> DN		sp.												
	~213	- Ro	ccus	sp.												
50																

	<400> 18	
	aatctcgctt gggcttccgt agcaatacac caggtgc	agg tgtgcagagg tgtgggaaa 60
5	datigacti cotgetegat gtateaa	aga cataceteca bassass
	acacatcato atatato	ICAA AAAATotoot oonaan
	ggaccacaag aacaag	age totacteons ontotata
	dadyayyy gaagcccgtc ttcaaga	aga ccaangagat appatett
10	agaccyclyg tcaagtggca agaacgg	gag aagteetgaa gattaataa aaa
	seed acceptant taacagggag gtggacc	tot acacagoeta taganama
	graded agraged agraged agraged	tga tcggtgtggt gggg-b
	aacaagatca gcggcagcgc cttctccaag acggatga	aga acaacttcaa gatgaaggg 540
15		5 - House Coda gacgaagggC 540
	<210> 19	
20	<211> 178	
20	<212> PRT	
	<213> Rattus sp.	
	4400- 10	
25	<400> 19	
	Asn Leu Ala Trp Ala Ser Val Ala Ile His G	ln Val Gln Val Cys Arg
	5 10	15
	Gly Leu Ale Torogia	
30	Gly Leu Ala Lys Gln Thr Glu Leu Asn Asp Pl	he Leu Leu Asp Val Ser
	20 25	30
	Lys Thr Tyr Phe Asp Asp Tla Wall at	
	Lys Thr Tyr Phe Asp Asn Ile Val Ala Ile As	sp Ser Leu Leu Glu His
35	35 40	45
	Ile Met Ile Tvr Ala Ive Asp Ion III	
	Ile Met Ile Tyr Ala Lys Asn Leu Val Asn Al 50 55	
	33	60
40	Phe Gln Val Asp His Lys Asn Lys Glu Leu Ty	m Cau h
	65 70 7:	E
		80
45	Ile Gly Glu Glu Lys Glu Gly Lys Pro Val Phe	A Luc Luc Mar v
.=	85 90	
		95
	Ile Arg Phe Ser Ile Glu Lys Gly Ile Ala Gly	y Gln Val Ala ara mb-
	100	THE THE ALL THE

Gly Glu Val Leu Asn Ile Pro Asp Ala Tyr Ala Asp Pro Arg Phe Asn Arg Glu Val Asp Leu Tyr Thr Gly Tyr Thr Thr Arg Asn Ile Leu Cys Met Pro Ile Val Ser Arg Gly Ser Val Ile Gly Val Val Gln Met Val Asn Lys Ile Ser Gly Ser Ala Phe Ser Lys Thr Asp Glu Asn Asn Phe Lys Met <210> 20 <211> 37 <212> PRT <213> Artificial Sequence <220> <223> Z1 in Formula I and Formula II <220> <223> Description of Artificial Sequence: Synthetic sequence <400> 20 Leu Thr Asp Glu Lys Val Lys Ala Tyr Leu Ser Leu His Pro Gln Val Leu Asp Glu Phe Val Ser Glu Ser Val Ser Ala Glu Thr Val Glu Lys Trp Leu Lys Arg Lys

	<210> 21											
	<211> 33											
5	<212> PRT											
	<213> Artificial Sequence											
	<220>											
10	<223> Z4 in Formula I and Formula II											
	<220>											
	<223> Description of Artificial Sequence: Synthetic											
15	sequence											
	<400> 21											
20	Pro Lys Glu Val Ser Arg Tyr Gln Asp Thr Asn Met Gln Gly Val Val											
20	1 5 10 15											
	Tyr Glu Leu Asn Ser Tyr Ile Glu Gln Arg Leu Asp Thr Gly Gly Asp											
25	20 25 30											
	Asn											
30												
	<210> 22											
25	<211> 10											
35	<212> PRT											
	<213> Artificial Sequence											
	<220>											
40	<223> Z5 in Formula I and Formula II											
	<220>											
45	<223> Description of Artificial Sequence: Synthetic											
	sequence											
50												
50												

<400> 22 Leu Leu Tyr Glu Leu Ser Ser Ile Ile 1 5 5 <210> 23 10 <211> 21 <212> PRT <213> Artificial Sequence 15 <220> <223> Z6 in Formula I and Formula II <220> 20 <223> Description of Artificial Sequence: Synthetic sequence <400> 23 25 Ile Ala Thr Lys Ala Asp Gly Phe Ala Leu Tyr Phe Leu Gly Glu Cys 5 10 15 Asn Asn Ser Leu Cys 30 20 35 <210> 24 <211> 14 <212> PRT 40 <213> Artificial Sequence <220> <223> Z10 in Formula I and Formula II

<223> Description of Artificial Sequence: Synthetic sequence
50

55

45

<220>

	<40	0> 2	4													
	Pro	Arg	Lev	Ile	Pro	Ala	a Gly	y Pro	Ile	Thi	Glr	ı Gly	/ Thr	Thr	•	
5	1				5					10		_				
	<21	.0> 2	5													
10	<21	1> 1	.63													
	<21	.2> F	RT													
	<21	.3> A	rtif	icia	l Se	quer	ice									
15	<22	0>														
	<22	3> z	11 i	n Fo	rmul	a I	and	Form	ula	II						
	<22	0>														
20	<22	3> D	escr	ipti	on o	f Ar	tifi	cial	Seq	uenc	e: S	ynth	etic			
		s	eđre	nce												
05	<40	0> 2	5		•											
25	Ser	Ala	Tyr	Val	Ala	Lys	Ser	Arg	Lys	Thr	Leu	Leu	Val	Glu	Asp	Ile
	1				5					10					15	
30	Leu	Gly	Asp	Glu	Arg	Phe	Pro	Arg	Gly	Thr	Gly	Leu	Glu	Ser	Gly	Thr
				20					25					30		
	_															
	Arg	Ile		Ser	Val	Leu	Суѕ	Leu	Pro	Ile	Val	Thr	Ala	Ile	Gly	Asp
35			35					40					45			
	.	-1 -	01		_											
	rea		GIĀ	IIe	Leu	Glu		Tyr	Arg	His	Trp		Lys	Glu	Ala	Phe
		50					55					60				
40	Circ	T 011	C	*** -	G1	~7					_					
	65	neu	Ser	птэ	GIN	70	vaı	Ala	Thr	Ala		Leu	Ala	Trp	Ala	
	03					70					75					80
	Val	Ala	Ile	His	Glr	Va I	Glr	17a1	Cys	A ~~~	C111	T 011	77-	T	C1-	~ 1
45					85	Val	GIII	vai	Cys	90	GIY	neu	ALG	ьуs		Thr
					5,5					90					95	
	Glu	Leu	Asn	Asp	Phe	Lev	Len	Asn	Val	Ser	Tare	ጥኮ፦	ጥረም	Pho	A c.~	7 ~~
							~~ u	لإدء	Val	Det	פעע	7117	TAT	FIIG	vah	MSII

	Ile	Val	Ala 115	Ile	Asp	Ser	Léu	Leu 120	Glu	His	Ile	Met	Ile 125	Tyr	Ala	Lys
5	Asn	Leu 130	Val	Asn	Ala	Asp	Arg 135	Cys	Ala	Leu	Phe	Gln 140	Val	Asp	His	Lys
10	Asn 145	Lys	Glu	Leu	Tyr	Ser 150	Asp	Leu	Phe	Asp	Ile 155	Gly	Glu	Glu	Lys	Glu 160
15	Gly	Lys	Pro													
20	<210 <211 <212	> 13	5													
25	<213 <220 <223	> Ar >	tifi					ormu	ıla]	ıı						
30	<220 <223	> > De		ptic							e: Sչ	nthe	etic			
35	<400:			Thr		Glu	Ile	Arg	Phe		Ile	Glu	Lys	Gly		Ala
40	1 Gly (Gln	Val	Ala 20	5 Arg	Thr	Gly	Glu	Val 25	10 Leu	Asn	Ile	Pro	Asp 30	15 Ala	Tyr
45	Ala A	Asp	Pro 35	Arg	Phe	Asn	Arg	Glu 40	Val	Asp	Leu	Tyr	Thr 45	Gly	Tyr	Thr
50	Thr A	Arg	Asn	Ile	Leu	Cys	Met 55	Pro	Ile	Val	Ser	Arg 60	Gly	Ser	Val	Ile

	Gly Vol. Vol. or
5	Gly Val Val Gln Met Val Asn Lys Ile Ser Gly Ser Ala Phe Ser Lys 65 70 75 80
	Thr Asp Glu Asn Asn Phe Lys Met Phe Ala Val Phe Cys Ala Leu Ala 85 90 95
10	Leu His Cys Ala Asn Met Tyr His Arg Ile Arg His Ser Glu Cys Ile 100 105 110
15	Tyr Arg Val Thr Met Glu Lys Leu Ser Tyr His Ser Ile Cys Thr Ser 115 120 125
20	Glu Glu Trp Gln Gly Leu Met 130 135
25	<210> 27 <211> 22 <212> PRT <213> Artificial Sequence
30	<220> <223> Z17 in Formula I and Formula II
35	<220> <223> Description of Artificial Sequence: Synthetic sequence
40	<400> 27 Ile Glu Leu Phe His Phe Asp Ile Gly Pro Phe Glu Asn Met Trp Pro 1 5 10 15
45	Gly Ile Phe Val Tyr Met

	<210> 28
	<211> 50
5	<212> PRT
J	<213> Artificial Sequence
	<220>
10	<223> Z18 in Formula I and Formula II
	<220>
	<223> Description of Artificial Sequence: Synthetic
15	sequence
	<400> 28
	His Arg Ser Cys Gly Thr Ser Cys Phe Glu Leu Glu Lys Leu Cys Arg
20	1 5 10 15
	Phe Ile Met Ser Val Lys Lys Asn Tyr Arg Arg Val Pro Tyr His Asn
	20 25 30
25	
	Trp Lys His Ala Val Thr Val Ala His Cys Met Tyr Ala Ile Leu Gln
	35 40 45
30	Asn Asn
	50
35	
	<210> 29
	<211> 36
40	<212> PRT
40	<213> Artificial Sequence
	<220>
	<223> Z19 in Formula I and Formula II
45	
	<220>
	<223> Description of Artificial Sequence: Synthetic
	sequence
50	

	<400> 29
	Leu Phe Thr Asp Leu Glu Arg Lys Gly Leu Leu Ile Ala Cys Leu Cys
5	5 10 15
	His Asp Leu Asp His Arg Gly Phe Ser Asn Ser Tyr Leu Gln Lys Phe
	20 25 30
10	Asp His Pro Leu
	35
	33
15	
15	<210> 30
	<211> 72
	<212> PRT
20	<213> Artificial Sequence
	table of the sequence
	<220>
	<223> Z20 in Formula I and Formula II
25	and formula II
	<220>
	<223> Description of Artificial Sequence: Synthetic
	sequence
30	
	<400> 30
	Ala Leu Tyr Ser Thr Ser Thr Met Glu Gln His His Phe Ser Gln Thr
	7.0
35	15
	Val Ser Ile Leu Gln Leu Glu Gly His Asn Ile Phe Ser Thr Leu Ser
	20 25 30
40	
	Ser Ser Glu Tyr Glu Gln Val Leu Glu Ile Ile Arg Lys Ala Ile Ile
	35 40 45
	Ala Thr Asp Leu Ala Va
45	Ala Thr Asp Leu Ala Leu Tyr Phe Gly Asn Arg Gln Leu Glu Glu Met
	55 60
	Tyr Gln Thr Gly Ser Leu Asn Leu
	65

	<210> 31
	<211> 23
5	<212> PRT
	<213> Artificial Sequence
	<220>
10	<223> Z21 in Formula I and Formula II
	<220>
15	<223> Description of Artificial Sequence: Synthetic sequence
	<400> 31
20	Asn Gln Ser His Arg Asp Arg Val Ile Gly Leu Met Met Thr Ala Cys
20	1 5 10 15
	Asp Leu Cys Ser Val Thr Lys
25	20
30	<210> 32
	<211> 37 <212> PRT
	<213> Artificial Sequence
05	va-vi-loudi boquonec
35	<220>
	<223> 222 in Formula I and Formula II
40	<220>
	<pre><223> Description of Artificial Sequence: Synthetic sequence</pre>
45	<400> 32
	Trp Pro Val Thr Lys Leu Thr Ala Asn Asp Ile Tyr Ala Glu Phe Trp
	1 5 10 15
50	

Ala Glu Gly Asp Glu Met Lys Lys Leu Gly Ile Gln Pro Ile Pro Met 20 25 30 Met Asp Arg Asp Lys 35

10

5

<210> 33 <211> 40

<212> PRT 15

<213> Artificial Sequence

<220>

<223> Z23 in Formula I and Formula II 20

<220>

<223> Description of Artificial Sequence: Synthetic sequence

<400> 33

Asp Glu Val Pro Gln Gly Gln Leu Gly Phe Tyr Asn Ala Val Ala Ile 5 10

Pro Cys Tyr Thr Thr Leu Thr Gln Ile Leu Pro Pro Thr Glu Pro Leu 20 25 30

Leu Lys Ala Cys Arg Asp Asn Leu 35 40

40

35

25

30

<210> 34 <211> 12

<212> PRT

45 <213> Artificial Sequence

<220>

<223> Z24 in Formula I and Formula II 50

<220> <223> Description of Artificial Sequence: Synthetic sequence <400> 34 Gln Trp Glu Lys Val Ile Arg Gly Glu Glu Thr Ala <210> 35 <211> 727 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic sequence <400> 35 Leu Thr Asp Glu Lys Val Lys Ala Tyr Leu Ser Leu His Pro Gln Val Leu Asp Glu Phe Val Ser Glu Ser Val Ser Ala Glu Thr Val Glu Lys Trp Leu Lys Arg Lys Asn Lys Asp Glu Pro Lys Glu Val Ser Arg Tyr Gln Asp Thr Asn Met Gln Gly Val Val Tyr Glu Leu Asn Ser Tyr Ile Glu Gln Arg Leu Asp Thr Gly Gly Asp Asn Leu Leu Leu Tyr Glu Leu Ser Ser Ile Ile Ile Ala Thr Lys Ala Asp Gly Phe Ala Leu Tyr Phe

	Leu Che Che c
5	Leu Gly Glu Cys Asn Asn Ser Leu Cys Phe Pro Pro Gly Lys Glu Gly 100 105 110
·	Pro Arg Leu Ile Pro Ala Gly Pro Ile Thr Gln Gly Thr Thr Ser Ala 115 120 125
10	Tyr Val Ala Lys Ser Arg Lys Thr Leu Leu Val Glu Asp Ile Leu Gly 130 135 140
15	Asp Glu Arg Phe Pro Arg Gly Thr Gly Leu Glu Ser Gly Thr Arg Ile 145 150 155 160
20	Gln Ser Val Leu Cys Leu Pro Ile Val Thr Ala Ile Gly Asp Leu Ile 165 170 175
	Gly Ile Leu Glu Leu Tyr Arg His Trp Gly Lys Glu Ala Phe Cys Leu 180 185 190
25	Ser His Gln Glu Val Ala Thr Ala Asn Leu Ala Trp Ala Ser Val Ala 195 200 205
30	Ile His Gln Val Gln Val Cys Arg Gly Leu Ala Lys Gln Thr Glu Leu 210 215 220
35	Asn Asp Phe Leu Leu Asp Val Ser Lys Thr Tyr Phe Asp Asn Ile Val 225 230 235 240
40	Ala Ile Asp Ser Leu Leu Glu His Ile Met Ile Tyr Ala Lys Asn Leu 245 250 255
	Val Asn Ala Asp Arg Cys Ala Leu Phe Gln Val Asp His Lys Asn Lys 260 265 270
45	Glu Leu Tyr Ser Asp Leu Phe Asp Ile Gly Glu Glu Lys Glu Gly Lys 275 280 285
50	Pro Phe Lys Lys Thr Lys Glu Ile Arg Phe Ser Ile Glu Lys Gly Ile 290 295 300

	Ala	Gly	Gln	Va1	Ala	Arg	Thr	Gly	Glu	Val	Leu	Asn	Ile	Pro	Asp	Ala
5	305					310					315					320
5	Tyr	Ala	Asp	Pro	Arg 325	Phe	Asn	Arg	Glu	Val 330	Asp	Leu	Tyr	Thr	Gly 335	туг
10	Thr	Thr	Arg	Asn 340	Ile	Leu	Cys	Met	Pro 345	Ile	Val	Ser	Arg	Gly 350	Ser	Val
15	Ile	Gly	Val 355	Val	Gln	Met	Val	Asn 360	Lys	Ile	Ser	Gly	Ser 365	Ala	Phe	Ser
20	Lys	Thr 370	Asp	Glu	Asn	Asn	Phe 375	Lys	Met	Phe	Ala	Val 380	Phe	Суѕ	Ala	Leu
	Ala 385	Leu	His	Cys	Ala	Asn 390	Met	Tyr	His	Arg	Ile 395	Arg	His	Ser	Glu	Cys 400
25	Ile	Tyr	Arg	Val	Thr 405	Met	Glu	Lys	Leu	Ser 410	Tyr	His	Ser	Ile	Cys 415	Thr
30	Ser	Glu	Glu	Trp 420	Gln	Gly	Leu	Met	Phe 425	Leu	Pro	Arg	Cys	Ile 430	Glu	Leu
35	Phe	His	Phe 435	Asp	Ile	Gly	Pro	Phe 440	Glu	Asn	Met	Trp	Pro 445	Gly	Ile	Phe
	Val	Tyr 450	Met	His	Arg	Ser	Cys 455	Gly	Thr	Ser	Cys	Phe 460	Glu	Leu	Glu	Lys
40	Leu 465	Cys	Arg	Phe	Ile	Met 470	Ser	Val	Lys	Lys	Asn 475	Tyr	Arg	Arg	Val	Pro 480
45	Tyr	His	Asn	Trp	Lys 485	His	Ala	Val	Thr	Val 490	Ala	His	Суз	Met	Tyr 495	Ala
50	Ile	Leu	Gln	Asn 500	Asn	Leu	Phe	Thr	Asp 505	Leu	Glu	Arg	Lys	Gly 510	Leu	Leu

	The Alice
5	Ile Ala Cys Leu Cys His Asp Leu Asp His Arg Gly Phe Ser Asn Ser 515 520 525
	Tyr Leu Gln Lys Phe Asp His Pro Leu Ala Leu Tyr Ser Thr Ser Thr 530 535 540
10	Met Glu Gln His His Phe Ser Gln Thr Val Ser Ile Leu Gln Leu Glu 545 550 555 560
15	Gly His Asn Ile Phe Ser Thr Leu Ser Ser Ser Glu Tyr Glu Gln Val 565 570 575
20	Leu Glu Ile Ile Arg Lys Ala Ile Ile Ala Thr Asp Leu Ala Leu Tyr 580 585 590
	Phe Gly Asn Arg Gln Leu Glu Glu Met Tyr Gln Thr Gly Ser Leu Asn 595 600 605
25	Leu Asn Gln Ser His Arg Asp Arg Val Ile Gly Leu Met Met Thr Ala 610 615 620
30	Cys Asp Leu Cys Ser Val Thr Lys Trp Pro Val Thr Lys Leu Thr Ala 625 630 635 640
35	Asn Asp Ile Tyr Ala Glu Phe Trp Ala Glu Gly Asp Glu Met Lys Lys 645 650 655
	Leu Gly Ile Gln Pro Ile Pro Met Met Asp Arg Asp Lys Asp Glu Val 660 665 670
40	Pro Gln Gly Gln Leu Gly Phe Tyr Asn Ala Val Ala Ile Pro Cys Tyr 675 680 685
45	Thr Thr Leu Thr Gln Ile Leu Pro Pro Thr Glu Pro Leu Leu Lys Ala 690 695 700
50	Cys Arg Asp Asn Leu Gln Trp Glu Lys Val Ile Arg Gly Glu Glu Thr 705 710 715 720

Ala Trp Ile Ser Pro Ala Glu 725

5

	<210> 36
10	<211> 749
	<212> PRT
	<213> Artificial Sequence
15	<220>
	<223> Description of Artificial Sequence: Synthetic
	sequence
20	<220>
	<221> SITE
	<222> (38)
	<223> Xaa=Asn or Thr
25	
	<220>
	<221> SITE
30	<222> (41)
50	<223> Xaa=Ser or Ala
	<220>
35	<221> SITE
	<222> (42)
	<223> Xaa=Glu or Lys
40	<220>
	<221> SITE
	<222> (45)
	<223> Xaa=Ser or Pro
45	<220>
	<220> <221> SITE
	-441- 311D

<222> (46)

<223> Xaa=Ala or Ser

55

	<220>
	<221> SITE
5	<222> (80)
	<223> Xaa=Gln or His
	<220>
10	<221> SITE
	<222> (91)
	<223> Xaa=Lys or Arg
15	<220>
	<221> SITE
	<222> (113)
20	<223> Xaa=Ile or Val
	<220>
	<221> SITE
25	<222> (115)
	<223> Xaa=Thr or Ile
	<220>
30	<221> SITE
-	<222> (119)
	<223> Xaa=Ile or Met
35	<220>
	<221> SITE
	<222> (123)
	<223> Xaa=Lys or Gln
40	<220>
	<221> SITE
	<222> (138)
15	<223> Xaa=Val or Ile

	<220>
	<221> SITE
5 .	<222> (302)
	<223> Xaa=Val or Ile
	<220>
10	<221> SITE
	<222> (438)
	<223> Xaa=Gln or Arg
15	<220>
	<221> SITE
	<222> (440)
	<223> Xaa=Thr or Asn
20	
	<220>
	<221> SITE
	<222> (443)
25	<223> Xaa=Val or Ala
	<220>
30	<221> SITE
30	<222> (445)
	<223> Xaa=Leu or Ile
	<220>
35	<221> SITE
	<222> (447)
	<223> Xaa=Lys or Arg
	• • • • • • • • • • • • • • • • • • • •
40	<220>
	<221> SITE
	<222> (448)
45	<223> Xaa=Glu or Asp
45	
50	

	<220>
	<221> SITE
5	<222> (471)
	<223> Xaa=Val or Ile
	<220>
10	<221> SITE
	<222> (522)
	<223> Xaa=His or Asn
15	<220>
	<221> SITE
	<222> (523)
20	<223> Xaa=Thr or Gly
	<220>
	<221> SITE
25	<222> (560)
	<223> Xaa=Thr or Ala
	<220>
30	<221> SITE
	<222> (634)
	<223> Xaa=Asn or His
35	<220>
	<221> SITE
	<222> (658)
	<223> Xaa=Pro or Leu
40	<220>
	<221> SITE
	<222> (696)
15	<223> Xaa=Lys or Arg

	<220)>														
	<221	L> SI	(TE													
		2> (7														
5				er o	c Ası	n.										
	<400)> 36	5													
10	Leu	Thr	Asp	Glu	Lys	Val	Lys	Ala	Tyr	Leu	Ser	Leu	His	Pro	Gln	Val
10	1				5					10					15	
	Leu	Asp	Glu		Val	Ser	Glu	Ser	Va1	Ser	Ala	Glu	Thr	Val	Glu	Lys
15				20					25					30		
						••					_	-1			•	•
	Trp	Leu		Arg	Lys	Xaa	Asn	_	Xaa	Xaa	Asp	GIu		Xaa	Pro	rys
			35					40					45			
20	Glu	Val	Ser	Ara	ጥረም	Gln	Aan	ጥኮ፦	Yan	Met	Gln	Gly	Val	Val	ጥህን	Glu
	014	50	501	9	-3-	0411	55	****			U 2	60	•	•	-1-	024
25	Leu	Asn	Ser	Tyr	Ile	Glu	Gln	Arg	Leu	Asp	Thr	Gly	Gly	Asp	Asn	Xaa
	65					70					75					80
	Leu	Leu	Leu	Tyr	Glu	Leu	Ser	Ser	Ile	Ile	Xaa	Ile	Ala	Thr	Lys	Ala
30					85					90					95	
		01	D L -	• • •	•		51	•	03	61	^	.	3	C	T	a
	Asp	GIA	Pne	100	rea	Tyr	Pne	rea	105	GIU	cys	ASII	ASII	110	nea	Суз
35				100					103					110		
	Xaa	Phe	Xaa	Pro	Pro	Gly	Xaa	Lys	Glu	Gly	Xaa	Pro	Arg	Leu	Ile	Pro
			115			-		120		_			125			
40	Ala	Gly	Pro	Ile	Thr	Gln	Gly	Thr	Thr	Xaa	Ser	Ala	Tyr	Val	Ala	Lys
		130					135					140				
		Arg	Lys	Thr	Leu	Leu	Val	Glu	Asp	Ile		Gly	Asp	Glu	Arg	
45	145					150					155					160
	Pro	Δτα	Gl ₁₂	ጥኩ፦	Gl.	Leu	Gl v	Ser	Glv	ጥኮ፦	Arm	Tle	Gln	Ser	Va 1	T.e.n
			GLY	****	165	neu,	914	OCI	GLY	170	ar y			JGL	175	neu.

	Cys	Leu	Pro	Ile 180	Val	Thr	Ala	Ile	Gly 185		Leu	Ile	Gly	Ile 190	Leu	Glu
5	Leu	Tyr	Arg 195	His	Trp	Gly	Lys	Glu 200	Ala	Phe	Cys	Leu	Ser 205	His	Gln	Glu
10	Val	Ala 210	Thr	Ala	Asn	Leu	Ala 215	Trp	Ala	Ser	Val	Ala 220	Ile	His	Gln	Val
15	Gln 225	Val	Суѕ	Arg	Gly	Leu 230	Ala	Lys	Gln	Thr	Glu 235	Leu	Asn	Asp	Phe	Leu 240
20	Leu	K sp	Val	Ser	Lys 245	Thr	Tyr	Phe	Asp	Asn 250	Ile	Val	Ala	Ile	Asp 255	Ser
	Leu	Leu	Glu	His 260	Ile	Met	Ile	Tyr	Ala 265	Lys	Asn	Leu	Val	Asn 270	Ala	Asp
25	Arg	Cys	Ala 275	Leu	Æhe	Gln	Val	Asp 280	His	Lys	Asn	Lys	Glu 285	Leu	Tyr	Ser
30	Asp	Leu 290	Phe	Asp	Ile	_	Glu 295	Glu	Lys	Glu	Gly	Lys 300	Pro	Xaa	Phe	Lys
35	Lys 305	Thr	Lys	Glu	Ile	Arg 310	Phę	Ser	Ile	Glu	Lys 315	Gly	Ile	Ala	Gly	Gln 320
	Val	Ala	Arg	Thr	Gly 325	Glu	Val	Leu	Asn	Ile 330	Pro	Asp	Ala	Туr	Ala 335	Asp
40	Pro	Arg	Phe	Asn 340	Arg	Glu	Val	Asp	Leu 345		Thr	Gly	Tyr	Thr 350	Thr	Arg
45	Asn	Ile	Leu 355	Суз	Met	Pro	Ile	Val 360	Ser	Arg	Gly	Ser	Val 365	Ile	Gly	Val
50	Val	Gln 370	Met	Val	Asn		Ile 375	Ser	Gly	Ser	Ala	Phe 380 •	Ser	Lys	Thr	Asp

		•											^			
_	Glu 385	Asn	Asn	Phe	Lys	Met 390	Phe	Ala	Val	Phe	Cys 395	Ala	Leu	Ala	Leu	His 400
5	Cys	Ala	Asn	Met	Tyr 405	His	Arg	Ile	Arg	His 410	Ser	Glu	Cys	Ile	Туг 415	Arg
10	Val	Thr	Met	Glu 420	Lys	Leu	Ser	Tyr	His 425	Ser	Ile	Cys	Thr	Ser 430	Glu	Glu
15	Trp	Gln	Gly 435	Leu	Met	Xaa	Phe	Xaa 440	Leu	Pro	Xaa	Arg	Xaa 445	Cys	Xaa	Xaa
20	Ile	Glu 450	Leu	Phe	His	Phe	Asp 455	Ile	Gly	Pro	Phe	Glu 460	Asn	Met	Trp	Pro
20	Gly 465	Ile	Phe	Val	Tyr	Met 470	Xaa	His	Arg	Ser	Cys 475	Gly	Thr	Ser	Суз	Phe 480
25	Glu	Leu	Glu	Lys	Leu 485	Cys	Arg	Phe	Ile	Met 490	Ser	Val	Lys	Lys	Asn 495	Tyr
30	Arg	Arg	Val	Pro 500	Tyr	His	Asn	Trp	Lys 505	His	Ala	Val	Thr	Val 510	Ala	His
35	Cys	Met	Tyr 515	Ala	Ile	Leu	Gln	Asn 520	Asn	Xaa	Xaa	Leu	Phe 525	Thr	Asp	Leu
	Glu	Arg 530	Lys	Gly	Leu	Leu	Ile 535	Ala	Cys	Leu	Cys	His 540	Asp	Leu	Asp	His
40	Arg 545	Gly	Phe	Ser	Asn	Ser 550	Tyr	Leu	Gln	Lys	Phe 555	Asp	His	Pro	Leu	Xaa 560
45	Ala	Leu	Tyr	Ser	Thr 565	Ser	Thr	Met	Glu	Gln 570	His	His	Phe	Ser	Gln 575	Thr
50	Val	Ser	Ile	Leu 580	Gln	Leu	Glu	Gly	His 585	Asn	Ile	Phe	Ser	Thr 590	Leu	Ser

	Ser	Ser	Glu 595	Tyr	Glu	Gln	Val	Leu 600	Glu	Ile	Ile	Arg	Lys 605	Ala	Ile	Ile
5	Ala	Thr 610	Asp	Leu	Ala	Leu	Tyr 615	Phe	Gly	Asn	Arg	Lys 620	Gln	Leu	Glu	Glu
10	Met 625		Gln	Thr	Gly	Ser 630	Leu	Asn	Leu	Xaa	Asn 635	Gln	Ser	His	Arg	Asp 640
15	Arg	Val	Ile	Gly	Leu 645	Met	Met	Thr	Ala	Суs 650	Asp	Leu	Cys	Ser	Val 655	Thr
20	Lys	Xaa	Trp	Pro 660	Val	Thr	Lys	Leu	Thr 665	Ala	Asn	Asp	Ile	туr 670	Ala	Glu
	Phe	Trp	Ala 675	Glu	Gly	Asp	Gl u	Met 680	Lys	Lys	Leu	Gly	Ile 685	Gln	Pro	Ile
25	Pro	Met 690	Met	Asp	Arg	Asp	Lys 695	Xaa	Asp	Glu	Val	Pro 700	Gln	Gly	Gln	Leu
30	Gly 705	Phe	Tyr	Asn	Ala	Val 710	Ala	Ile	Pro	Cys	Tyr 715	Thr	Thr	Leu	Thr	Gln 720
35	Ile	Leu	Pro	Pro	Thr 725	Glu	Pro	Leu	Leu	Lys 730	Ala	Cys	Arg	Asp	Asn 735	Leu
	Xaa	Gln	Trp	Glu 740	Lys	Val	Ile	Arg	Gly 745	Glu	Glu	Thr	Ala			
40	<211)> 37 .> 75	0													
45		!> PR i> Ar		cial	Seq	uenc	e									
	<220															
50	<223	> De se	scri quen		n of	Art	ific	ial	Sequ	ence	: Sy	nthe	tic			

	<220>			
	<221>	SITE		
5	<222>	(1)		
	<223>	Xaa=Ser	or	Gly
	<220>			
10	<221>	SITE		
	<222>	(39)		
	<223>	Xaa=Asn	or	Thr
15	<220>			
	<221>	SITE		
	<222>	(42)		
	<223>	Xaa=Ser	or	Ala
20				
	<220>			
	<221>	SITE		
	<222>	(43)		
25	<223>	Xaa=Glu	or	Lys
	<220>			
	<221>	SITE		
30	<222>	(46)		
	<223>	Xaa=Ser	or	Pro
35	<220>			
	<221>	SITE		
	<222>			
	<223>	Xaa=Ala	or	Ser
40				
	<220>			
	<221>	SITE		
	<222>			
45	<223>	Xaa=Gln	or	His
50				

	<220>
	<221> SITE
5	<222> (92)
	<223> Xaa=Lys or Arg
	<220>
10	<221> SITE
	<222> (114)
	<223> Xaa=Ile or Val
15	<220>
	<221> SITE
	<222> (116)
20	<223> Xaa=Thr or Ile
	<220>
	<221> SITE
	<222> (120)
25	<223> Xaa=Ile or Met
	<220>
30	<221> SITE
50	<222> (124)
	<223> Xaa≃Lys or Gln
	<220>
35	<221> SITE
	<222> (139)
	<223> Xaa=Val or Ile
40	<220>
	<221> SITE
	<222> (303)
45	<223> Xaa=Val or Ile
το	
50	

	<220>	
	<221>	SITE
5	<222>	(439)
	<223>	Xaa=Gln or Arg
	<220>	
10	<221>	SITE
	<222>	(441)
	<223>	Xaa=Thr or Asn
15	<220>	
	<221>	SITE
	<222>	(444)
	<223>	Xaa=Val or Ala
20		
	<220>	
	<221>	SITE
	<222>	(446)
25	<223>	Xaa=Leu or Ile
	<220>	
30	<221>	SITE
30	<222>	(448)
	<223>	Xaa=Lys or Arg
35	<220>	
	<221>	
	<222>	
	<223>	Xaa=Glu or Asp
40	-000	
	<220>	
	<221>	
	<222>	(4/2) Xaa=Val or Ile
45	<223>	xaa=vai or lie
50		

```
<220>
             <221> SITE
 5
             <222> (523)
            <223> Xaa=His or Asn
             <220>
 10
             <221> SITE
             <222> (524)
            <223> Xaa=Thr or Gly
 15
            <220>
            <221> SITE
            <222> (561)
            <223> Xaa=Thr or Ala
20
            <220>
            <221> SITE
            <222> (635)
25
            <223> Xaa=Asn or His
            <220>
            <221> SITE
30
            <222> (659)
            <223> Xaa=Pro or Leu
            <220>
35
            <221> SITE
            <222> (697)
            <223> Xaa=Lys or Arg
40
           <220>
           <221> SITE
           <222> (738)
           <223> Xaa=Ser or Asn
45
           <400> 37
           Xaa Leu Thr Asp Glu Lys Val Lys Ala Tyr Leu Ser Leu His Pro Gln
             1
                              5
50
                                                 10
                                                                      15
```

		•														
5	Val	Leu	Asp	Glu 20	Phe	Val	Ser	Glu	Ser 25	Val	Ser	Ala	Glu	Thr 30	Val	Glu
	Lys	Trp	Leu 35	Lys	Arg	Lys	Xaa	Asn 40	Lys	Xaa	Xaa	Asp	Glu 45	Xaa	Xaa	Pro
10	Lys	Glu 50	Val	Ser	Arg	Tyr	Gln 55	Asp	Thr	Asn	Met	Gln 60	Gly	Val	Val	Tyr
15	Glu 65	Leu	Asn	Ser	Tyr	Ile 70	Glu	Gln	Arg	Leu	Asp 75	Thr	Gly	Gly	Asp	Asn 80
20	Xaa	Leu	Leu	Leu	Tyr 85	Glu	Leu	Ser	Ser	Ile 90	Ile	Xaa	Ile	Ala	Thr 95	Lys
	Ala	Asp	Gly	Phe 100	Ala	Leu	Tyr	Phe	Leu 105	Gly	Glu	Cys	Asn	Asn 110	Ser	Leu
25	Cys	Xaa	Phe 115	Xaa	Pro	Pro	Gly	Xaa 120	Lys	Glu	Gly	Xaa	Pro 125	Arg	Leu	Ile
30	Pro	Ala 130	Gly	Pro	Ile	Thr	Gln 135	Gly	Thr	Thr	Xaa	Ser 140	Ala	Tyr	Val	Ala
35	Lys 145	Ser	Arg	Lys	Thr	Leu 150	Leu	Val	Glu	Asp	Ile 155	Leu	Gly	Asp	Glu	Arg 160
40	Phe	Pro	Arg	Gly	Thr 165	Gly	Leu	Glu	Ser	Gly 170	Thr	Arg	Ile	Gln	Ser 175	Val
40	Leu	Cys	Leu	Pro 180	Ile	Val	Thr	Ala	Ile 185	Gly	Asp	Leu	Ile	Gly 190	Ile	Leu
45	Glu	Leu	Tyr 195	Arg	His	Trp	Gly	Lys 200	Glu	Ala	Phe	Суз	Leu 205	Ser	His	Gln
50	Glu	Val 210	Ala	Thr	Ala	Asn	Leu 215	Ala	Trp	Ala	Ser	Val 220	Ala	Ile	His	Gln

														•			
5		Val 225		Val	Cys	Arg	230 230		Ala	Lys	Gln	Thr 235		Let	Asn	Asp	Phe 240
		Leu	Leu	Asp	Val	Ser 245		Thr	Туг	Phe	250		Ile	Val	. Ala	11e 255	Asp
10)	Ser	Leu	Leu	Glu 260		Ile	Met	Ile	Tyr 265		Lys	Asn	Leu	Val 270		Ala
15	;	Asp	Arg	Cys 275		Leu	Phe	Gln	Val 280		His	Lys	Asn	Lys 285		Leu	Tyr
20	,	Ser	Asp 290	Leu	Phe	Asp	Ile	Gly 295	Glu	Glu	Lys	Glu	Gly 300	Lys	Pro	Xaa	Phe
		Lys 305	Lys	Thr	Lys	Glu	Ile 310	Arg	Phe	Ser	Ile	Glu 315	Lys	Gly	Ile	Ala	Gly 320
25		Gln	Val	Ala	Arg	Thr 325	Gly	Glu	Val	Leu	Asn 330	Ile	Pro	Asp	Ala	Tyr 335	Ala
30		Asp	Pro	Arg	Phe 340	Asn	Arg	Glu	Val	Asp 345	Leu	Tyr	Thr	Gly	Tyr 350	Thr	Thr
35		Arg	Asn	Ile 355	Leu	Cys	Met	Pro	Ile 360	Val	Ser	Arg	Gly	Ser 365	Val	Ile	Gly
40		Val	Val 370	Gln	Met	Val	Asn	Lys 375	Ile	Ser	Gly		Ala 380	Phe	Ser	Lys	Thr
		Asp 385	Glu	Asn	Asn	Phe	Lys 390	Met	Phe	Ala	Val	Phe 395	Cys	Ala	Leu	Ala	Leu 400
45		His	Cys	Ala		Met 405	Tyr	His	Arg		Arg 410	His	Ser	Glu		Ile 415	Tyr
50		Arg	Val		Met 420	Glu	Lys	Leu		Tyr 425	His	Ser :	Ile	Cys	Thr 430	Ser	Glu

		1														
	Glu	Trp	Gln 435	Gly	Leu	Met	Xaa	Phe	Xaa	Leu	Pro	Xaa	Arg 445	Xaa	Cys	Xaa
5	Xaa	Ile 450	Glu	Leu	Phe	His	Phe 455		Ile	Gly	Pro	Phe 460		Asn	Met	Trp
10	Pro 465	Gly	Ile	Phe	Val	Tyr 470	Met	Xaa	His	Arg	Ser 475	Суз	Gly	Thr	Ser	Cys 480
15	Phe	Glu	Leu	Glu	Lys 485	Leu	Cys	Arg	Phe	Ile 490	Met	Ser	Val	Lys	Lys 495	Asn
20	Tyr	Arg	Arg	Val 500	Pro	Tyr	His	Asn	Trp 505	Lys	His	Ala	Val	Thr 510	Val	Ala
	His	Cys	M et 515	Tyr	Ala	Ile	Leu	Gln 520	Asn	Asn	Xaa	Xaa	Leu 525	Phe	Thr	Asp
25	Leu	Glu 530	Arg	Lys	Gly	Leu	Leu 535	Ile	Ala	Cys	Leu	Cys 540	His	Asp	Leu	Asp
30	His 545	Arg	Gly	Phe	Ser	Asn 550	Ser	Tyr	Leu	Gln	Lys 555	Phe	Asp	His	Pro	Leu 560
35	Xaa	Ala	Leu	Tyr	Ser 565	Thr	Ser	Thr	Met	Glu 570	Gln	His	His	Phe	Ser 575	Gln
	Thr	Val	Ser	Ile 580	Leu	Gln	Leu	Glu	Gly 585	His	Asn	Ile	Phe	Ser 590	Thr	Leu
40	Ser	Ser	Ser 595	Glu	Tyr	Glu	Gln	Val 600	Leu	Glu	Ile	Ile	Arg 605	Lys	Ala	Ile
45	Ile	Ala 610	Thr	Asp	Leu		Leu 615	Tyr	Phe	Gly	Asn	Arg 620	Lys	Gln	Leu	Glu
50	Glu 625	Met	Tyr	Gln	Thr	Gly 630	Ser	Leu	Asn		Xaa 635	Asn	Gln	Ser	His	Arg 640

	Asp Arg Val Ile Gly Leu Met Met Thr Ala Cys Asp Leu Cys Ser Val
5	Thr Lys Xaa Trp Pro Val Thr Lys Leu Thr Ala Asn Asp Ile Tyr Ala 660 665 670
10	Glu Phe Trp Ala Glu Gly Asp Glu Met Lys Lys Leu Gly Ile Gln Pro 675 680 685
15	Ile Pro Met Met Asp Arg Asp Lys Xaa Asp Glu Val Pro Gln Gly Gln 690 695 700
20	Leu Gly Phe Tyr Asn Ala Val Ala Ile Pro Cys Tyr Thr Thr Leu Thr 705 710 715 720
	Gln Ile Leu Pro Pro Thr Glu Pro Leu Leu Lys Ala Cys Arg Asp Asn 725 730 735
25	Leu Xaa Gln Trp Glu Lys Val Ile Arg Gly Glu Glu Thr Ala 740 745 750
30	
35	<210> 38 <211> 754 <212> PRT <213> Artificial Sequence
40	<220> <223> Description of Artificial Sequence: Synthetic sequence
45	<220> <221> SITE <222> (1) <223> Xaa=Ser or Gly
50	

	<220>
	<221> SITE
5	<222> (39)
	<223> Xaa=Asn or Thr
	<220>
10	<221> SITE
	<222> (42)
	<223> Xaa=Ser or Ala
15	<220>
	<221> SITE
	<222> (43)
	<223> Xaa=Glu or Lys
20	
	<220>
	<221> SITE
	<222> (46)
25	<223> Xaa=Ser or Pro
	<220>
30	<221> SITE
30	<222> (47)
	<223> Xaa=Ala or Ser
35	<220>
	<221> SITE
	<222> (81)
	<223> Xaa=Gln or His
40	-222-
	<220> <221> SITE
	<221> SITE <222> (92)
45	<223> Xaa=Lys or Arg
50	

	<220>
	<221> SITE
5	<222> (114)
	<223> Xaa=Ile or Val
	<220>
10	<221> SITE
	<222> (116)
	<223> Xaa=Thr or Ile
15	<220>
	<221> SITE
	<222> (120)
20	<223> Xaa=Ile or Met
	<220>
	<221> SITE
	<222> (124)
25	<223> Xaa=Lys or Gln
	<220>
20	<221> SITE
30	<222> (139)
	<223> Xaa=Val or Ile
25	<220>
35	<221> SITE
	<222> (303)
	<223> Xaa=Val or Ile
40	<220>
	<221> SITE
	<222> (439)
45	<223> Xaa=Gln or Arg
50	

	<220>			
	<221>	SITE		
5	<222>	(441)		
	<223>	Xaa=Thr	or	Asn
	<220>			
10	<221>	SITE		
	<222>	(444)		
	<223>	Xaa=Val	or	Ala
15	<220>			
	<221>	SITE		
	<222>	(446)		
	<223>	Xaa=Leu	or	Ile
20				
	<220>			
	<221>	SITE		
	<222>	(448)		
25	<223>	Xaa=Lys	or	Arg
	<220>			
	<221>	SITE		
30	<222>	(449)		
	<223>	Xaa=Glu	or	Asp
25	<220>			
35	<221>	SITE		
	<222>	(472)		
	<223>	Xaa=Val	or	Ile
40				
•	<220>			
	<221>	SITE		
	<222>	(523)		
45	<223>	Xaa=His	or	Asn
50				

```
<220>
               <221> SITE
 5
               <222> (524)
              <223> Xaa=Thr or Gly
              <220>
 10
              <221> SITE
              <222> (561)
              <223> Xaa=Thr or Ala
 15
              <220>
              <221> SITE
              <222> (635)
              <223> Xaa=Asn or His
 20
              <220>
              <221> SITE
25
              <222> (659)
              <223> Xaa=Pro or Leu
              <220>
30
              <221> SITE
              <222> (697)
             <223> Xaa=Lys or Arg
35
             <220>
             <221> SITE
             <222> (738)
             <223> Xaa=Ser or Asn
40
             <220>
             <221> SITE
             <222> (751)
45
             <223> Xaa=Thr or Met
             <400> 38
             Xaa Leu Thr Asp Glu Lys Val Lys Ala Tyr Leu Ser Leu His Pro Gln
50
               1
                                5
                                                   10
                                                                       15
```

5	Val	Leu	Asp	Glu 20	Phe	Val	Ser	Glu	Ser 25	Val	Ser	Ala	Glu	Thr 30	Val	Glu
	Lys	Trp	Leu 35	Lys	Arg	Lys	Xaa	Asn 40	Lys	Xaa	Xaa	Asp	Glu 45	Xaa	Xaa	Pro
	Lys	Glu 50	Val	Ser	Arg	Tyr	Gln 55	Asp	Thr	Asn	Met	Gln 60	Gly	Val	Val	Tyr
15	Glu 65	Leu	Asn	Ser	Tyr	Ile 70	Glu	Gln	Arg	Leu	Asp 75	Thr	Gly	Gly	Asp	Asn 80
20	Xaa	Leu	Leu	Leu	Туг 85	Glu	Leu	Ser	Ser	Ile 90	Ile	Xaa	Ile	Ala	Thr 95	Lys
	Ala	Asp	Gly	Phe 100	Ala	Leu	Tyr	Phe	Leu 105	Gly	Glu	Cys	Asn	Asn 110	Ser	Leu
25	Cys	Xaa	Phe 115	Xaa	Pro	Pro	Gly	Xaa 120	Lys	Glu	Gly	Xaa	Pro 125	Arg	Leu	Ile
30	Pro	Ala 130	Gly	Pro	Ile	Thr	Gln 135	Gly	Thr	Thr	Xaa	Ser 140	Ala	Tyr	Val	Ala
35	Lys 145	Ser	Arg	Lys	Thr	Leu 150	Leu	Val	Glu	Asp	Ile 155	Leu	Gly	Asp	Glu	Arg 160
40	Phe	Pro	Arg	Gly	Thr 165	Gly	Leu	Glu	Ser	Gly 170	Thr	Arg	Ile	Gln	Ser 175	Val
	Leu	Cys	Leu	Pro 180	Ile	Val	Thr	Ala	Ile 185	Gly	Asp	Leu	Ile	Gly 190	Ile	Leu
45	Glu	Leu	туг 195	Arg	His	Trp	Gly	Lys 200	Glu	Ala	Phe	Суз	Leu 205	Ser	His	Gln
50	Glu	Val 210	Ala	Thr	Ala	Asn	Leu 215	Ala	Trp	Ala	Ser	Val 220	Ala	Ile	His	Gln

	**-															
	va 22	1 G1 5	n Va	ıl Cy	s Ar	g Gl ₃ 23		u Al	a Ly:	s Gl	n Thr 235		ı Le	u Ası	n Ası	Phe 240
5	Le	u Le	u As	p Va	l Sei 245	r Lys	s Thi	с Ту:	r Phe	e Ası 25(Ile	e Vai	l Ala	11e 255	e Asp
10	Se	r Le	u Le	u Gl: 26	His	s Il∈	e Met	: Ile	265		Lys	Asn	Lei	val 270		Ala
15	Ası	Arq	27:	s Ala	a Leu	Phe	e Gln	Val 280) His	Lys	Asn	Lys 285		Leu	Tyr
20	Ser	290	Lei	ı Phe	Asp	Ile	Gly 295		Glu	Lys	Glu	Gly 300	Lys	Pro	Xaa	Phe
	Lys 305	Lys	Thi	: Lys	Glu	Ile 310		Phe	Ser	Ile	Glu 315	Lys	Gly	Ile	Ala	Gly 320
25	Gln	Val	Ala	Arg	Thr 325	Gly	Glu	Val	Leu	Asn 330	Ile	Pro	Asp	Ala	Tyr 335	Ala
30	Asp	Pro	Arg	Phe 340	Asn	Arg	Glu	Val	Asp 345	Leu	Tyr	Thr	Gly	Tyr 350	Thr	Thr
35	Arg	Asn	11e 355	Leu	Cys	Met	Pro	11e 360	Val	Ser	Arg		Ser 365	Val	Ile	Gly
	Val	Val 370	Gln	Met	Val	Asn	Lys 375	Ile	Ser	Gly	Ser .	Ala 380	Phe	Ser	Lys	Thr
40	Asp 385	Glu	Asn	Asn		Lys 390	Met	Phe	Ala		Phe (Cys /	Ala	Leu .		Leu 400
45	His	Cys	Ala	Asn	Met 4	Tyr 1	His .	Arg		Arg :	His S	Ser (3lu		Ile ' 415	Tyr
50	Arg	Val	Thr	Met 420	Glu 1	Lys 1	Leu :		Tyr 1 425	His :	Ser 1	le (Thr s	Ser (Glu

	Glu	Trp	Gln 435	Gly	Leu	Met	Xaa	Phe	Xaa	Leu	Pro	Xaa	Arg	Xaa	Суѕ	Xaa
5	Xaa	Ile 450	Glu	Leu	Phe	His	Phe 455	Asp	Ile	Gly	Pro	Phe 460	Glu	Asn	Met	Trp
10	Pro 465	Gly	Ile	Phe	Val	Tyr 470	Met	Xaa	His	Arg	Ser 475	Cys	Gly	Thr	Ser	Cys 480
15	Phe	Glu	Leu	Glu	Lys 485	Leu	Cys	Arg	Phe	Ile 490	Met	Ser	Val	Lys	Lys 495	Asn
20	Tyr	Arg	Arg	Val 500	Pro	Tyr	His	Asn	Trp 505	Lys	His	Ala	Val	Thr 510	Val	Ala
	His	Cys	Met 515	Tyr	Ala	Ile	Leu	Gln 520	Asn	Asn	Xaa	Xaa	Leu 525	Phe	Thr	Asp
25	Leu	Glu 530	Arg	Lys	Gly	Leu	Leu 535	Ile	Ala	Cys	Leu	Cys 540	His	Asp	Leu	Asp
30	His 545	Arg	Gly	Phe	Ser	Asn 550	Ser	Tyr	Leu	Gln	Lys 555	Phe	Asp	His	Pro	Leu 560
35	Xaa	Ala	Leu	Tyr	Ser 565	Thr	Ser	Thr	Met	Glu 570	Gln	His	His	Phe	Ser 575	Gln
	Thr	Val	Ser	Ile 580	Leu	Gln	Leu	Glu	Gly 585	His	Asn	Ile	Phe	Ser 590	Thr	Leu
40	Ser	Ser	Ser 595	Glu	Tyr	Glu	Gln	Val 600	Leu	Glu	Ile	Ile	Arg 605	Lys	Ala	Ile
45	Ile	Ala 610	Thr	Asp	Leu	Ala	Leu 615	Tyr	Phe	Gly	Asn	Arg 620	Lys	Gln	Leu	Glu
50	Glu 625	Met	Tyr	Gln	Thr	Gly 630	Ser	Leu	Asn	Leu	Xaa 635	Asn	Gln	Ser	His	Arg 640

5	Asp Arg Val Ile Gly Leu Met Met Thr Ala Cys Asp Leu Cys Ser Va 645 650 655
	Thr Lys Xaa Trp Pro Val Thr Lys Leu Thr Ala Asn Asp Ile Tyr Al 660 665 670
10	Glu Phe Trp Ala Glu Gly Asp Glu Met Lys Lys Leu Gly Ile Gln Pr 675 680 685
15	Ile Pro Met Met Asp Arg Asp Lys Xaa Asp Glu Val Pro Gln Gly Gl 690 695 700
20	Leu Gly Phe Tyr Asn Ala Val Ala Ile Pro Cys Tyr Thr Thr Leu Th. 705 710 715 72
	Gln Ile Leu Pro Pro Thr Glu Pro Leu Leu Lys Ala Cys Arg Asp Ass 725 730 735
25	Leu Xaa Gln Trp Glu Lys Val Ile Arg Gly Glu Glu Thr Ala Xaa Trp 740 745 750
30	Ile Ser
35	<210> 39 <211> 759 <212> PRT <213> Artificial Sequence
40	<220> <223> Description of Artificial Sequence: Synthetic sequence
45	<220> <221> SITE <222> (1)
50	<223> Xaa=Ser or Gly

	<220>
	<221> SITE
5	<222> (39)
	<223> Xaa=Asn or Thr
	<220>
10	<221> SITE
	<222> (42)
	<223> Xaa=Ser or Ala
15	
	<220>
	<221> SITE
	<222> (43)
20	<223> Xaa=Glu or Lys
	<220>
	<221> SITE
	<222> (46)
25	<223> Xaa=Ser or Pro
	industrial of 110
	<220>
30	<221> SITE
30	<222> (47)
	<223> Xaa=Ala or Ser
35	<220>
	<221> SITE
	<222> (81)
	<223> Xaa=Gln or His
40	
	<220>
	<221> SITE
	<222> (92)
45	<223> Xaa=Lys or Arg

	<220>
	<221> SITE
5	<222> (114)
	<223> Xaa=Ile or Val
	<220>
10	<221> SITE
	<222> (116)
	<223> Xaa=Thr or Ile
15	<220>
	<221> SITE
	<222> (120)
20	<223> Xaa=Ile or Met
20	000
	<220>
	<221> SITE
25	<222> (124)
	<223> Xaa=Lys or Gln
	<220>
	<221> SITE
30	<222> (139)
	<223> Xaa=Val or Ile
	and the of the
	<220>
35	<221> SITE
	<222> (303)
	<223> Xaa=Val or Ile
40	
40	<220>
	<221> SITE
	<222> (439)
45	<223> Xaa=Gln or Arg
50	

	<220>			
	<221>	SITE		
5	<222>	(441)		
	<223>	Xaa=Thr	or	Asn
	<220>			
10	<221>	SITE		
	<222>	(444)		
	<223>	Xaa=Val	or	Ala
15	<220>			
	<221>	SITE		
	<222>	(446)		
	<223>	Xaa=Leu	or	Ile
20				
	<220>			
	<221>	SITE		
	<222>	(448)		
25	<223>	Xaa=Lys	or	Arg
	<220>			
30	<221>			
30	<222>			
	<223>	Xaa=Glu	or	Asp
35	<220>			
	<221>			
	<222>			
	<223>	Xaa=Val	or	Ile
40	.000			
	<220>			
	<221>			
	<222>	•		.
45	<223>	Xaa=His	or	ASN

	<220>
	<221> SITE
5	<222> (524)
	<223> Xaa=Thr or Gly
10	<220>
,,,	<221> SITE
	<222> (561)
	<223> Xaa=Thr or Ala
15	<220>
	<221> SITE
	<222> (635)
20	<223> Xaa=Asn or His
	<220>
	<221> SITE
25	<222> (659)
	<223> Xaa=Pro or Leu
	<220>
30	<221> SITE
	<222> (697)
	<223> Xaa=Lys or Arg
35	<220>
	<221> SITE
	<222> (738)
40	<223> Xaa=Ser or Asn
	<220>
	<221> SITE
	<222> (751)
15	<223> Xaa=Thr or Met

	<22	0>	_													
		1> S	ITE													
5		2> (
		3> X		er o	r Gl	Y										
	<22	0>														
10	<22	1> S	ITE													
	<22	2> (757)													
•	<22	3> X	aa=S	er o	r Gl	Y										
15	<22	0>														
	<22	1> S	ITE													
	<22	2> ('	758)													
20	<22	3> Xa	aa=V	al o	r Pr	0										
	<400	0> 39	9													
	Xaa	Leu	Thr	qaA	Glu	Lys	Val	Lys	Ala	Tyr	Leu	Ser	Leu	His	Pro	Gln
	1				5			-		10					15	
25																
	Val	Leu	Asp	Glu	Phe	Val	Ser	Glu	Ser	Val	Ser	Ala	Glu	Thr	Val	Glu
				20					25					30		
30																
	Lys	Trp	Leu	Lys	Arg	Lys	Xaa	Asn	Lys	Xaa	Xaa	Asp	Glu	Xaa	Xaa	Pro
			35					40					45			
	Lys	Glu	Val	Ser	Ara	Tvr	Gln	Asp	Thr	Asn	Met	Gln	Glv	Val	Val	Tvr
35	_	50			•		55					60	2			-2-
	Glu	Leu	Asn	Ser	Tyr	Ile	Glu	Gln	Arg	Leu	Asp	Thr	Gly	Gly	Asp	Asn
40	65					70					75					80
-																
	Xaa	Leu	Leu	Leu	Tyr	Glu	Leu	Ser	Ser	Ile	Ile	Xaa	Ile	Ala	Thr	Lys
					85					90					95	
45																
	Ala	Asp	Gly		Ala	Leu	Tyr	Phe	Leu	Gly	Glu	Суз	Asn	Asn	Ser	Leu
				100					105					110		

	Су	s Xa	a Ph	e Xa	a Pro	Pro	o G1	y Xaa	a Ly:	s Glu	ı Gly	y Xaa	a Pro	o Arg	ī Le	u Ile
			11	.5				120					129			
5	Pr	o Al 13	a Gl 0	y Pro) Ile	Thi	Glr 135	n Gly	Th:	Thr	: Xaa	Ser 140		а Туг	Va.	l Ala
10	Ly 14	s Se 5	r Ar	g Lys	Thr	Leu 150		ı Val	Glu	ı Asp	155		Gly	/ Asp	Glu	Arg
15	Ph	e Pr	o Ar	g Gly	Thr 165	Gly	Leu	Glu	Ser	Gly 170		Arg	Ile	Gln	Ser 175	
20	Le	ı Cy:	s Lei	180	Ile	Val	Thr	Ala	Ile 185		Asp	Leu	Ile	Gly 190	Ile	Leu
	Glı	ı Let	1 Tyr 195	Arg	His	Trp	Gly	Lys 200	Glu	Ala	Phe	Cys	Leu 205	Ser	His	Gln
25	Glu	Va]	. Ala	Thr	Ala	Asn	Leu 215	Ala	Trp	Ala	Ser	Val 220	Ala	Ile	His	Gln
30	Val 225	Gln	Val	Cys	Arg	Gly 230	Leu	Ala	Lys	Gln	Thr 235	Glu	Leu	Asn	Asp	Phe 240
35	Leu	Leu	Asp	Val	Ser 245	Lys	Thr	Tyr	Phe	Asp 250	Asn	Ile	Val		Ile 255	Asp
	Ser	Leu	Leu	Glu 260	His .	Ile	Met		Tyr 265	Ala	Lys	Asn		Val 270	Asn	Ala
40	Asp	Arg	Cys 275	Ala	Leu 1	Phe		Val . 280	Asp :	His :	Lys .		Lys 285	Glu :	Leu	Tyr
45	Ser	Asp 290	Leu	Phe .	Asp 1		Gly (295	Glu (Glu 1	Lys (Gly 1 300	Lys :	Pro 2	(aa	Phe
50	Lys 305	Lys	Thr	Lys (le <i>1</i>	Arg 1	Phe S	Ser 1		Glu I B15	yys (Sly 1	Ile A		Gly B20

				,								•				
	Gln	Val	Ala	Arg	Thr 325	Gly	Glu	Val	Leu	Asn 330	Ile	Pro	Asp	Ala	Tyr 335	Ala
5	Asp	Pro	Arg	Phe 340	Asn	Arg	Glu	Val	Asp 345	Leu	Tyr	Thr	Gly	Туг 350	Thr	Thr
10	Arg	Asn	Ile 355	Leu	Cys	Met	Pro	Ile 360	Val	Ser	Arg	Gly	Ser 365	Val	Ile	Gly
15	Val	Val 370	Gln	Met	Val	Asn	Lys 375	Ile	Ser	Gly	Ser	Ala 380	Phe	Ser	Lys	Thr
20	Asp 385	Glu	Asn	Asn	Phe	Lys 390	Met	Phe	Ala	Val	Phe 395	Cys	Ala	Leu	Ala	Leu 400
	His	Cys	Ala	Asn	Met 405	Tyr	His	Arg	Ile	Arg 410	His	Ser	Glu	Cys	Ile 415	Tyr
25	Arg	Val	Thr	Met 42 0	Glu	Lys	Leu	Ser	Tyr 425	His	Ser	Ile	Cys	Thr 430	Ser	Glu
30	Glu	Trp	Gln 435	Gly	Leu	Met	Xaa	Phe 440	Xaa	Leu	Pro	Xaa	Arg 445	Xaa	Cys	Xaa
35	Xaa	Ile 450	Glu	Leu	Phe	His	Phe 455	Asp	Ile	Gly	Pro	Phe 460	Glu	Asn	Met	Trp
	Pro 465	Gly	Ile	Phe	Val	Tyr 470	Met	Xaa	His	Arg	Ser 475	Cys	Gly	Thr	Ser	Cys 480
.	Phe	Glu	Leu	Glu	Lys 485	Leu	Cys	Arg	Phe	Ile 490	Met	Ser	Val	Lys	Lys 495	Asn
45	Tyr	Arg	Arg	Val 500	Pro	Tyr	His	Asn	Trp 505	Lys	His	Ala	Val	Thr 510	Val	Ala
50	His	Суз	Met 515	Tyr	Ala	Ile	Leu	Gln 520	Asn	Asn	Xaa	Xaa	Leu 525	Phe	Thr	qzA

															,	
	Let	530	Arc	J Lys	Gly	Leu	535		Ala	a Cys	s Lev	Cys 540		S Asp	Lev	ı Asp
5	His 545	arg	Gly	Phe	Ser	Asn 550		Туг	· Le	ı Glr	1 Lys 555		e Asp	His	Pro	Leu 560
10	Xaa	ı Ala	Leu	Tyr	Ser 565		Ser	Thr	Met	: Glu 570		His	His	Phe	Ser 575	
15	Thr	Val	Ser	Ile 580	Leu	Gln	Leu	Glu	Gly 585		Asn	Ile	Phe	Ser 590		Leu
20	Ser	Ser	Ser 595		Tyr	Glu	Gln	Val 600	Leu	Glu	Ile	Ile	Arg 605		Ala	Ile _.
	Ile	Ala 610	Thr	Asp	Leu	Ala	Leu 615	Tyr	Phe	Gly	Asn	Arg 620	Lys	Gln	Leu	Glu
25	Glu 625	Met	Tyr	Gln	Thr	Gly 630	Ser	Leu	Asn	Leu	Xaa 635	Asn	Gln	Ser	His	Arg 640
30	Asp	Arg	Val	Ile	Gly 645	Leu	Met	Met	Thr	Ala 650	Cys	Asp	Leu	Cys	Ser 655	Val
35	Thr	Lys	Xaa	Trp 660	Pro	Val	Thr	Lys	Leu 665	Thr	Ala	Asn	Asp	Ile 670	Tyr	Ala
	Glu	Phe	Trp 675	Ala	Glu	Gly	Asp	Glu 680	Met	Lys	Lys	Leu	Gly 685	Ile	Gln	Pro
40	Ile	Pro 690	Met	Met	Asp	Arg	Asp 695	Lys	Xaa	Asp	Glu	Val 700	Pro	Gln	Gly	Gln
45	Leu 705	Gly	Phe	Tyr .		Ala 710	Val .	Ala	Ile	Pro	Cys 715	Tyr	Thr	Thr	Leu	Thr 720
50	Gln	Ile	Leu		Pro 1	Thr :	Glu :	Pro	Leu	Leu 730	Lys	Ala	Cys	Arg	Asp 735	Asn

Leu Xaa Gln Trp Glu Lys Val Ile Arg Gly Glu Glu Thr Ala Xaa Trp
740 745 750

5 Ile Ser Xaa Pro Xaa Xaa Ala 755

10

<210> 40

<211> 767

15 <212> PRT

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence: Synthetic

sequence

<220>

25 <221> SITE

<222> (1)

<223> Xaa=Ser or Gly

30 <220>

<221> SITE

<222> (39)

<223> Xaa=Asn or Thr

35

<220>

<221> SITE

<222> (42)

40 <223> Xaa=Ser or Ala

<220>

<221> SITE

<222> (43)

<223> Xaa=Glu or Lys

50

45

	<220>
5	<221> SITE
	<222> (46)
	<223> Xaa=Ser or Pro
10	<220>
	<221> SITE
	<222> (47)
15	<223> Xaa=Ala or Ser
	<220>
	<221> SITE
	<222> (81)
20	<223> Xaa=Gln or His
	<220>
	<221> SITE
25	<222> (92)
	<223> Xaa=Lys or Arg
	<220>
30	<221> SITE
	<222> (114)
	<223> Xaa=Ile or Val
35	<220>
	<221> SITE
	<222> (116)
40	<223> Xaa=Thr or Ile
	<220>
	<221> SITE
45	<222> (120)
	<223> Xaa=Ile or Met
50	

	<220>
	<221> SITE
5	<222> (124)
	<223> Xaa=Lys or Gln
	<220>
10	<221> SITE
	<222> (139)
	<223> Xaa=Val or Ile
15	<220>
	<221> SITE
	<222> (303)
	<223> Xaa=Val or Ile
20	
	<220>
	<221> SITE
	<222> (439)
25	<223> Xaa=Gln or Arg
	<220>
30	<221> SITE
30	<222> (441)
	<223> Xaa=Thr or Asn
35	<220>
	<221> SITE
	<222> (444)
	<223> Xaa=Val or Ala
40	
	<220>
	<221> SITE
	<222> (446)
45	<223> Xaa=Leu or Ile
50	

	<220>
	<221> SITE
5	<222> (448)
	<223> Xaa=Lys or Arg
	<220>
10	<221> SITE
	<222> (449)
	<223> Xaa=Glu or Asp
15	<220>
	<221> SITE
	<222> (472)
20	<223> Xaa=Val or Ile
	<220>
	<221> SITE
25	<222> (523)
	<223> Xaa=His or Asn
	<220>
30	<221> SITE
	<222> (524)
	<223> Xaa=Thr or Gly
35	<220>
	<221> SITE
	<222> (561)
40	<223> Xaa=Thr or Ala
40	<220>
	<221> SITE
	<222> (635)
45	<223> Xaa=Asn or His
50	

	<220>			
	<221>	SITE		
5	<222>	(659)		
	<223>	Xaa=Pro	or	Leu
	<220>			
10	<221>	SITE		
	<222>	(697)		
	<223>	Xaa=Lys	or	Arg
15	<220>			
	<221>	SITE		
	<222>	(738)		
	<223>	Xaa=Ser	or	Asn
20				
	<220>			
	<221>	SITE		
25	<222>	(751)		
	<223>	Xaa=Thr	or	Met
	<220>			
30	<221>	SITE		
	<222>			
	<223>	Xaa=Ser	or	Gly
35	<220>			
	<221>			
	<222>			
	<223>	Xaa=Ser	or	Gly
40	-200-			
	<220>			
	<221>			
	<222>	(/58) Xaa=Val	~~	D==
45	~ 223>	xaa=va1	or	PIO
50				
50				

```
<220>
             <221> SITE
5
             <222> (760)
             <223> Xaa=Gln or Pro
             <220>
10
             <221> SITE
             <222> (761)
             <223> Xaa=Lys or Ser
15
             <220>
             <221> SITE
             <222> (762)
             <223> Xaa=Ala or Lys
20
             <220>
             <221> SITE
             <222> (763)
25
             <223> Xaa=Ala or Ser
             <220>
             <221> SITE
30
             <222> (764)
             <223> Xaa=Ala or Thr
             <220>
35
             <221> SITE
             <222> (765)
             <223> Xaa=Ser or Pro
40
            <220>
            <221> SITE
             <222> (767)
            <223> Xaa=Asp or Lys
45
            <400> 40
            Xaa Leu Thr Asp Glu Lys Val Lys Ala Tyr Leu Ser Leu His Pro Gln
              1
                                                   10
                                                                       15
```

	Val	Leu	Asp	Glu 20	Phe	Val	Ser	Glu	Ser 25	Val	Ser	Ala	Glu	Thr	Val	Glu
5	Lys	Trp	Leu 35	Lys	Arg	Lys	Xaa	Asn 40	Lys	Xaa	Xaa	Asp	Glu 45	Xaa	Xaa	Pro
10	Lys	Glu 50	Val	Ser	Arg	Tyr	Gln 55	Asp	Thr	Asn	Met	Gln 60	Gly	Val	Val	Tyr
15	Glu 65	Leu	Asn	Ser	Tyr	Ile 70	Glu	Gln	Arg	Leu	Asp 75	Thr	Gly	Gly	Asp	Asn 80
20	Xaa	Leu	Leu	Leu	Туг 85	Glu	Leu	Ser	Ser	Ile 90	Ile	Xaa	Ile	Ala	Thr 95	Lys
	Ala	Asp	Gly	Phe 100	Ala	Leu	Tyr	Phe	Leu 105	Gly	Glu	Cys	Asn	Asn 110	Ser	Leu
25	Cys	Xaa	Phe 115	Xaa	Pro	Pro	Gly	Xaa 120	Lys	Glu	Gly	Xaa	Pro 125	Arg	Leu	Ile
30	Pro	Ala 130	Gly	Pro	Ile	Thr	Gln 135	Gly	Thr	Thr	Xaa	Ser 140	Ala	Tyr	Val	Ala
35	Lys 1 4 5	Ser	Arg	Lys	Thr	Leu 150	Leu	Val	Glu	Asp	Ile 155	Leu	Gly	Asp	Glu	Arg 160
	Phe	Pro	Arg	Gly	Thr 165	Gly	Leu	Glu	Ser	Gly 170	Thr	Arg	Ile	Gln	Ser 175	Val
40	Leu	Cys	Leu	Pro 180	Ile	Val	Thr	Ala	Ile 185	Gly	Asp	Leu	Ile	Gly 190	Ile	Leu
45	Glu	Leu	Tyr 195	Arg	His	Trp	Gly	Lys 200	Glu	Ala	Phe	Cys	Leu 205	Ser	His	Gln
50	Glu	Val 210	Ala	Thr	Ala	Asn	Leu 215	Ala	Trp	Ala	Ser	Val 220	Ala	Ile	His	Gln

5	Va]	l Glı	n Val	l Cy:	s Arq	G1 ₂		u Ala	a Lys	3 Glr	235		ı Lei	u Asr	a Asp	Phe 240
	Leu	ı Leı	ı Asp	Va]	245		5 Thi	ту1	Phe	250		Ile	va:	l Ala	11e 255	. Asp
10	Ser	Leu	ı Lev	Glu 260		: Ile	e Met	: Ile	265		Lys	Asn	Leu	1 Val 270		. Ala
15	Asp	Arg	7 Cys 275		Leu	Phe	: Gln	Val 280		His	Lys	Asn	Lys 285		Leu	Туг
20	Ser	Asp 290	Leu	Phe	Asp	Ile	Gly 295		Glu	Lys	Glu	Gly 300	Lys	Pro	Xaa	Phe
25	Lys 305	Lys	Thr	Lys	Glu	Ile 310	Arg	Phe	Ser	Ile	Glu 315	Lys	Gly	Ile	Ala	Gly 320
25	Gln	Val	Ala	Arg	Thr 325	Gly	Glu	Val	Leu	Asn 330	Ile	Pro	Asp	Ala	Tyr 335	Ala
30	Asp	Pro	Arg	Phe 340	Asn	Arg	Glu	Val	Asp 345	Leu	Туг	Thr	Gly	Tyr 350	Thr	Thr
35	Arg	Asn	Ile 355	Leu	Cys	Met	Pro	Ile 360	Val	Ser	Arg	Gly	Ser 365	Val	Ile	Gly
40	Val	Val 370	Gln	Met	Val	Asn	Lys 375	Ile	Ser	Gly	Ser	Ala 380	Phe	Ser	Lys	Thr
	Asp 385	Glu	Asn	Asn	Phe	Lys 390	Met	Phe	Ala		Phe 395	Cys	Ala	Leu		Leu 400
45	His	Cys	Ala	Asn.	Met 405	Tyr	His	Arg		Arg	His	Ser	Glu		Ile 415	Tyr
50	Arg	Val		Met 420	Glu	Lys	Leu		Tyr 1 425	His :	Ser	Ile (Thr :	Ser (Glu

5	Glu	Trp	Gln 435	Gly	Leu	Met	Xaa	Phe 440	Xaa	Leu	Pro	Xaa	Arg 445	Xaa	Cys	Xaa
	Xaa	Ile 450	Glu	Leu	Phe	His	Phe 455	Asp	Ile	Gly	Pro	Phe 460	Glu	Asn	Met	Trp
10	Pro 465	Gly	Ile	Phe	Val	Tyr 470	Met	Xaa	His	Arg	Ser 475	Cys	Gly	Thr	Ser	Cys 480
15	Phe	Glu	Leu	Glu	Lys 485	Leu	Суѕ	Arg	Phe	Ile 490	Met	Ser	Val	Lys	Lys 495	Asn
20	Tyr	Arg	Arg	Val 500	Pro	Tyr	His	Asn	Trp 505	Lys	His	Ala	Val	Thr 510	Val	Ala
	His	Cys	Met 515	Tyr	Ala	Ile	Leu	Gln 520	Asn	Asn	Xaa	Xaa	Leu 525	Phe	Thr	Asp
25	Leu	Glu 530	Arg	Lys	Gly	Leu	Leu 535	Ile	Ala	Суз	Leu	Cys 540	His	Asp	Leu	Asp
30	His 545	Arg	Gly	Phe	Ser	Asn 550	Ser	Туг	Leu	Gln	Lys 555	Phe	Asp	His	Pro	Leu 560
35	Xaa	Ala	Leu	Tyr	Ser 565	Thr	Ser	Thr	Met	Glu 570	Gln	His	His	Phe	Ser 575	Gln
	Thr	Val	Ser	Ile 580	Leu	Gln	Leu	Glu	Gly 585	His	Asn	Ile	Phe	Ser 590	Thr	Leu
40	Ser	Ser	Ser 595	Glu	Tyr	Glu	Gln	Val 600	Leu	Glu	Ile	Ile	Arg 605	Lys	Ala	Ile
45	Ile	Ala 610	Thr	qeA	Leu	Ala	Leu 615	Tyr	Phe	Gly	Asn	Arg 620	Lys	Gln	Leu	Glu
50	Glu 625	Met	Tyr	Gln		Gly 630	Ser	Leu	Asn	Leu	Xaa 635	Asn	Gln	Ser	His	Arg 640

5	Asp	Arg Va	l Ile	Gly 645		Met	Met	Thr	Ala 650		Asp	Leu	Суѕ	Ser 655	
	Thr	Lys Xa	a Trp 660		Val	Thr	Lys	Leu 665	Thr	Ala	Asn	Asp	Ile 670	Tyr	Ala
10	Glu	Phe Tr	Ala	Glu 	Gly	Asp	Glu 680	Met	Lys	Lys	Leu	Gly 685	Ile	Gln	Pro
15		Pro Me	Met	Asp	Arg	Asp 695	Lys	Xaa	Asp	Glu	Val 700	Pro	Gln	Gly	Gln
20	Leu (705	Gly Phe	Tyr	Asn	Ala 710	Val	Ala	Ile	Pro	Cys 715	Tyr	Thr	Thr	Leu	Thr 720
25	Gln 1	Ile Leu	Pro	Pro 725	Thr	Glu	Pro	Leu	Leu 730	Lys	Ala	Cys	Arg	Asp 735	Asn
23	Leu }	Kaa Glr	740	Glu	Lys	Val	Ile	Arg 745	Gly	Glu	Glu	Thr	Ala 750	Xaa	Trp
30	Ile S	Ser Xaa 755		Xaa	Xaa		Xaa 760	Xaa	Xaa	Xaa		Xaa 765	Glu	Xaa	
35	<210> <211> <212> <213>	. 8	icial	Sea	uenc	e									
40	<220>	Descr	iptio				ial :	Seque	ence	: Syı	nthe	tic			
45		seque	ice												
	<220>														
	<221>														
50	<222> <223>	(4) Xaa=As	sn or	Thr											

	<220>	
	<221> SITE	
5	<222> (7)	
	<223> Xaa=Ser or Ala	
	<220>	
10	<221> SITE	
	<222> (8)	
	<223> Xaa=Glu or Lys	
15		
	<400> 41	
	Lys Arg Lys Xaa Asn Lys Xaa Xaa	
	1 5	
20		
	<210> 42	
	<211> 8	
	<212> PRT	
25	<213> Artificial Sequence	
	<220>	
30	<223> Description of Artificial Sequence: Sy	nthetic
30	sequence	
	<220>	
35	<221> SITE	
	<222> (4)	
	<223> Xaa=Asn or Thr	
	<220>	
40	<221> SITE	
	<222> (7)	
	<223> Xaa=Ser or Ala	
45		
· -	<220>	
	<221> SITE	
	<222> (8)	
50	<223> Xaa=Glu or Lys	

```
<400> 42
               Lys Arg Lys Xaa Asp Lys Xaa Xaa
5
              <210> 43
10
              <211> 11
              <212> PRT
              <213> Artificial Sequence
15
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    sequence
20
              <220>
              <221> SITE
              <222> (11)
              <223> Xaa=Lys or Arg
25
              <400> 43
              Leu Leu Tyr Glu Leu Ser Ser Ile Ile Xaa
30
                1
                                 5
              <210> 44
35
              <211> 12
              <212> PRT
              <213> Artificial Sequence
40
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    sequence
45
              <220>
              <221> SITE
              <222> (12)
```

<223> Xaa=Lys or Arg

55

<400> 44 Leu Leu Leu Tyr Glu Leu Asn Ser Ser Ile Ile Xaa <210> 45 <211> 73 <212> PRT <213> Homo sapiens <400> 45 Met Glu Asp Gly Pro Ser Asn Asn Ala Ser Cys Phe Arg Arg Leu Thr Glu Cys Phe Leu Ser Pro Ser Leu Thr Asp Glu Lys Val Lys Ala Tyr Leu Ser Leu His Pro Gln Val Leu Asp Glu Phe Val Ser Glu Ser Val Ser Ala Glu Thr Val Glu Lys Trp Leu Lys Arg Lys Asn Asn Lys Ser Glu Asp Glu Ser Ala Pro Lys Glu Val <210> 46 <211> 75 <212> PRT <213> Homo sapiens

<400> 46

Met Glu Gly Ser Thr Ala Trp Ser Ser Glu Ala Glu Pro Gln Glu Gly

5	Arg	Ser	Gln	Met 20		ı Glr	ı Arç	y Al	a Gl ₃		ı Thi	: As	p Glu	1 Lys		l Lys
	Ala	Туг	Leu 35	Ser	Leu	His	Pro	Gl:		l Let	Asp	Gl:	ı Phe		. Se	c Glu
10	Ser	Val	Ser	Ala	Glu	Thr	Val		ı Lys	Trp	Leu	Ly:		l Lys	Asr	Asn
15	Lys 65	Ser	Glu	Asp	Glu	Ser 70		Pro	Lys	: Glu	. Val					
20	<212 <212		00	sapi	ens											
30	<400 Phe			Glu	Cys 5	Asn	Asn	Ser	Leu	Cys	Ile	Phe	Thr	Pro	Pro 15	Gly
	Ile	Lys	Glu	Gly 20	Lys	Pro	Arg	Leu	Ile 25	Pro	Ala	Gly	Pro	Ile 30	Thr	Gln
35	Gly	Thr	Thr 35	Val	Ser	Ala	Tyr	Val 40	Ala	Lys	Ser	Arg	Lys 45	Thr	Leu	Leu
40	Val	Glu 50	Asp	Ile	Leu	Gly	Asp 55	Glu	Arg	Phe	Pro	Arg 60	Gly	Thr	Gly	Leu
45	65		Gly			70					75					80
50	Ala	Ile	Gly .	Asp	Leu 85	Ile	Gly	Ile	Leu	G1u 90	Leu	Tyr	Arg	His	Trp 95	Gly

5	Lys Glu	Ala Ph	_	Leu	Ser	His	Gln 105	Glu	Val	Ala	Thr	Ala 110	Asn	Leu
5	Ala Tr	Ala Se	r Val	Ala	Ile	His 120	Gln	Val	Gln	Val	Cys 125	Arg	Gly	Leu
10	Ala Lys		r Glu	Leu	Asn 135	Asp	Phe	Leu	Leu	Asp 140	Val	Ser	Lys	Thr
15	Tyr Phe	e Asp As	n Ile	Val 150	Ala	Ile	Asp	Ser	Leu 155	Leu	Glu	His	Ile	Met 160
20	Ile Tyr	Ala Ly	rs Asn 165		Val	Asn	Ala	Asp 170	Arg	Cys	Ala	Leu	Phe 175	Gln
	Val Ası	His Ly		Lys	Glu	Leu	Туг 185	Ser	Asp	Leu	Phe	Asp 190	Ile	Gly
25	Glu Glu	195 195	u Gly	Lys	Pro	Val 200	Phe	Lys	Lys	Thr	Lys 205	Glu	Ile	Arg
30	Phe Sec	r Ile G	u Lys	Gly	Ile 215	Ala	Gly	Gln	Val	Ala 220	Arg	Thr	Gly	Glu
35	Val Le	ı Asn I	le Pro	Asp 230	Ala	Tyr	Ala	Asp	Pro 235	Arg	Phe	Asn	Arg	Glu 240
	Val As	Leu T	r Thr 245		Tyr	Thr	Thr	Arg 250	Asn	Ile	Leu	Cys	Met 255	Pro
40	Ile Va	l Ser A	rg Gly 50	Ser	Val	Ile	Gly 265	Val	Val	Gln	Met	Val 270	Asn	Lys
45	Ile Se	c Gly S 275	er Ala	Phe	Ser	Lys 280		Asp	Glu	Asn	Asn 285	Phe	Lys	Met
50	Phe Al	a Val P	ne Cys	Ala	Leu 295		Leu	His	Суз	Ala 300				

Claims

- An amino acid sequence comprising the sequence presented as Formula I or a variant, homologue, fragment or derivative thereof.
 - 2. An amino acid sequence comprising the sequence presented as Formula I.

- 3. A nucleotide sequence entering the amino acid sequence as defined in claim 1 of the 2.
- A nucleotide sequence comprising the sequence presented as SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 14
 or a variant, homologue, fragment or derivative thereof.
- 5. A nucleotide sequence comprising the sequence presented as SEQ ID No. 1 or SEQ ID No. 3 or SED ID No. 14.
- A nucleotide sequence that is capable of hybridising to the nucleotide sequence according to any one of claims 3 to 5.
- 7. A nucleotide sequence that is capable of hybridising to the nucleotide sequence according to claim 6.
- 8. A vector comprising the nucleotide sequence according to any one of claims 3 to 7.
- 9. A host cell into which has been incorporated the nucleotide sequence according to any one of claims 3 to 7.
 - 10. An assay method for identifying an agent that can affect PDE11 activity or expression, the assay method comprising
 - contacting an agent with an amino acid according to claim 1 or claim 2 or a nucleotide sequence according to any one of claims 3 to 7; and
 - measuring the activity or expression of PDE11;
- wherein a difference between a) PDE activity or expression in the absence of the agent and b) PDE activity or expression in the presence of the agent is indicative that the agent can affect PDE11 activity or expression.
 - 11. An assay method according to claim 10 wherein the assay is to screen for agents useful in the treatment of sexual dysfunction.
- 30 12. A process comprising the steps of:

5

10

20

- (a) performing the assay according to claim 10 or claim 11;
- (b) identifying one or more agents that do affect PDE11 activity or expression; and
- (c) preparing a quantity of those one or more identified agents.
- 13. A method of affecting in vivo PDE11 activity or expression with an agent;
- 40 wherein the agent is capable of affecting PDE11 activity or expression in an in vitro assay method;
 - wherein the in vitro assay method is the assay method defined in claim 10 or claim 11.
- 14. Use of an agent in the preparation of a pharmaceutical composition for the treatment of a disease or condition associated with PDE11, the agent is capable of having an effect on the activity or expression of PDE when assayed in vitro by the assay method according to claim 10 or claim 11.
 - 15. An enzyme capable of having an immunological reaction with an antibody raised against PDE11.
- 50 16. A nucleotide sequence coding for a PDE, wherein the nucleotide sequence is obtainable from NCIMB 40925 or NCIMB 40926 or NCIMB 41007.
 - 17. A PDE wherein the PDE is expressable from a nucleotide sequence obtainable from NCIMB 40925 or NCIMB 40926 or NCIMB 41007.
 - **18.** Use of an agent which has an effect on the activity of PDE11 or the expression thereof in the preparation of a pharmaceutical composition for the treatment of a disease or condition associated with PDE11.

EP 0 967 284 A1 19. Use of a PDE11 and/or expression product thereof in the preparatio medicament for the treatment and/ or modulation of disturbances associated with an inbalance or disturbance of PDE11. 20. Use according to claim 19 wherein the PDE11 and/or expression product thereof is used to screen for agents that can modulate the activity of the PDE11 and/or expression product thereof. 21. A PDE11 agonist wherein the PDE11 is as defined in claim 1 or is the nucleotide sequence coding for same. 22. A PDE11 antagonist wherein the PDE11 is as defined in claim 1 or is the nucleotide sequence coding for same. 23. A recombinant PDE11 enzyme. 24. A recombinant nucleotide sequence encoding a PDE11 enzyme. 25. A PDE11 enzyme substantially as described herein.

5

10

15

20

25


30


35

40

45

50








Figure 4A SEQ ID No.1

TTCGGCTCCGACATGGAAGATGGACCTTCTAATAATGCGAGCTGCTTCCGAAGGCTGACC 60 GAGTGCTTCCTGAGCCCCAGTTTGACAGATGAAAAGTGAAGGCATATCTTTCTCTTCAC 120 CCCCAGGTATTAGATGAATTTGTATCTGAAAGTGTTAGTGCAGAGACAGTAGAGAAATGG 180 CTGAAGAGAAGAACAACAAATCAGAAGATGAATCAGCTCCTAAGGAAGTCAGCAGGTAC 240 CAAGATACGAATATGCAGGGAGTTGTATATGAACTAAACAGCTATATAGAACAACGGTTG 300 GACACAGGAGGAGACAACCAGCTACTCCTCTATGAACTGAGCAGCATCATTAAAATAGCC 360 ACAAAAGCCGATGGATTTGCACTGTATTTCCTTGGAGAGTGCAATAATAGCCTGTGTATA 420 TTCACGCCACCTGGGATAAAGGAAGGAAAACCCCGCCTCATCCCTGCTGGGCCCATCACT 480 CAGGGCACCACCGTCTCTGCTTATGTGGCCAAGTCCAGGAAAACACTGCTAGTAGAAGAC 540 ATCCTTGGAGATGAACGATTTCCAAGAGGTACTGGACTGGAATCAGGGACTCGTATCCAG 600 TCTGTTCTTTGCTTACCAATTGTCACTGCAATTGGTGACTTGATTGGTATTCTCGAGCTG 660 TATCGGCACTGGGGCAAAGAAGCCTTCTGTCTTAGTCACCAGGAGGTTGCAACAGCAAAT 720 CTTGCCTGGGCTTCAGTAGCAATACATCAGGTGCAGGTATGCAGAGGCCTTGCCAAACAG 780 ACAGAATTGAATGACTTCCTACTCGACGTATCAAAAACATATTTTGATAACATAGTTGCA 840 ATAGATTCTCTACTTGAACACATAATGATATATGCAAAAAACCTGGTGAATGCCGATCGT 900 TGTGCACTTTTCCAGGTGGACCATAAGAACAAGGAGTTATATTCAGACCTTTTTGATATT 960 GGAGAGGAAAAGGAAAACCTGTCTTCAAGAAGACCAAAGAGATAAGATTTTCAATT 1020 GAGAAAGGAATTGCTGGCCAAGTAGCAAGAACAGGGGAAGTCCTGAACATTCCAGATGCC 1080 TATGCAGACCCACGCTTTAACAGAGAAGTAGACTTGTACACAGGCTACACCACGCGGAAC 1140 ATCCTGTGCATGCCCATCGTCAGCCGAGGCGTGATAGGTGTGGTGCAGATGGTCAAC 1200 AAAATCAGTGGCAGTGCCTTCTCTAAAACAGATGAAAACAACTTCAAAATGTTTGCCGTC 1260 TTTTGTGCTTTAGCCTTACACTGTGCTAATATGTATCATAGAATTCGCCACTCAGAGTGC 1320 ATTTACCGGGTAACGATGGAAAAGCTGTCCTACCATAGCATTTGTACTTCAGAAGAGTGG 1380 CAAGGTCTCATGCAATTCACCCTTCCCGTGCGTCTCTGCAAAGAAATTGAATTATTCCAC 1440 TTTGACATTGGTCCTTTTGAAAACATGTGGCCTGGAATTTTTGTCTACATGGTTCATCGG 1500 TCCTGTGGGACATCCTGCTTTGAGCTTGAAAAGTTGTGTCGTTTTATTATGTCTGTGAAG 1560 AAGAACTATCGGCGGGTTCCTTATCACAACTGGAAGCATGCGGTCACTGTAGCACACTGC 1620 ATGTATGCCATACTTCAGAACAATCACGCTTTTCACAGACCTTGAGCGCAAAGGACTG 1680 CTGATTGCGTGTCTGTCATGACCTGGACCACAGGGGCTTCAGTAACAGCTACCTGCAG 1740 AAGTTCGACCACCTCTGACCGCTCTCTACTCCACCTTCCACCATGGAGCAGCACCACTTC 1800 TCCCAGACTGTGTCCATCCTTCAGTTGGAAGGGCACAATATCTTCTCCACTCTGAGCTCC 1860 AGTGAATATGAGCAGGTGCTTGAGATCATCCGCAAAGCCATCATTGCCACAGACCTTGCT 1920 TTATACTTTGGAAACAGGAAGCAGTTGGAAGAGATGTACCAGACCGGATCACTAAACCTT 1980 AATAATCAATCACATAGAGACCGTGTAATTGGTTTGATGATGACTGCCTGTGACCTTTGT 2040 TGGGCTGAGGGTGATGAAATGAAGAAATTGGGAATACAGCCTATTCCTATGATGGACAGA 2160 GACAAGAAGGATGAAGTCCCCCAAGGCCAGCTTGGGTTCTACAATGCCGTGGCCATTCCC 2220 TGCTATACAACCCTTACCCAGATCCTCCCTCCCACGGAGCCTCTTCTGAAAGCATGCAGG 2280 GATAATCTCAGTCAGTGGGAGAAGGTGATTCGAGGGGAGAGACTGCAACCTGGATTTCA 2340 TCCCCATCCGTGGCTCAGAAGGCAGCTGCATCTGAAGATTGAGCACTGGTCACCCTGACA 2400 CGCTGTCCCACCTACAGATCCTCATCTTGCTTCTTTGACATTCTTTTCCTTTTTTGGGGG 2460 GGGTGGGGGGACCTGCACCTGGTAACTGGGGTGCAAACCTCTTCAAGAAGGTAACATCA 2520 AATAAATAAGTCAAGCAGAAAAAAAAAAAAAAAA 2557

FIGURE 4 Continued

Figure 4B SEQ ID No.2

MEDGPSNNASCERLTECFLSPSLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRK 60

NNKSEDESAPKEVSRYQDTNMQGVVYELNSYIEQRLDTGGDNQLLLYELSSIIKIATKAD 120

GFALYFLGECNNSLCIFTPPGIKEGKPRLIPAGPITQGTTVSAYVAKSRKTLLVEDILGD 180

ERFPRGTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLAWA 240

SVAIHQVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALF 300

QVDHKNKELYSDLFDIGEEKEGKPVFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADP 360

RFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCAL 420

ALHCANMYHRIRHSECIYRVTMEKLSYHSICTSEEWQGLMQFTLPVRLCKEIELFHFDIG 480

PFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAI 540

LQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLTALYSTSTMEQHHFSQTV 600

SILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQS 660

HRDRVIGLMMTACDLCSVTKPWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKD 720

EVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSV 780

AQKAAASED 789

Figure 5A SEQ ID No.3

ACATAGCTGGGTGCAATGTAAGTGCCTGGCTGAAGTTTGACACGCGAACGGCCCGC 60 TGGAATTCTGTGCTATGAGCCGGAGTAGAAAGAGAGATTTGGACTCTGCAACACCAAGGT 120 AGTCGTTGAAGCCACAGTCGTGAATGGAGACCAGGAGTGAATAGTGGGAGTGAGCAGAAG 180 TCGGAGGATAGGACAGAAGAAGGCAGAGCCATGGAGCACCCTGGAGAGGTGTGACCCGGC 240 AAGATCCTGAGATGGAAGGTAGCACGGCCTGGAGTTCAGAAGCGGAGCCTCAAGAGGGGAA 300 GAAGCCAGATGCTCCAGAGAGCAGGTTTGACAGATGAAAAAGTGAAGGCATATCTTTCTC 360 TTCACCCCCAGGTATTAGATGAATTTGTATCTGAAAGTGTTAGTGCAGAGACAGTAGAGA 420 AATGGCTGAAGAGGAAGAACAAAATCAGAAGATGAATCAGCTCCTAAGGAAGTCAGCA 480 GGTACCAAGATACGAATATGCAGGGAGTTGTATATGAACTAAACAGCTATATAGAACAAC 540 GGTTGGACACAGGAGGAGACAACCAGCTACTCCTCTATGAACTGAGCAGCATCATTAAAA 600 TAGCCACAAAAGCCGATGGATTTGCACTGTATTTCCTTGGAGAGTGCAATAATAGCCTGT 660 GTATATTCACGCCACCTGGGATAAAGGAAGGAAAACCCCGCCTCATCCCTGCTGGGCCCA 720 TCACTCAGGGCACCACCGTCTCTGCTTATGTGGCCAAGTCCAGGAAAACACTGCTAGTAG 780 AAGACATCCTTGGAGATGAACGATTTCCAAGAGGTACTGGACTGGAATCAGGGACTCGTA 840 TCCAGTCTGTTCTTTGCTTACCAATTGTCACTGCAATTGGTGACTTGATTGGTATTCTCG 900 AGCTGTATCGGCACTGGGGCAAAGAAGCCTTCTGTCTTAGTCACCAGGAGGTTGCAACAG 960 CAAATCTTGCCTGGGCTTCAGTAGCAATACATCAGGTGCAGGTATGCAGAGGCCTTGCCA 1020 AACAGACAGAATTGAATGACTTCCTACTCGACGTATCAAAAACATATTTTGATAACATAG 1080 TTGCAATAGATTCTCTACTTGAACACATAATGATATATGCAAAAAACCTGGTGAATGCCG 1140 ATCGTTGTGCACTTTTCCAGGTGGACCATAAGAACAAGGAGTTATATTCAGACCTTTTTG 1200 ATATTGGAGAGGAAAAGGAAGGAAAACCTGTCTTCAAGAAGACCAAAGAGATAAGATTTT 1260 CAATTGAGAAAGGAATTGCTGGCCAAGTAGCAAGAACAGGGGAAGTCCTGAACATTCCAG 1320 ATGCCTATGCAGACCCACGCTTTAACAGAGAAGTAGACTTGTACACAGGCTACACCACGC 1380 GGAACATCCTGTGCATGCCCATCGTCAGCCGAGGCAGCGTGATAGGTGTGGTGCAGATGG 1440 TCAACAAAATCAGTGGCAGTGCCTTCTCTAAAACAGATGAAAACAACTTCAAAAATGTTTG 1500 CCGTCTTTTGTGCTTTAGCCTTACACTGTGCTAATATGTATCATAGAATTCGCCACTCAG 1560 AGTGCATTTACCGGGTAACGATGGAAAAGCTGTCCTACCATAGCATTTGTACTTCAGAAG 1620 AGTGGCAAGGTCTCATGCAATTCACCCTTCCCGTGCGTCTCTGCAAAGAAATTGAATTAT 1680 TCCACTTTGACATTGGTCCTTTTGAAAACATGTGGCCTGGAATTTTTGTCTACATGGTTC 1740 ATCGGTCCTGTGGGACATCCTGCTTTGAGCTTGAAAAGTTGTGTCGTTTTATTATGTCTG 1800 TGAAGAAGAACTATCGGCGGGTTCCTTATCACAACTGGAAGCATGCGGTCACTGTAGCAC 1860 ACTGCATGTATGCCATACTTCAGAACAATCACACGCTTTTCACAGACCTTGAGCGCAAAG 1920 GACTGCTGATTGCGTGTCTGTGTCATGACCTGGACCACAGGGGGCTTCAGTAACAGCTACC 1980 TGCAGAAGTTCGACCACCCTCTGACCGCTCTCTACTCCACTTCCACCATGGAGCAGCACC 2040 ACTTCTCCCAGACTGTGTCCATCCTTCAGTTGGAAGGGCACAATATCTTCTCCACTCTGA 2100 GCTCCAGTGAATATGAGCAGGTGCTTGAGATCATCCGCAAAGCCATCATTGCCACAGACC 2160 TTGCTTTATACTTTGGAAACAGGAAGCAGTTGGAAGAGATGTACCAGACCGGATCACTAA 2220 ACCTTAATAATCAATCACATAGAGACCGTGTAATTGGTTTGATGATGACTGCCTGTGACC 2280 AATTCTGGGCTGAGGGTGAAATGAAGAAATTGGGAATACAGCCTATTCCTATGATGG 2400 ACAGAGACAAGAAGGATGAAGTCCCCCAAGGCCAGCTTGGGTTCTACAATGCCGTGGCCA 2460 TTCCCTGCTATACAACCCTTACCCAGATCCTCCCTCCCACGGAGCCTCTTCTGAAAGCAT 2520 GCAGGGATAATCTCAGTCAGTGGGAGAAGGTGATTCGAGGGGAGGAGACTGCAACCTGGA 2580 TTTCATCCCCATCCGTGGCTCAGAAGGCAGCTGCATCTGAAGATTGAGCACTGGTCACCC 2640 TGACACGCTGTCCCACCTACAGATCCTCATCTTGCTTCTTTGACATTCTTTTCCTTTTTT 2700 GGGGGGGTGGGGGAACCTGCACCTGGTAACTGGGGTGCAAACCTCTTCAAGAAGGTAA 2760 CATCAAATAAATAAGTCAAGCAGAAAAAAAAAAAAAAA 2799

FIGURE 5 Continued

Figure 5B SEQ ID No.4

MEGSTAWSSEAEPQEGRSQMLQRAGLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLK 60

RKNNKSEDESAPKEVSRYQDTNMQGVVYELNSYIEQRLDTGGDNQLLLYELSSIIKIATK 120

ADGFALYFLGECNNSLCIFTPPGIKEGKPRLIPAGPITQGTTVSAYVAKSRKTLLVEDIL 180

GDERFPRGTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLA 240

WASVAIHQVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCA 300

LFQVDHKNKELYSDLFDIGEEKEGKPVFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYA 360

DPRFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFC 420

ALALHCANMYHRIRHSECIYRVTMEKLSYHSICTSEEWQGLMQFTLPVRLCKEIELFHFD 480

IGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMY 540


AILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLTALYSTSTMEQHHFSQ 600

TVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNN 660

QSHRDRVIGLMMTACDLCSVTKPWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDK 720


KDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSP 780

FIGURE 5 Continued
Figure SC
PDE11A1 MEDGPSNNASCFRRLTECFLSPSLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRKNNKSEDESAPKEV
++++++++++++++++++++++++++++++++++++++
MEGSTAWSSEAFPOEGRSOMLORAGI.TDEKVKAYI.SI.HDOVI.DEFVSESVSAFTVEKWI.KDKNNKSFDES.DKFV




7A

7B




Variable Value Std. Err.

Intercept 0.0238 0.0029 (Km/Vmax) Slope 0.0521 0.0011 (1/Vmax) Km 0.456



Variable Value Std. Err.

Intercept 0.0360 0.0038 (Km/Vmax) Slope 0.0090 0.0002 (1/Vmax) Km 4.0






Figure 10

Length = 789 Score = 1527 (709.8 bits). Expect = 1.7e-213. P = 1.7e-213 Identities = 292/300 (97%), Positives = 298/300 (99%) Query: 1 FLGECNNSLCVFIPPGMKEGQPRLIPAGPITQGTTISAYVAKSRKTLLVEDILGDERFPR 60 FLGECNNSLC+F PPG+KEG+PRLIPAGPITQGTT+SAYVAKSRKTLLVEDILGDERFPR 126 FLGECNNSLCIFTPPGIKEGKPRLIPAGPITQGTTVSAYVAKSRKTLLVEDILGDERFPR 185 Sbjct: Query: 61 GTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHWDKEAFCLSHQEVATANLAWASVAIH 120 GTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHW KEAFCLSHQEVATANLAWASVAIH Sbjct: 186 GTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLAWASVAIH 245 121 QVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIIIYAKNLVNADRCALFQVDHK 180 Query: QVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHI+IYAKNLVNADRCALFQVDHK 246 QVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALFQVDHK 305 Sbjct: Query: 181 NKELYSDLFDIGEEKEGKPIFKKTKEIRFSIEKGIAGOVARTGEVLNIPDAYADPRENRE 240 NKELYSDLFDIGEEKEGKP+FKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNRE Sbjct: 306 NKELYSDLFDIGEEKEGKPVFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNRE 365 Query: 241 VDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCALALHCA 300 VDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCALALHCA Sbjct: 366 VDLYTGYTTRNILCMPIVSRGSVIGVVOMVNKISGSAFSKTDENNFKMFAVFCALALHCA 425



HumanPDE11A1_	MEDGPSNNASCFRRLTECFLSPSLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLK
HumanPDE11A2	MEGSTAWSSEAEPQEGRSQMLQRAGLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLK
-	
MousePDE11A3_	MEDGPSNNASCFRRLTECFLSPSLTDEKVKAYLSLKPQVLDEFVSESVSAETVEKWLK
	** . *.:* :: :*******************
HumanPDE11A1_	RKNINKSEDESAPKEVSRYQDTNMQGVVYELNSYIEQRLDTGGDNQLLLYELSSIIKIATK
HumanPDE11A2	RKNNKSEDESAPKEVSRYQDTNMQGVVYELNSYIEQRLDTGGDNQLLLYELSSIIKIATK
MousePDE11A3	
	RKTNKAKDEPSPKEVSRYQDTNMQGVVYELNSYIEQRLDTGGDNHLLLYELSSIIRIATK
	'::**':****************************
HumanPDE11A1_	adgfalyflgecnnslciftppgikegkprlipagpitqgttvsayvaksrktllvedil
HumanPDE11A2_	ADGFALYFLGECNNSLCIFTPPGIKEGKPRLIPAGPITQGTTVSAYVAKSRKTLLVEDIL
MousePDE11A3	ADGFALYFLGECNNSLCVFIPPGMKEGQPRLIPAGPITQGTTISAYVAKSRKTLLVEDIL
_	*****************
HumanPDE11A1_	GDERFPRGTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLA
HumanPDE11A2	GDERFPRGTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLA
Mouse?DE11A3_	GDERFPRGTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLA
	APPEARM AND THE CONTRACT AND THE CONTRACT CONTRA
Virgin 10001111	LIR CUIT TUTATION OF A WARREN AND A RESIDENCE OF THE COLUMN AS A SHARE
HumanPDE11A1_	WASVAIHQVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCA
HumanPDE11A2_	wasvaihqvqvcrglakqtelndflldvsktyfdnivaidsllehimiyaknlvnadrca
MousePDEllA3_	WASVAIHQVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIHIYAKNLVNADRCA

KumanPDE11A1_	LFQVDHKNKELYSDLFDIGEEKEGKPVFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYA
HumanPDE11A2	LFQVDHKNKELYSDLFDIGEEKEGKPVFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYA
MousePDEllAJ	
Modserberths_	LFQVDHKVKELYSDLFDIGEEKEGKPIFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYA

Visco DDP1131	
HumanPDE11A1_	DPRFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFC
HumanPDE11A2_	DPRFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFRMFAVFC
MousePDE11A3_	DPRFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFC

HumanPDE11A1_	ALALHCANMYHRIRHSECIYRVTMEKLSYHSICTSEEWQGLMQFTLPVRLCKEIELFHFD
HumanPDE11A2_	ALALHCANMYHRIRHSECIYRVTMEKLSYHSICTSEEWQGLMQFTLPVRLCKEIELFHFD
MousePDE11A3	ALALHCANNYHRIRHSECIYRVTMEKLSYHSICTSEEWQGLMRFNLPARICRDIELFHFD
-	************************************
HumanPDE11A1	IGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKXNYRRVPYHNWKHAVTVAHCMY
HumanPDELLA2	IGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKONYRRVPYHNWKHAVTVAHCMY
-	IGPFENMWPGIFVYMIHRSCGTSCFELEKLCRFIMSVKXNYRRVPYHNWKHAVTVAHCMY
MousePDE11A3_	zatemment meruscolocismismismismismismismismismismismismismi
HumanPDE11A1	AILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLTALYSTSTMEQHHFSQ
_	
HumanPDE11A2_	AILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLTALYSTSTMEQHHFSQ
MousePDE11A3_	AILQNNNGLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQ

HumanPDE11A1_	TVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNN
HumanPDE11A2_	TVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNN
MousePDE11A3_	TVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLHN

HumanPDEl1A1_	QSHRDRVIGLMHTACDLCSVTKPWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDK
HumanPDE11A2_	QSHRDRVIGLMMTACDLCSVTKPWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDK
MousePDE11A3	QSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDK

HumanPDE11A1	KDEVPOGOLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSP
HumanPDE11A2	KDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQMEKVIRGEETATWISSP
MousePDE11A3_	RDEVPQQQLGFYNAVAIPCYTTLTQILPPTEPLLKACRONLNQWEKVIRGEETAMWISGP

V	·
HumanPDE11A1_	SVAQKAAASED
HumanPDE11A2_	SVAQKAAASED
MousePDE11A3_	GPAPSKSTPEKLNVKVED
	. * . 11.*.



PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent ConventionEP 99 30 3985 shall be considered, for the purposes of subsequent proceedings, as the European search report

	DOCUMENTS CONSIDE	RED TO BE RELEVANT			
Category	Citation of document with income of relevant passa	dication, where appropriate,	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CI.6)	
P,X	WO 99 19495 A (ICOS LOUGHNEY KATE (US)) 22 April 1999 (1999- * the whole document	1-10, 12-25	C12N15/55 C12N9/16 G01N33/68 C1201/44		
χ	Nucleotide Sequence Database EMBL Entry HS835337; Accession number W04835 8 May 1996 96% identity with Seq.ID:1 nt.1338-1763 96% identity with Seq.ID:3 nt.1583-2008 84% identity with Seq.ID:14 nt.1783-2208 reverse orientation XP002119752			C07K16/40 C12N15/11 A61K38/46 A61K35/00 A61K48/00	
Y	* the whole document	10-14, 18-22			
Y	WO 97 03675 A (LABO S.A. (FR); DAUGAN A 6 February 1997 (1997)				
	* page 1, line 31 - * page 4, line 17-2 * page 16, line 10		TECHNICAL FIELDS SEARCHED (Int.Cl.6)		
	* page 18 – page 22	; claims * 		C12N G01N C12Q C07K	
INCO	MPLETE SEARCH		·L	A61K	
not comple carrie Claims s Claims s Claims n Reason	rich Division considers that the present that you with the EPC to such an extent that dout, or can only be carried out partial earched completely: earched Incompletely: out searched: for the limitation of the search: sheet C	application, or one or more of its claims, doe: a meaningful search into the state of the art o ly, for these claims.	s/do cannot		
	Place of search	Date of completion of the search		Examiner	
	THE HAGUE	21 October 1999	Ma	cchia, G	
X:pa Y:pa do A:teo	CATEGORY OF CITED DOCUMENTS ricularly relevant if taken alone ricularly relevant if combined with anotourned of the same category shnological background mo-written disclosure emediate document	E : earlier patent do after the filing da ther D : document cited L : document cited t	le underlying the curnent, but put ite in the applicatio for other reason	e invention olished on, or n s	



INCOMPLETE SEARCH SHEET C

Application Number EP 99 30 3985

Remark: Although claim 13 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Claim(s) searched completely: 4, 5, 15-20, 23-25

Claim(s) searched incompletely: 1-3, 6-14, 21, 22

Reason for the limitation of the search:

Present claims 1, 2 and 3, 6-14, 21, 22 (as far as they refer to claims 1, 2), relate to an extremely large number of possible aminoacid sequences. In fact, formula I, as it is disclosed on pages 6-15, contains so many variables, that a lack of clarity (and conciseness) within the meaning of Article 84 EPC arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and concise), namely those compounds whose nucleotide sequence is disclosed as Seq.ID:1, 3, 14, the corresponding encoded polypeptides, and closely related homologous compounds.

Present claims 21, 22 relate to an extremely large number of possible compounds. Support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to peptides derived from the disclosed polypeptides, specific antibodies and antisense molecules.



PARTIAL EUROPEAN SEARCH REPORT

Application Number EP 99 30 3985

	DOCUMENTS CONSIDERED TO BE RELEVANT		CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages		
A	WO 94 28902 A (PFIZER LTD (GB) PFIZER INC (US) PFIZER RES & DEV CO NV/SA (IE); ELLIS) 22 December 1994 (1994-12-22) * page 2, paragraph 2 * page 7, paragraph 3 * page 8, paragraph 2 - page 10, line 4 * page 13 - page 17; claims *	10-14, 18-22	
A,D	WO 97 35989 A (INCYTE PHARMA INC (US) AU-YOUNG J; COCKS B.G; COLEMAN R; SEILHAMER J.J) 2 October 1997 (1997-10-02) * abstract * * page 21, line 27 - page 23, line 18 * * page 24, line 29 - page 27, line 1 * * page 43 - page 44; claims *	10-14, 18-22	TECHNICAL FIELDS SEARCHED (InLCI.6)
X	Nucleotide Sequence Database EMBL Entry AA973152; Accession number AA973152 21 May 1998 98% identity with Seq.ID:1 nt.2186-2539 98% identity with Seq.ID:3 nt.2431-2784 reverse orientation XP002119753 * the whole document *	4,6-9	
х	Nucleotide Sequence Database EMBL Entry MM1276640 Accession number AA386789 25 June 1997 86% identity with Seq.ID:1 nt.360-833 86% identity with Seq.ID:3 nt.605-1078 99% identity with Seq.ID:14 nt.805-1278 XP002119754 * the whole document *	4,6-9	



PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 99 30 3985

Category	DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document with indication, where appropriate,	Relevant	APPLICATION (IntCi.6)
ategory	of relevant passages	to claim	
X	Nucleotide Sequence Database EMBL Entry RS7341; Accession number H32734 6 April 1998 84% identity with Seq.ID:1 nt.853-1254 84% identity with Seq.ID:3 nt.1098-1499 94% identity with Seq.ID:14 nt.1298-1699 XP002119755 * the whole document *	6-9	
A	BEAVO J.A.: "Cyclic Nucleotide Phosphodiesterases: functional implications of multiple isoforms" PHYSIOLOGICAL REVIEWS, vol. 75, no. 4, 1 October 1995 (1995-10-01), pages 725-748, XPO02034532 ISSN: 0031-9333 * page 741, right-hand column, paragraph 4 - page 743 *	10-14, 18-22	TECHNICAL FIELDS SEARCHED (IM.CI.6)
A	LOUGHNEY K. AND FERGUSON K.: "Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods" PHOSPHODIESTERASE INHIBITORS,1996, pages 1-19, XP002105161		



EP 99 30 3985

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-10-1999

	Patent documer led in search rep		Publication date		Patent family member(s)	Publication date
WO	9919495	A	22-04-1999	US	5932465 A	03-08-1
				AU	1097499 A	
				ËP	0944725 A	03-05-1
				NO		29-09-1
			·		992916 A	06-08-1
WO	9703675	Α	06-02-1997	AU	704955 B	13-05-1
				ΑU	6419196 A	18-02-1
				BR	9609758 A	26-01-1
				CA	2226784 A	06-02-1
				CN	1195290 A	07-10-1
				CZ	9800033 A	13-05-1
				EΡ	0839040 A	06-05-1
				HU	9900065 A	28-05-1
				JP	11509221 T	17-08-1
				NO	980153 A	10-03-1
				PL	324495 A	25-05-1
				SK	3998 A	08-07-1
WO	9428902	Α	22-12-1994	AT	163852 T	15-03-1
				AU	676571 B	13-03-19
				AŬ	6797394 A	
				CA	2163446 A.C	03-01-1
				ČN	1124926 A	22-12-19
				CZ	9503242 A	19-06-1
				DE		17-07-1
				DE		16-04-19
				DK	69408981 T 702555 T	02-07-19
				EP		06-04-19
				ES	0702555 A	27-03-19
				FI	2113656 T	01-05-19
			•		955911 A	08-12-19
				GR	3026520 T	31-07-19
				IL	109873 A	27-12-19
				IL	121836 A	27-12-19
				JP	2925034 B	26-07-19
				JP	9503996 T	22-04-19
				LV	12269 A	20-05-19
				NO NO	954757 A	24-11-19
				NZ	266463 A	24-03-19
				PL	311948 A	18-03-19
				ZA	9404018 A	08-12-19
WO	9735989	Α	02-10-1997	AU	2542797 A	17-10-19
				CA	2248675 A	02-10-19
				EP	0907742 A	14-04-19

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS
HMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
□ OTHER:

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)